Professor Clive Ballard
Professor of Age Related Diseases
C.Ballard@exeter.ac.uk
2911
722911
Medical School Building G.03
Medical School Building, St Luke's Campus, Magdalen Road, Exeter, EX1 2LU, UK
Overview
Clive is a psychiatrist who was driven to study dementia after witnessing the poor conditions in which people with dementia were cared for. He has led or co-authored well over 600 research papers and attracted grant income in excess of £150m over his research career, and has won several awards including the Weston Brain Institute Outstanding Achievement Award. Clive has led more dementia and cognitive health trials than anyone else in Europe over the last decade. He was featured in the Lancet Neurology for his achievements.
His main research specialisms are drug discovery, dementia prevention and improving care for people with dementia in residential homes. He is also an expert in Lewy Body Dementia and Parkinson’s Disease Dementia, and is an advocate of better prescribing and treatment pathways to improve outcomes for individuals. Before joining Exeter, Clive held directorship roles at King’s College London Institute of Psychiatry and at the Alzheimer’s Society. He was pivotal in the successful campaign to overturn a NICE decision and make anti-dementia drugs available for people with dementia.
As Pro-Vice-Chancellor and Executive Dean for Medicine, he focused on expanding the University of Exeter's College of Medicine and Health (additional places for Medical Students, Nursing and Neuroscience Programmes and broadened PGT offering) and raising its profile through collaboration across the board with other highly esteemed scientists and institutions. He has also focused strongly on obtaining philanthropic support for the College such as the Mireille Gillings Neuroimaging Centre at the RD&E.
Clive continues to maintain his busy research portfolio, focusing especially on Commercial Clinical Trial opportunities and publishing prolifically in high-ranking journals.
Qualifications
Education and awards
1987 - Leicester University, MB ChB (Medicine)
1991 - University of Birmingham, MMedSci
1992 - University of Birmingham, M.R.C.Psych.
1995 - Leicester University, MD
2015 - Fellow Academy Medical Sciences
Career
Current and previous posts
1992–1995: Lecturer in Psychiatry, University of Birmingham
1995–2000: MRC clinical Fellow/Senior Lecturer Old Age Psychiatry, University of Newcastle
2000–2002: Reader in Old Age Psychiatry, University of Newcastle, UK
2002–2003: Professor of Old Age Psychiatry, University of Newcastle, UK
2003–2013: Director of Research, Alzheimer’s Society
2003–2016: Professor of Age Related Diseases, King’s College London
2016–2022: Pro-Vice-Chancellor and Executive Dean of Medicine, University of Exeter
2022-2023: Interim Deputy Pro-Vice-Chancellor and Dean, University of Exeter Medical School
2016-present: Professor of Age Related Diseases, University of Exeter
Links
Research
Research interests
Clive’s work has highlighted the harms of antipsychotic medications in people with dementia and made a massive contribution to the 50% reduction in the use of these agents nationally and internationally. Further work has demonstrated the benefits of non-pharmacological treatments for the management of agitation in people with dementia.
Clive has led studies which highlighted the substantial benefits to neuropsychiatric symptoms from more effective treatment of pain. He has led pivotal studies with the novel and safer antipsychotic pimavanserin for the treatment of psychosis in people with Parkinson’s disease psychosis and Alzheimer’s disease, and was a principle investigator on another recent trial of mirtazapine for the treatment of agitation in people with Alzheimer’s disease. Other current work includes: the SMART-AD drug discovery programme funded by the Wellcome Trust, which has led to new ongoing clinical trials of the novel, re-purposed treatments fasudil, liraglutide and phenserine for the treatment of Alzheimer’s disease and dementia with Lewy bodies; the MRC funded Deep and Frequent Phenotyping cohort study; and further RCTs to evaluate a digital adaptation of our WHELD care home programme to improve person-centred care, which includes a study specifically adapting the programme for the needs of care homes during the COVID19 pandemic.
An additional strand of work in Clive’s portfolio has focussed on the maintenance of cognitive health and the prevention of cognitive decline. Key clinical trials have demonstrated the potential utility of online brain training for maintaining cognitive health and function in later life, the interaction of lifestyle and genetic factors and the role of mental health in maintaining cognitive function. Building on this, the ongoing PROTECT programme is an online cohort study supported by more than 30,000 participants over the age of 50, with nested intervention studies including further studies of brain training, physical exercise and vitamin D. The programme has excellent support from participants, 90% of who have supported the programme for more than 5 years, and PROTECT is now also live in the USA, Norway, Spain and Canada, and will soon have more than 100,000 participants worldwide. We have recently integrated a cutting-edge new neuropsychological test battery (FLAME) into the PROTECT platform, which is free of major learning effects, has milli-sec accuracy for reaction times and is highly sensitive to change.
Research projects
|
Title and funding organisation |
From |
To |
|
2021 |
|
|
2021 |
2026 |
|
2021 |
|
|
2020 |
2021 |
|
2021 |
2025 |
|
2019 |
2022 |
|
2018 |
2021 |
|
2019 |
2021 |
Publications
Books
Ballard CG, Friedman J (2019). Psychosis in Parkinson's Disease. Abingdon, Oxford, UK, Karger.
Burns A, Ballard C, Banerjee S, Calabrese P, De Deyn PP, Grossberg G, Jones R, Sandman PO, Selmes J, Vellas B, et al (2005). The clinical use of memantine. Abstract.
Journal articles
Creese B (In Press). A Data-Driven Examination of Apathy and Depressive Symptoms in Dementia with Independent Replication. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Ballard C (In Press). Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study. BMC Medicine
Corbett A, Creese B, Hayman V, Palmer A, Filakovsky A, Ballard C (In Press). Cognitive decline in older adults during and after the COVID-19 pandemic: a longitudinal analysis of the PROTECT UK study data. The Lancet Healthy Longevity
Creese B, Ballard C (In Press). Cost-effectiveness of Dementia Care Mapping in care home settings – Evaluation of a randomised controlled trial. Applied Health Economics and Health Policy
Sabatini S, Ukoumunne O, Ballard C, Collins R, Anstey K, Diehl M, Brothers A, Wahl H-W, Corbett A, Hampshire A, et al (In Press). Cross-Sectional Association between Objective Cognitive Performance and Perceived Age-related Gains and Losses in Cognition. International Psychogeriatrics
Sabatini S, Ukoumunne O, Brothers A, Diehl M, Wahl H-W, Clive B, Collins R, Corbett A, Brooker H, Clare L, et al (In Press). Differences in awareness of positive and negative age-related changes account for variability in health outcomes. European Journal of Ageing Abstract.
Surr C, Holloway I, Walwyn REA, Grifiths AW, Meads D, Martin A, Kelley R, Ballard C, Fossey J, Burnley N, et al (In Press). Effectiveness of Dementia Care Mapping™ to reduce agitation in care home residents with dementia: an open-cohort cluster randomised controlled trial. Aging and Mental Health
Ballard C (In Press). Efficacy Results of Pimavanserin from a Multi-Center, Open-label Extension Study in Parkinson’s Disease Psychosis Patients. Parkinsonism and Related Disorders
Ballard C, Brooker H, Corbett A, Ismail Z, Creese B, Wesnes K (In Press). FLAME: a computerized neuropsychological composite for trials in early dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Wolfova K, Creese B, Aarsland D, Ismail Z, Corbett A, Ballard C, Hampshire A, Cermakova P (In Press). Gender/sex differences in the association of mild behavioral impairment with cognitive aging. Journal of Alzheimer's Disease
Creese B, Arathimos R, Brooker H, Aarsland D, Corbett A, Lewis C, Ballard C, Ismail Z (In Press). Genetic risk for Alzheimer’s disease, cognition and Mild Behavioral Impairment in healthy older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Wang J, Spencer A, Hulme C, Corbett A, Khan Z, Vasconcelos Da Silva M, O'Dwyer S, Wright N, Testad I, Ballard C, et al (In Press). Healthcare utilisation and physical activities for older adults with comorbidities in the UK during COVID-19. Health and Social Care in the Community
Wang J, Spencer A, Hulme C, Khan Z, Vasconcelos Da Silva M, O'Dwyer S, Wright N, Testad I, Ballard C, Creese B, et al (In Press). Healthcare utilisation, physical activity and mental health during COVID-19 lockdown: an interrupted time-series analysis of older adults in England. European Journal of Ageing
Creese B, Arathimos R, Aarsland D, Ballard C, Brooker H, Hampshire A, Corbett A, Ismail Z (In Press). Late-life onset psychotic symptoms and incident cognitive impairment in people without dementia: modification by genetic risk for Alzheimer’s disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions
Arathimos R, Fabbri C, Vassos E, Davis KAS, Pain O, Gillett A, Coleman JRI, Hanscombe K, Hagenaars S, Jermy B, et al (In Press). Latent subtypes of manic and/or irritable episode symptoms in two 1 population-based cohorts. British Journal of Psychiatry
Lennon M, Brooker H, Creese B, Thayanandan T, Rigney G, Aarsland D, Hampshire A, Ballard C, Corbett A, Raymont V, et al (In Press). Lifetime TBI and cognitive domain deficits in late life: the PROTECT-TBI cohort study. Journal of Neurotrauma
Creese B, Khan Z, Henley W, O'Dwyer S, Corbett A, Vasconcelos Da Silva M, Mills K, Wright N, Testad I, Aarsland D, et al (In Press). Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety in adults over 50 between 2015 and 2020. International Psychogeriatrics
Creese BA, Brooker H, Ismail Z, Wesnes K, Adam H, Khan Z, Maria M, Corbett A, Aarsland D, Ballard C, et al (In Press). Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults. American Journal of Geriatric Psychiatry
Ballard C (In Press). Mild Cognitive Impairment: the Manchester Consensus. Age and Ageing
Daunt P, Ballard C, Creese B, Davidson G, Hardy J, Oshota O, Pither RJ, Gibson AM (In Press). Polygenic Risk Scoring is an Effective Approach to Predict Those Individuals Most Likely to Decline Cognitively Due to Alzheimer’s Disease. The journal of prevention of Alzheimer's disease
Silarova B (In Press). Protocol for the IDEAL-2 longitudinal study: following the experiences of people with dementia and their primary carers to understand what contributes to living well with dementia and enhances active life. BMC Public Health
Pishva SE, Creese B, Smith A, Ballard C, Mill J, Lunnon K (In Press). Psychosis-associated DNA methylomic variation in Alzheimer’s disease cortex. Neurobiology of Aging
Creese B, Ballard C (In Press). Revisiting criteria for psychosis in Alzheimer’s disease and related dementias- towards better phenotypic classification and biomarker research. Journal of Alzheimer's Disease
Rao R, Creese B, Aarsland D, Kalafatis C, Khan Z, Corbett A, Ballard C (In Press). Risky drinking and cognitive impairment in community residents. aged 50 and over. Aging and Mental Health
Allan LM (In Press). Small Vessel Disease Pathological Changes in Neurodegenerative and Vascular Dementias concomitant with Autonomic Dysfunction. Brain Pathology
Sabatini S, Ukoumunne O, Ballard C, Collins R, Corbett A, Brooker H, Clare L (In Press). The Cross-sectional Relationship between Pain and Awareness of Age-Related Changes. British Journal of Pain
Stewart G, Corbett A, Ballard C, Creese B, Aarsland D, Hampshire A, Brooker H, Charlton R, Happe F (In Press). The cognitive profile of middle-aged and older adults with high vs. low autistic traits. Autism Research
Creese B, Corbett A, Ballard C (In Press). The mental and physical health of older adults with a genetic predisposition for autism. Autism Research: official journal of the International Society for Autism Research
Malekizadeh Y, Williams G, Kelson M, Whitfield D, Mill J, Collier D, Ballard C, Jeffries A, Creese B (In Press). Whole transcriptome in-silico screening implicates cardiovascular and infectious disease in the mechanism of action underlying atypical antipsychotic side-effects. Alzheimer's and Dementia: Translational Research and Clinical Interventions
McDermid J, Henley W, Corbett A, Williams G, Fossey J, Clare L, Fox C, Aarsland D, Khan Z, Soto M, et al (2024). Impact of the iWHELD digital person-centered care program on quality of life, agitation and psychotropic medications in people with dementia living in nursing homes during the COVID-19 pandemic: a randomized controlled trial. Alzheimers Dement, 20(3), 1797-1806. Abstract. Author URL.
Akhanemhe R, Stevelink SAM, Corbett A, Ballard C, Brooker H, Creese B, Aarsland D, Hampshire A, Greenberg N (2024). Is lifetime traumatic brain injury a risk factor for mild cognitive impairment in veterans compared to non-veterans?. Eur J Psychotraumatol, 15(1). Abstract. Author URL.
Soto M, Rosenberg P, Ballard C, Vellas B, Miller D, Gauthier S, Carrillo MC, Lyketsos C, Ismail Z, Abushakra S, et al (2024). Neuropsychiatric Symptoms in AD: Clinical Trials Targeting Mild Behavioral Impairment: a Report from the International CTAD Task Force. JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 11(1), 56-64. Author URL.
Vetere G, Williams G, Ballard C, Creese B, Hampshire A, Palmer A, Pickering E, Richards M, Brooker H, Corbett A, et al (2024). The relationship between playing musical instruments and cognitive trajectories: Analysis from a UK ageing cohort. Int J Geriatr Psychiatry, 39(2). Abstract. Author URL.
Banerjee S, Farina N, Henderson C, High J, Stirling S, Shepstone L, Fountain J, Ballard C, Bentham P, Burns A, et al (2023). A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial. Health technology assessment (Winchester, England), 27(23), 1-108. Abstract.
Ballard C, Corbett A (2023). Antipsychotic drug presribing in dementia: changes from the pandemic. The Lancet Healthy Longevity, 4(8), e366-e367.
Sabatini S, Wilton-Harding B, Ballard C, Brooker H, Corbett A, Hampshire A, Windsor TD (2023). Bidirectional Associations of Awareness of Age-Related Change and Attitudes Toward Own Aging with Social Media Use. J Gerontol B Psychol Sci Soc Sci, 78(8), 1349-1359. Abstract. Author URL.
Ballard C (2023). Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimer Disease. JAMA Neurology, 80(12), 1272-1273.
Angioni D, Hansson O, Bateman RJ, Rabe C, Toloue M, Braunstein JB, Agus S, Sims JR, Bittner T, Carrillo MC, et al (2023). Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? a Report from the EU/US CTAD Task Force. Journal of Prevention of Alzheimer's Disease, 10(3), 418-425. Abstract.
Sinclair LI, Lawton MA, Palmer JC, Initiative FTADN, Ballard CG (2023). Characterization of Depressive Symptoms in Dementia and Examination of Possible Risk Factors. Journal of Alzheimer's Disease Reports, 7(1), 213-225.
Gibson LL, Abdelnour C, Chong J, Ballard C, Aarsland D (2023). Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers. Current Opinion in Neurology, 36(4), 264-275.
Sabatini S, Cosentino S, Chapman S, Ballard C, Brooker H, Corbett A, Stephan BCM (2023). Cognitive trajectories: exploring the predictive role of subjective cognitive decline and awareness of age-related changes for cognitive functioning. Front Psychiatry, 14 Abstract. Author URL.
Chong JR, Chai YL, Xing H, Herr DR, Wenk MR, Francis PT, Ballard C, Aarsland D, Silver DL, Chen CP, et al (2023). Decreased DHA-containing phospholipids in the neocortex of dementia with Lewy bodies are associated with soluble Aβ42 , phosphorylated α-synuclein, and synaptopathology. Brain Pathol, 33(6). Abstract. Author URL.
Abdelnour C, Gonzalez MC, Gibson LL, Poston KL, Ballard CG, Cummings JL, Aarsland D (2023). Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022. Neurology and Therapy, 12(3), 727-749.
Zheng B, Vivaldi G, Daines L, Leavy OC, Richardson M, Elneima O, McAuley HJC, Shikotra A, Singapuri A, Sereno M, et al (2023). Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls. The Lancet Regional Health - Europe, 29 Abstract.
Leahy TP, Simpson A, Sammon C, Ballard C, Gsteiger S (2023). Estimating the prevalence of diagnosed Alzheimer disease in England across deprivation groups using electronic health records: a clinical practice research datalink study. BMJ Open, 13(10). Abstract.
Pisani S, Gunasekera B, Lu Y, Vignando M, Ffytche D, Aarsland D, Chaudhuri KR, Ballard C, Lee J-Y, Kim YK, et al (2023). Grey matter volume loss in Parkinson’s disease psychosis and its relationship with serotonergic gene expression: a meta-analysis. Neuroscience & Biobehavioral Reviews, 147
McDermid J, Ballard C, Khan Z, Aarsland D, Fox C, Fossey J, Clare L, Moniz-Cook E, Soto-Martin M, Sweetnam A, et al (2023). Impact of the Covid-19 pandemic on neuropsychiatric symptoms and antipsychotic prescribing for people with dementia in nursing home settings. Int J Geriatr Psychiatry, 38(1). Abstract. Author URL.
Rogowska M, Thornton M, Creese B, Velayudhan L, Aarsland D, Ballard C, Tsamakis K, Stewart R, Mueller C (2023). Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: a 2011-2022 Update. Drugs Aging, 40(1), 21-32. Abstract. Author URL.
Chai YL, Lee JH, Chong JR, Ballard C, Francis PT, Kennedy BK, Arumugam TV, Chen CP, Aarsland D, Lai MKP, et al (2023). Inflammatory panel cytokines are elevated in the neocortex of late-stage Alzheimer's disease but not Lewy body dementias. J Neuroinflammation, 20(1). Abstract. Author URL.
Khan Z, Israel-McLeish K, Ballard C, Da Silva MV, Nunez K-M, Kitas F, Aarsland D (2023). Levels of Loneliness and Mental Health in Older Adults across Ethnic Groups During the COVID-19 Pandemic in the UK. Journal of the American Medical Directors Association, 24(5), 710-711.
Brightling CE, Evans RA, Singapuri A, Smith N, Wain LV, Evans RA, Chalmers JD, Harris VC, Ho LP, Horsley A, et al (2023). Long COVID research: an update from the PHOSP-COVID Scientific Summit. The Lancet Respiratory Medicine, 11(11), e93-e94.
Cousins O, Schubert JJ, Chandra A, Veronese M, Valkimadi P, Creese B, Khan Z, Arathimos R, Hampshire A, Rosenzweig I, et al (2023). Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge. J Neuroinflammation, 20(1). Abstract. Author URL.
Killick R, Elliott C, Ribe E, Broadstock M, Ballard C, Aarsland D, Williams G (2023). Neurodegenerative Disease Associated Pathways in the Brains of Triple Transgenic Alzheimer’s Model Mice Are Reversed Following Two Weeks of Peripheral Administration of Fasudil. International Journal of Molecular Sciences, 24(13). Abstract.
Ismail Z, Leon R, Creese B, Ballard C, Robert P, Smith EE (2023). Optimizing detection of Alzheimer’s disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO. Molecular Neurodegeneration, 18(1). Abstract.
Sabatini S, Turner S, Brooker H, Ballard C, Corbett A, Hampshire A (2023). Physical and mental health conditions account for variability in awareness of age-related changes. Front Psychiatry, 14 Abstract. Author URL.
Sant AM, Portelli S, Ballard C, Bezzina-Xuereb M, Scerri C, Sultana J (2023). Prevalence of Opioid Use in Nursing Homes over the Last Decade: a Systematic Literature Review. Journal of Pharmacy Technology Abstract.
McAuley HJC, Evans RA, Bolton CE, Brightling CE, Chalmers JD, Docherty AB, Elneima O, Greenhaff PL, Gupta A, Harris VC, et al (2023). Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study. eClinicalMedicine, 57 Abstract.
Lancaster T, Creese B, Escott-Price V, Driver I, Menzies G, Khan Z, Corbett A, Ballard C, Williams J, Murphy K, et al (2023). Proof-of-concept recall-by-genotype study of extremely low and high Alzheimer's polygenic risk reveals autobiographical deficits and cingulate cortex correlates. Alzheimers Res Ther, 15(1). Abstract. Author URL.
Garcia MJ, Leadley R, Lang S, Ross J, Vinand E, Ballard C, Gsteiger S (2023). Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease. J Alzheimers Dis, 91(1), 151-167. Abstract. Author URL.
Sabatini S, Dritschel B, Rupprecht FS, Ukoumunne OC, Ballard C, Brooker H, Corbett A, Clare L (2023). Rumination moderates the longitudinal associations of awareness of age-related change with depressive and anxiety symptoms. Aging Ment Health, 27(9), 1711-1719. Abstract. Author URL.
Stewart GR, Corbett A, Ballard C, Creese B, Aarsland D, Hampshire A, Charlton RA, HappĂŠ F (2023). Self-harm and Suicidality Experiences of Middle-Age and Older Adults with vs. Without High Autistic Traits. J Autism Dev Disord, 53(8), 3034-3046. Abstract. Author URL.
Aakre JA, Schulz J, Ballard C, Corbett A, Bjorvatn B, Aarsland D, Creese B, Hampshire A, Brooker H, Testad I, et al (2023). Self-reported sleep fragmentation and sleep duration and their association with cognitive function in PROTECT, a large digital community-based cohort of people over 50. Int J Geriatr Psychiatry, 38(11). Abstract. Author URL.
Sabatini S, Wahl H-W, Diehl M, Clare L, Ballard C, Brooker H, Corbett A, Hampshire A, Stephan BCM (2023). Testing Bidirectionality in Associations of Awareness of Age-Related Gains and Losses with Physical, Mental, and Cognitive Functioning Across 1 Year: the Role of Age. J Gerontol B Psychol Sci Soc Sci, 78(12), 2026-2036. Abstract. Author URL.
Turner SG, Brooker H, Ballard C, Corbett A, Hampshire A, Sabatini S (2023). The Role of Awareness of Age-Related Change in the Longitudinal Association between Pain and Physical Activity. Int J Aging Hum Dev Abstract. Author URL.
RĂśmer B, Dalen I, Ballard C, Aarsland D (2023). The course of depressive symptoms in Lewy body dementia and Alzheimer's disease. Journal of Affective Disorders, 333, 459-467. Abstract.
Fusdahl P, Cummings J, Ballard C, Borda MG, Aarsland D (2023). The impact of low dementia research funding on brain health for decision makers: a reflection on current health statistics. J Neurol Sci, 447 Author URL.
Blake J, Aryankhesal A, Allan L, Ballard C, Briscoe S, Broomfield N, Green L, Hilton A, van Horik J, Khondoker M, et al (2023). Understanding primary care diagnosis and management of sleep disturbance for people with dementia or mild cognitive impairment: a realist review. The British journal of general practice : the journal of the Royal College of General Practitioners, 73 Abstract.
Aarsland D, Khalifa K, Bergland AK, Soennesyn H, Oppedal K, Holteng LBA, Oesterhus R, Nakling A, Jarholm JA, de Lucia C, et al (2022). A Randomised Placebo-Controlled Study of Purified Anthocyanins on Cognition in Individuals at Increased Risk for Dementia. American Journal of Geriatric Psychiatry, 31(2), 141-151.
McDermid J, Da Silva MV, Williams G, Khan Z, Corbett A, Ballard C (2022). A Randomized Controlled Trial of a Digital Adaptation of the WHELD Person-Centered Nursing Home Training Program. J Am Med Dir Assoc, 23(7), 1166-1170. Abstract. Author URL.
McDermid J, Khan Z, Sweetnam A, Ballard CG (2022). Antipsychotic prescriptions and neuropsychiatric symptoms (NPS) in nursing home (NH)residents with dementia: a comparison of preâ and during COVID pandemic. Alzheimer's & dementia : the journal of the Alzheimer's Association, 18(Suppl 7). Abstract.
Singham T, Saunders R, Brooker H, Creese B, Aarsland D, Hampshire A, Ballard C, Corbett A, Desai R, Stott J, et al (2022). Are subtypes of affective symptoms differentially associated with change in cognition over time: a latent class analysis. J Affect Disord, 309, 437-445. Abstract. Author URL.
Sabatini S, Martyr A, Ukoumunne OC, Ballard C, Collins R, Pentecost C, Rusted JM, Quinn C, Anstey KJ, Kim S, et al (2022). Attitudes toward own aging and cognition among individuals living with and without dementia: findings from the IDEAL programme and the PROTECT study. BMC Geriatrics, 22(1). Abstract.
Delgado J, Evans PH, Gray DP, Sidaway-Lee K, Allan L, Clare L, Ballard C, Masoli J, Valderas JM, Melzer D, et al (2022). Continuity of GP care for patients with dementia: impact on prescribing and the health of patients. Br J Gen Pract, 72(715), e91-e98. Abstract. Author URL.
Henderson C, Knapp M, Fossey J, Frangou E, Ballard C (2022). Cost-Effectiveness of an Online Intervention for Caregivers of People Living with Dementia. Journal of the American Medical Directors Association, 23(9), 1468-1473.
Henderson C, Knapp M, Stirling S, Shepstone L, High J, Ballard C, Bentham P, Burns A, Farina N, Fox C, et al (2022). Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trial. International Psychogeriatrics, 34(10), 905-917. Abstract.
Sabatini S, Ukoumunne OC, Brothers A, Diehl M, Wahl H-W, Ballard C, Collins R, Corbett A, Brooker H, Clare L, et al (2022). Differences in awareness of positive and negative age-related changes accounting for variability in health outcomes. Eur J Ageing, 19(4), 1087-1097. Abstract. Author URL.
Chua XY, Chong JR, Cheng AL, Lee JH, Ballard C, Aarsland D, Francis PT, Lai MKP (2022). Elevation of inactive cleaved annexin A1 in the neocortex is associated with amyloid, inflammatory and apoptotic markers in neurodegenerative dementias. Neurochem Int, 152 Abstract. Author URL.
Sabatini S, Ukoumunne OC, Ballard C, Collins R, Corbett A, Brooker H, Clare L (2022). Exploring awareness of age-related changes among over 50s in the UK: findings from the PROTECT study. Int Psychogeriatr, 34(9), 789-803. Abstract. Author URL.
Choi A, Martyr A, Clare L, Fossey J, Khan Z, McDermid J, Ballard C (2022). Impact of Psychotic Symptoms and Concurrent Neuropsychiatric Symptoms on the Quality of Life of People with Dementia Living in Nursing Homes. J Am Med Dir Assoc, 23(9), 1474-1479.e1. Abstract. Author URL.
Arathimos R, Fabbri C, Vassos E, Davis KAS, Pain O, Gillett A, Coleman JRI, Hanscombe K, Hagenaars S, Jermy B, et al (2022). Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts - ERRATUM. Br J Psychiatry, 1-2. Author URL.
Abler V, Brain C, Ballard C, Berrio A, Coate B, Espay AJ (2022). Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis. Frontiers in Neurology, 13
Cross JL, Hammond SP, Shepstone L, Poland F, Henderson C, Backhouse T, Penhale B, Donell S, Knapp M, Lewins D, et al (2022). PERFECTED enhanced recovery pathway (PERFECT-ER) versus standard acute hospital care for people after hip fracture surgery who have cognitive impairment: a feasibility cluster randomised controlled trial. BMJ Open, 12(2). Abstract.
Essery R, Pollet S, Bradbury K, Western MJ, Grey E, Denison-Day J, Smith KA, Hayter V, Kelly J, Somerville J, et al (2022). Parallel randomized controlled feasibility trials of the "Active Brains" digital intervention to protect cognitive health in adults aged 60-85. Front Public Health, 10 Abstract. Author URL.
GeiĂler J, Isham E, Hickey G, Ballard C, Corbett A, Lubbert C (2022). Patient involvement in clinical trials. Commun Med (Lond), 2 Abstract. Author URL.
Sinclair LI, Ballard CG, Initiative FTADN (2022). Persistent depressive symptoms are associated with frontal regional atrophy in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 38(1).
Tariot PN, Ballard C, Devanand DP, Cummings JL, Sultzer DL (2022). Pimavanserin and dementia-related psychosis. The Lancet Neurology, 21(2), 114-115.
Nirogi R, Jayarajan P, Benade V, Shinde A, Goyal VK, Jetta S, Ravula J, Abraham R, Grandhi VR, Subramanian R, et al (2022). Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses. Int J Geriatr Psychiatry, 37(10). Abstract. Author URL.
Ismail Z, Creese B, Aarsland D, Kales HC, Lyketsos CG, Sweet RA, Ballard C (2022). Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities. Nature reviews. Neurology, 18(3), 131-144. Abstract.
OâBrien JT, Chouliaras L, Sultana J, Taylor J-P, Ballard C (2022). RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus. Alzheimer's Research & Therapy, 14(1).
Gelegen C, Cash D, Ilic K, Sander M, Kim E, Simmons C, Bernanos M, Lama J, Randall K, Brown JT, et al (2022). Relevance of sleep and associated structural changes in GBA1 mouse to human rapid eye movement behavior disorder. Scientific Reports, 12(1). Abstract.
Delgado J, Masoli J, Hase Y, Akinyemi R, Ballard C, Kalaria RN, Allan LM (2022). Trajectories of cognitive change following stroke: stepwise decline towards dementia in the elderly. Brain Commun, 4(3). Abstract. Author URL.
Stewart GR, Corbett A, Ballard C, Creese B, Aarsland D, Hampshire A, Charlton RA, HappĂŠ F (2022). Traumatic life experiences and postâtraumatic stress symptoms in middleâaged and older adults with and without autistic traits. International Journal of Geriatric Psychiatry, 37(2).
Nørgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, Møller DV, Knudsen LB, Kvist K, Zinman B, Holm E, et al (2022). Treatment with glucagonâlike peptideâ1 receptor agonists and incidence of dementia: Data from pooled doubleâblind randomized controlled trials and nationwide disease and prescription registers. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 8(1).
Greene L, Aryankhesal A, Megson M, Blake J, Wong G, Briscoe S, Hilton A, Killett A, Reeve J, Allan L, et al (2022). Understanding primary care diagnosis and management of sleep disturbance for people with dementia or mild cognitive impairment: a realist review protocol. BMJ Open, 12(11). Abstract. Author URL.
Ballard CG, McDermid J, Aarsland D, Khan Z, Sweetnam A (2022). iWHELD, a Novel Digital Non-Pharmacological Intervention with Live Virtual Coaching Reduces Antipsychotic Use in Nursing Home Residents with Dementia Compared to Usual Care in a 16-week RCT. Alzheimer's and Dementia, 18(S8). Abstract.
Kim E, Di Censo D, Baraldo M, Simmons C, Rosa I, Randall K, Ballard C, Dickie BR, Williams SCR, Killick R, et al (2021). <i>In vivo</i> multi-parametric manganese-enhanced MRI for detecting senile plaques in rodent models of Alzheimer’s disease. Abstract.
Da Silva MV, MelendezâTorres GJ, Testad I, Ballard C, Creese B (2021). A dataâdriven examination of clustering of apathy and depression symptoms in people with dementia. Alzheimer's & Dementia, 17(S6).
Imm JL, Harvey J, Pishva E, Creese B, Chouliaras L, Dempster E, Ballard C, O'Brien JT, Aarsland D, Mill J, et al (2021). A role for epigenetic mechanisms in Lewy body dementias. Alzheimers Dement, 17 Suppl 3 Abstract. Author URL.
Mueller C, John C, Perera G, Aarsland D, Ballard C, Stewart R (2021). Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes. EUROPEAN JOURNAL OF EPIDEMIOLOGY, 36(1), 89-101. Author URL.
Sabatini S, Ballard C, Clare L, Collins R, Ukoumunne O (2021). Associations of subjective cognitive and memory decline with depression, anxiety, and two-year change in objectively-assessed global cognition and memory. Aging, Neuropsychology and Cognition: a Journal on Normal and Dysfunctional Development
Sabatini S, Martyr A, Ukoumunne OC, Ballard C, Collins R, Pentecost C, Rusted JM, Quinn C, Anstey KJ, Kim S, et al (2021). Attitudes Toward Own Aging and Cognition among Individuals Living with and without Dementia: Findings from the IDEAL Programme and the PROTECT Study. Abstract.
Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D (2021). Author Correction: Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers, 7(1). Author URL.
Da Silva MV, Velayudhan L, Khan Z, Manzar B, Aarsland D, Ballard C (2021). COVIDâ19 and vaccination programme in one residential home. Alzheimer's & Dementia, 17(Suppl 10).
Sauer J, Ballard C, Gibson A, Daunt P, Pither R (2021). Clinical experience with polygenic risk score in subjects with early cognitive concerns. Alzheimer's & Dementia, 17(S8).
Sabatini S, Ukoumunne O, Ballard C, Collins R, Corbett A, Brooker H, Clare L (2021). Cross-sectional and longitudinal associations between subjective sleep difficulties and self-perceptions of aging. Behavioral Sleep Medicine
Cummings JL, Ismail Z, Dickerson BC, Ballard C, Grossberg G, McEvoy B, Foff E, Atri A (2021). Development and assessment of a brief screening tool for psychosis in dementia. Alzheimer's & Dementia Diagnosis Assessment & Disease Monitoring, 13(1).
Cummings JL, Atri A, Ismail Z, Dickerson BC, Ballard C, Grossberg GT, McEvoy B, Foff E (2021). Development and assessment of a brief screening tool for psychosis in dementia. Alzheimers Dement, 17 Suppl 8 Abstract. Author URL.
Sabatini S, Ukoumunne O, Brothers A, Diehl M, Wahl H-W, Ballard C, Collins R, Corbett A, Brooker H, Clare L, et al (2021). Differences in Awareness of Positive and Negative Age-Related Changes Account for Variability in Health Outcomes. Abstract.
Gelegen C, Cash D, Ilic K, Sander M, Kim E, Simmons C, Bernanos M, Lama J, Randall K, Brown JT, et al (2021). Dispersed Sleep Microstates and Associated Structural Changes in GBA1 Mouse: Relevance to Rapid Eye Movement Behavior Disorder. Abstract.
Femminella GD, Livingston NR, Raza S, van der Doef T, Frangou E, Love S, Busza G, Calsolaro V, Carver S, Holmes C, et al (2021). Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer’s subjects?. Alzheimer's Research and Therapy, 13(1). Abstract.
Ballard C (2021). Evidence-Based Treatment and Monitoring Strategies for Dementia-Related Psychosis. The Journal of Clinical Psychiatry, 82(3).
Sun N, Ismail Z, Aarsland D, Brooker H, Corbett A, Ballard C, Creese B (2021). Examination of cognitive performance and mild behavioral impairment domains of apathy, mood, impulse dyscontrol, social inappropriateness and psychosis in cognitively normal adults aged 50 and over. Alzheimer's & Dementia, 17(S6).
DeMichele-Sweet MAA, Klei L, Creese B, Harwood JC, Weamer EA, McClain L, Sims R, Hernandez I, Moreno-Grau S, TĂĄrraga L, et al (2021). Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. Molecular Psychiatry, 26(10), 5797-5811.
Velayudhan L, French T, Ugochukwu A, Corbett A, Brooker H, Aarsland D, Ballard C, Proitsi P (2021). Hypertension, brain training and cognition in the healthy adults aged over 50 years: an online longitudinal study. Alzheimer's & Dementia, 17(S10).
Khan Z, Da Silva MV, Eno-Amooquaye J, Nowicki S, Nunez K, Francis P, Ballard C (2021). Identification of Nonverbal Communication Tools for Use in Dementia. Abstract.
Brooker H, Hayman V, Aarsland D, Creese B, Ballard C, Corbett A (2021). Impact of brisk walking on cognitive decline in adults with and without early impairment: a FLAME analysis in the PROTECT cohort. Alzheimer's & Dementia, 17(S10).
Kim E, Di Censo D, Baraldo M, Simmons C, Rosa I, Randall K, Ballard C, Dickie BR, Williams SCR, Killick R, et al (2021). In vivo multi-parametric manganese-enhanced MRI for detecting amyloid plaques in rodent models of Alzheimer’s disease. Scientific Reports, 11(1). Abstract.
Khan Z, Da Silva MV, Nunez K-M, Kalafatis C, Nowicki S, Walker Z, Testad I, Francis P, Ballard C (2021). Investigating the effects of impairment in non-verbal communication on neuropsychiatric symptoms and quality of life of people living with dementia. Alzheimers Dement (N Y), 7(1). Abstract. Author URL.
Low CYB, Lee JH, Lim FTW, Lee C, Ballard C, Francis PT, Lai MKP, Tan MGK (2021). Isoformâspecific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer's disease and Lewy body dementias. Brain Pathology, 31(2), 253-266. Abstract.
Arathimos R, Fabbri C, Vassos E, Davis KAS, Pain O, Gillett A, Coleman JRI, Hanscombe K, Hagenaars S, Jermy B, et al (2021). Latent subtypes of manic or irritable episode symptoms in two population-based cohorts. Abstract.
Rajkumar AP, Hye A, Lange J, Manesh YR, Ballard C, Fladby T, Aarsland D (2021). Next-Generation RNA-Sequencing of Serum Small Extracellular Vesicles Discovers Potential Diagnostic Biomarkers for Dementia with Lewy Bodies. American Journal of Geriatric Psychiatry, 29(6), 573-584. Abstract.
Richardson K, Savva GM, Boyd PJ, Aldus C, Maidment I, Pakpahan E, Loke YK, Arthur A, Steel N, Ballard C, et al (2021). Non-benzodiazepine hypnotic use for sleep disturbance in people aged over 55 years living with dementia: a series of cohort studies. Health Technol Assess, 25(1), 1-202. Abstract. Author URL.
Fossey J, Charlesworth G, Fowler J-A, Frangou E, Pimm TJ, Dent J, Ryder J, Robinson A, Kahn R, Aarsland D, et al (2021). Online Education and Cognitive Behavior Therapy Improve Dementia Caregivers' Mental Health: a Randomized Trial. J Am Med Dir Assoc, 22(7), 1403-1409.e1. Abstract. Author URL.
Lawn T, Aman Y, Rukavina K, Sideris-Lampretsas G, Howard M, Ballard C, Ray Chaudhuri K, Malcangio M (2021). Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease. Pain, 162(4), 999-1006. Author URL.
Da Silva MV, Khan Z, Comber T, Aarsland D, Testad I, Ballard C (2021). Pandemic impact in care homes: Care homes perspectives. Alzheimer's & Dementia, 17(Suppl 10).
Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D (2021). Parkinson disease-associated cognitive impairment. Nature Reviews Disease Primers, 7(1). Abstract.
Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, Elneima O, Docherty AB, Lone NI, Leavy OC, et al (2021). Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med, 9(11), 1275-1287. Abstract. Author URL.
Delgado J, Jones L, Bradley MC, Allan LM, Ballard C, Clare L, Fortinsky RH, Hughes CM, Melzer D (2021). Potentially inappropriate prescribing in dementia, multi-morbidity and incidence of adverse health outcomes. Age Ageing, 50(2), 457-464. Abstract. Author URL.
Roheger M, Kalbe E, Corbett A, Brooker H, Ballard C (2021). Predictors of activities of daily living in heathy older adults: Who benefits most from online cognitive training?. Brain Behav, 11(11). Abstract. Author URL.
Sabatini S, Ukoumunne OC, Martyr A, Ballard C, Lamont RA, Collins R, Pentecost C, Hunt A, Quinn C, Thom JM, et al (2021). Relationship between self-perceptions of aging and ‘living well’ among people with mild-to-moderate dementia: Findings from the ideal programme. Archives of Gerontology and Geriatrics, 94, 104328-104328.
Ballard C, Aarsland D (2021). Relieving Caregiver Burden Through Evidence-Based Treatment for Dementia-Related Psychosis. The Journal of Clinical Psychiatry, 82(4).
Lennon MJ, Thayanandan T, Corbett A, Aarsland D, Ballard C, Raymont V (2021). Repeated concussions associated with worsened working memory, attention and processing speed, but preserved delayed memory: a PROTECT study. Alzheimer's & Dementia, 17(S10).
Ball HA, McWhirter L, Ballard C, Bhome R, Blackburn DJ, Edwards MJ, Fox NC, Howard R, Huntley J, Isaacs JD, et al (2021). Reply: Functional cognitive disorder: dementia's blind spot. Brain, 144(9). Author URL.
Burns DK, Alexander RC, Welsh-Bohmer KA, Culp M, Chiang C, O'Neil J, Evans RM, Harrigan P, Plassman BL, Burke JR, et al (2021). Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Neurology, 20(7), 537-547. Abstract.
Creese B, Arathimos R, Brooker H, Corbett A, Aarsland D, Lewis C, Ballard C, Ismail Z (2021). Self and informantârated mild behavioral impairment and genetic risk for AD: the respondent matters. Alzheimer's & Dementia, 17(S6).
Wolfova K, Creese B, Aarsland D, Ismail Z, Corbett A, Ballard C, Hampshire A, Cermakova P (2021). Sex differences in the association of mild behavioral impairment with cognitive aging. Abstract.
Wasserman D, Bindman D, Nesbitt AD, Cash D, Milosevic M, Francis PT, Chaudhuri KR, Leschziner GD, Ferini-Strambi L, Ballard C, et al (2021). Striatal Dopaminergic Deficit and Sleep in Idiopathic Rapid Eye Movement Behaviour Disorder: an Explorative Study. Nat Sci Sleep, 13, 1-9. Abstract. Author URL.
Banerjee S, High J, Stirling S, Shepstone L, Swart AM, Telling T, Henderson C, Ballard C, Bentham P, Burns A, et al (2021). Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet, 398(10310), 1487-1497. Abstract. Author URL.
Stewart GR, Corbett A, Ballard C, Creese B, Aarsland D, Hampshire A, Charlton RA, HappĂŠ F (2021). The Mental and Physical Health Profiles of Older Adults Who Endorse Elevated Autistic Traits. J Gerontol B Psychol Sci Soc Sci, 76(9), 1726-1737. Abstract. Author URL.
Choi A, Ballard C, Martyr A, Collins R, Morris RG, Clare L (2021). The impact of auditory hallucinations on “living well” with dementia: Findings from the IDEAL programme. International Journal of Geriatric Psychiatry, 36(9), 1370-1377. Abstract.
Brooker H, Hayman V, Aarsland D, Creese B, Ballard C, Corbett A (2021). The impact of the COVIDâ19 pandemic on cognitive health. Alzheimer's & Dementia, 17(Suppl 10).
Brooker H, Hayman V, Aarsland D, Creese B, Ballard C, Corbett A (2021). The impact of the COVIDâ19 pandemic on cognitive health. Alzheimer's & dementia : the journal of the Alzheimer's Association, 17(Suppl 10). Abstract.
Tariot PN, Cummings JL, Soto-Martin ME, Ballard C, Erten-Lyons DE, Sultzer DL, Devanand DP, Weintraub D, McEvoy B, Youakim JM, et al (2021). Trial of pimavanserin in dementia-related psychosis. New England Journal of Medicine, 385(4), 309-319. Abstract.
Kaye J, Aisen P, Amariglio R, Au R, Ballard C, Carrillo M, Fillit H, Iwatsubo T, Jimenez-Maggiora G, Lovestone S, et al (2021). Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: the EU/US CTAD Task Force. Journal of Prevention of Alzheimer's Disease, 8(4), 513-519. Abstract.
Sabatini S, Ukoumunne OC, Ballard C, Collins R, Kim S, Corbett A, Aarsland D, Hampshire A, Brooker H, Clare L, et al (2021). What does feeling younger or older than one’s chronological age mean to men and women? Qualitative and quantitative findings from the PROTECT study. Psychology & Health, 38(3), 324-347.
McGoohan K, Amjad A, Ratcliffe N, Bhattacharyya S, Granville G, Sullivan M, Gosden L, Aarsland D, Chaudhuri KR, ffytche D, et al (2020). A Preliminary Investigation of the Views of People with Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: an Online Survey. Frontiers in Psychiatry, 11 Abstract.
Bateman DR, Gill S, Hu S, Foster ED, Ruthirakuhan MT, Sellek AF, Mortby ME, MatuĹĄkovĂĄ V, Ng KP, Tarawneh RM, et al (2020). Agitation and impulsivity in mid and late life as possible risk markers for incident dementia. Alzheimers Dement (N Y), 6(1). Abstract. Author URL.
Ashton NJ, Hye A, Rajkumar AP, Leuzy A, Snowden S, SuĂĄrez-Calvet M, Karikari TK, SchĂśll M, La Joie R, Rabinovici GD, et al (2020). An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol, 16(5), 265-284. Abstract. Author URL.
Enache D, Fereshtehnejad SM, Cermakova P, Garcia-Ptacek S, KĂĽreholt I, Johnell K, Religa D, Jelic V, Winblad B, Ballard C, et al (2020). Antidepressants and mortality risk in a dementia cohort – data from SveDem, the Swedish Dementia Registry. European Psychiatry, 33(S1).
Mueller C, John C, Perera G, Aarsland D, Ballard C, Stewart R (2020). Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes. Alzheimer's & Dementia, 16(S10).
Sabatini S, Silarova B, Martyr A, Collins R, Ballard C, Anstey KJ, Kim S, Clare L (2020). Associations of Awareness of Age-Related Change with Emotional and Physical Well-being: a Systematic Review and Meta-analysis. Gerontologist, 60(6), e477-e490. Abstract. Author URL.
Di Censo R, Abdelnour C, Blanc F, Bousiges O, Lemstra AW, van Steenoven I, Onofrj M, Aarsland D, Bonanni L, European DLB consortium, et al (2020). CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry, 91(1), 109-110. Author URL.
Kunst G, Green DW, Ballard C (2020). Can Intraoperative Optimization of Both Anesthetic Depth and Cerebral Oxygenation Really Result in Different Influences on Cognitive Function and Delirium in Elderly Patients Undergoing Cardiac Surgery? Response to Letter to the Editor by Xue et al. Journal of Cardiothoracic and Vascular Anesthesia, 34(11), 3166-3167.
Hampshire A, Ballard C, Williams G (2020). Computerized neuropsychological tests undertaken on digital platforms are cost effective, achieve high engagement, distinguish and are highly sensitive to longitudinal change: Data from the PROTECT and GBIT studies. Alzheimer's & Dementia, 16(S10).
Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, Lawrence R, McFarlane B, Tadros G, Ridha BH, et al (2020). Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: Study protocol for a randomised controlled trial (ELAD study) (Trials. (2019) 20 (191) DOI: 10.1186/s13063-019-3259-x). Trials, 21(1). Abstract.
Surr CA, Holloway I, Walwyn RE, Griffiths AW, Meads D, Kelley R, Martin A, McLellan V, Ballard C, Fossey J, et al (2020). Dementia Care Mapping™ to reduce agitation in care home residents with dementia: the EPIC cluster RCT. Health Technol Assess, 24(16), 1-172. Abstract. Author URL.
Ballard C (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet, 396, 413-446.
Getaneh MM, Ballard C, Brooker H (2020). Depression and anxiety are associated with decline in executive function over two years in adults 50 and over. Alzheimer's & Dementia, 16(S6).
Ballard C (2020). Diagnosing Dementia-Related Psychosis: Using Tools and Communicating with Patients and Caregivers. J Clin Psychiatry, 82(1). Abstract. Author URL.
Ballard C, Corbett A, Aarsland D, Cummings J, O'Brien J, Mills R, Molinuevo JL, Fladby T, Wiliams G, Doherty P, et al (2020). Drug repositioning and repurposing. for Alzheimer disease. Nature Reviews Neurology
Khalifa K, Bergland AK, Soennesyn H, Oppedal K, Oesterhus R, Dalen I, Larsen AI, Fladby T, Brooker H, Wesnes KA, et al (2020). Effects of Purified Anthocyanins in People at Risk for Dementia: Study Protocol for a Phase II Randomized Controlled Trial. Frontiers in Neurology, 11
Ballard CG, Coate B, Abler V, Stankovic S, Foff E (2020). Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: a post hoc analysis. International Journal of Geriatric Psychiatry, 35(11), 1402-1408. Abstract.
Creese B, Albertyn CP, Dworkin S, Thomas RS, Wan YM, Ballard C (2020). Executive function but not episodic memory decline associated with visual hallucinations in Parkinson's disease. J Neuropsychol, 14(1), 85-97. Abstract. Author URL.
Ball HA, McWhirter L, Ballard C, Bhome R, Blackburn DJ, Edwards MJ, Fleming SM, Fox NC, Howard R, Huntley J, et al (2020). Functional cognitive disorder: dementia's blind spot. Brain, 143(10), 2895-2903. Abstract. Author URL.
Creese B, Brooker H, Aarsland D, Corbett A, Ballard C, Ismail Z (2020). Genetic risk for Alzheimer disease, cognition and Mild Behavioral Impairment in healthy older adults. Abstract.
DeMichele-Sweet MAA, Klei L, Creese B, Harwood JC, Weamer EA, McClain L, Sims R, Hernandez I, Moreno-Grau S, TĂĄrraga L, et al (2020). Genome-Wide Association Identifies the First Risk Loci for Psychosis in Alzheimer Disease. Abstract.
Foff EP, Devanand DP, Ballard C, McEvoy B, Stankovic S (2020). HARMONY: Response to pimavanserin in the 12âweek, openâlabel treatment phase. Alzheimer's & Dementia, 16(S9).
Sabatini S, Ukoumunne O, Ballard C, Diehl M, Wahl H-W, Brothers A, Clare L (2020). Health Differences Among People with Varying Profiles of Awareness of Positive and Negative Age-Related Changes. Innovation in Aging, 4(Suppl 1), 480-480.
Sabatini S, Ukoumunne O, Ballard C, Diehl M, Wahl H-W, Brothers A, Clare L (2020). Health Differences Among People with Varying Profiles of Awareness of Positive and Negative Age-Related Changes. Innovation in aging, 4(Suppl 1), 480-480. Abstract.
Hayward JK, Nunez KM, Ballard C, Spector A (2020). Healthy adjustment for new residents with dementia using SettleIN: a feasibility study in UK care homes. Dementia, 19(6), 1811-1828. Abstract.
Sabatini S, Ukoumunne O, Ballard C, Anstey K, Diehl M, Brothers A, Wahl H-W, Clare L (2020). Higher Awareness of Positive and Negative Age-Related Changes Relate to Lower Objective Cognitive Scores. Innovation in aging, 4(Suppl 1), 597-598. Abstract.
Sabatini S, Ukoumunne O, Ballard C, Anstey K, Diehl M, Brothers A, Wahl H-W, Clare L (2020). Higher Awareness of Positive and Negative Age-Related Changes Relate to Lower Objective Cognitive Scores. Innovation in Aging, 4(Suppl 1), 597-598.
Sabatini S, Ukoumunne O, Ballard C, Collins R, Anstey KJ, Diehl M, Brothers A, Corbett A, Hampshire A, Brooker H, et al (2020). Higher perceived ageârelated gains and losses relate to lower objective cognitive scores. Alzheimer's & Dementia, 16(S6).
Choi A, Ballard C, Martyr A, Collins R, Morris RG, Clare L (2020). Impact of psychosis on quality of life and wellâbeing in dementia. Alzheimer's & Dementia, 16(S6).
Owens AP, Ballard C, Beigi M, Kalafatis C, Brooker H, Lavelle G, Brønnick KK, Sauer J, Boddington S, Velayudhan L, et al (2020). Implementing Remote Memory Clinics to Enhance Clinical Care During and After COVID-19. Frontiers in Psychiatry, 11 Abstract.
Owens AP, Ballard C, Beigi M, Kalafatis C, Brooker H, Lavelle G, Brønnick KK, Sauer J, Boddington S, Velayudhan L, et al (2020). Implementing Remote Memory Clinics to Enhance Clinical Care During and After COVID-19. Frontiers in psychiatry, 11 Abstract.
Ballard C, Orrell M, Moniz-Cook E, Woods R, Whitaker R, Corbett A, Aarsland D, Murray J, Lawrence V, Testad I, et al (2020). Improving mental health and reducing antipsychotic use in people with dementia in care homes: the WHELD research programme including two RCTs. Programme Grants for Applied Research, 8(6), 1-98. Abstract.
Sabatini S, Ukoumunne OC, Ballard C, Brothers A, Kaspar R, Collins R, Kim S, Corbett A, Aarsland D, Hampshire A, et al (2020). International relevance of Two Measures of Awareness of Age-Related Change (AARC). Abstract.
Sabatini S, Ukoumunne O, Ballard C, Brothers A, Kaspar R, Collins R, Kim S, Corbett A, Aarsland D, Hampshire A, et al (2020). International relevance of Two Measures of Awareness of Age-Related Change (AARC). BMC Geriatrics, 20
sabatini S, Ukoumunne OC, Ballard C, Brothers A, Kaspar R, Collins R, Kim S, Corbett A, Aarsland D, Hampshire A, et al (2020). International relevance of Two Measures of Awareness of Age-Related Change (AARC). Abstract.
Kunst G, Gauge N, Salaunkey K, Spazzapan M, Amoako D, Ferreira N, Green DW, Ballard C (2020). Intraoperative Optimization of Both Depth of Anesthesia and Cerebral Oxygenation in Elderly Patients Undergoing Coronary Artery Bypass Graft Surgery—A Randomized Controlled Pilot Trial. Journal of Cardiothoracic and Vascular Anesthesia, 34(5), 1172-1181. Abstract.
Creese B, Malekizadeh Y, Williams G, Whitfield D, Kelson M, Ballard C, Mill J, Jeffries A (2020). Inâsilico high throughput whole transcriptome screening implicates cardiovascular disease and the immune system in the mechanism of action underlying adverse effects of atypical antipsychotics. Alzheimer's & Dementia, 16(S9).
Husebo BS, Allore H, Achterberg W, Angeles RC, Ballard C, Bruvik FK, FÌø SE, Gedde MH, Hillestad E, Jacobsen FF, et al (2020). LIVE@Home.Path-innovating the clinical pathway for home-dwelling people with dementia and their caregivers: Study protocol for a mixed-method, stepped-wedge, randomized controlled trial. Trials, 21(1). Abstract.
Mueller C, FitzGerald JM, Perera G, Rajamani APR, Bhattarai M, Price A, Ballard C, Stewart R, Aarsland D (2020). Linking electronic dementia care records to national inpatient data in dementia with Lewy bodies: Frequency, duration and cost implications of hospitalization and recording of delirium episodes. Alzheimer's & Dementia, 16(S10).
Ballard C, Nørgaard CH, Friedrich S, Mørch LS, Gerds T, Møller DV, Knudsen LB, Kvist K, Zinman B, Holm E, et al (2020). Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes. Alzheimer's & Dementia, 16(S9).
Ballard CG, Kreitzman DL, Isaacson S, Liu IY, Norton JC, Demos G, Fernandez HH, Ilic TV, Azulay JP, Ferreira JJ, et al (2020). Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. Parkinsonism and Related Disorders, 77, 100-106. Abstract.
Roheger M, Kalbe E, Corbett A, Brooker H, Ballard C (2020). Lower cognitive baseline scores predict cognitive training success after 6 months in healthy older adults: Results of an online <scp>RCT</scp>. International Journal of Geriatric Psychiatry, 35(9), 1000-1008. Abstract.
Velayudhan L, Aarsland D, Ballard C (2020). Mental health of people living with dementia in care homes during COVID-19 pandemic. International Psychogeriatrics, 32(10), 1253-1254.
Howard R, Zubko O, Gray R, Bradley R, Harper E, Kelly L, Pank L, OâBrien J, Fox C, Tabet N, et al (2020). Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT. Abstract.
Howard R, Zubko O, Bradley R, Harper E, Pank L, O'Brien J, Fox C, Tabet N, Livingston G, Bentham P, et al (2020). Minocycline at 2 Different Dosages vs Placebo for Patients with Mild Alzheimer Disease: a Randomized Clinical Trial. JAMA Neurology, 77(2), 164-174. Abstract.
O'Connor RC, Hotopf M, Worthman CM, Perry VH, Tracey I, Wessely S, Arseneault L, Ballard C, Christensen H, Silver RC, et al (2020). Multidisciplinary research priorities for the COVID-19 pandemic – Authors' reply. The Lancet Psychiatry, 7(7), e44-e45.
Holmes EA, O'Connor RC, Perry VH, Tracey I, Wessely S, Arseneault L, Ballard C, Christensen H, Cohen Silver R, Everall I, et al (2020). Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. The Lancet Psychiatry, 7(6), 547-560.
Borda MG, Aarsland D, Tovar-Rios DA, Giil LM, Ballard C, Gonzalez MC, Brønnick K, Alves G, Oppedal K, Soennesyn H, et al (2020). Neuropsychiatric Symptoms and Functional Decline in Alzheimer's Disease and Lewy Body Dementia. J Am Geriatr Soc, 68(10), 2257-2263. Abstract. Author URL.
VikâMo AO, Giil LM, Ballard C, Aarsland D (2020). Neuropsychiatric symptoms and cognitive decline: Trait or state effects?. Alzheimer's & Dementia, 16(S6).
Rongve A, Nilsen OB, Ballard C, Aarsland D (2020). P01-371 - Shorter time until nursing home admission in lewy body dementias as compared to Alzheimer's dementia. European Psychiatry, 25(S1).
Rongve A, Brønnick K, Ballard C, Aarsland D (2020). PW01-89 - Symtoms of dementia with lewy bodies cluster in persons with mild dementia. European Psychiatry, 25(S1).
Wright P, Veronese M, Mazibuko N, Turkheimer FE, Rabiner EA, Ballard CG, Williams SCR, Hari Narayanan AK, Osrah B, Williams R, et al (2020). Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: an in vivo PET Study with Neuropathological Comparison. Frontiers in Neurology, 11 Abstract.
Rajkumar AP, Bidkhori G, Shoaie S, Clarke E, Morrin H, Hye A, Williams G, Ballard C, Francis P, Aarsland D, et al (2020). Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. American Journal of Geriatric Psychiatry, 28(1), 75-86. Abstract.
Roheger M, Kalbe E, Corbett A, Brooker H, Ballard C (2020). Predictors of changes after reasoning training in healthy adults. Brain and Behavior, 10(12). Abstract.
Velayudhan L, Aarsland D, Ballard C (2020). Psychiatric and neuropsychiatric syndromes and COVID-19. The Lancet Psychiatry, 7(8), 663-664.
Ballard C, Kales HC, Lyketsos C, Aarsland D, Creese B, Mills R, Williams H, Sweet RA (2020). Psychosis in Alzheimer's Disease. Curr Neurol Neurosci Rep, 20(12). Abstract. Author URL.
Ballard C, Corbett A (2020). Reducing psychotropic drug use in people with dementia living in nursing homes. International Psychogeriatrics, 32(3), 291-294.
Creese B, Brooker H, Aarsland D, Corbett A, Ballard C, Ismail Z (2020). Relationship between genetic risk for Alzheimer's, cognition and neuropsychiatric symptoms: a case study of DNA sampling and analysis through digital platform cohort studies. Alzheimer's & Dementia, 16(S10).
McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, Kantarci K, Muscio C, O'Brien JT, Postuma RB, et al (2020). Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology, 94(17), 743-755. Abstract. Author URL.
Stewart GR, Corbett A, Ballard C, Creese B, Aarsland D, Hampshire A, Charlton RA, HappĂŠ F (2020). Sleep problems and mental health difficulties in older adults who endorse high autistic traits. Research in Autism Spectrum Disorders, 77 Abstract.
Desai R, Charlesworth GM, Brooker HJ, Potts HWW, Corbett A, Aarsland D, Ballard CG (2020). Temporal Relationship Between Depressive Symptoms and Cognition in Mid and Late Life: a Longitudinal Cohort Study. Journal of the American Medical Directors Association, 21(8), 1108-1113. Abstract.
Vik-Mo AO, Giil LM, Borda MG, Ballard C, Aarsland D (2020). The individual course of neuropsychiatric symptoms in people with Alzheimer's and Lewy body dementia: 12-year longitudinal cohort study. British Journal of Psychiatry, 216(1), 43-48. Abstract.
Killick R, Ballard C, Doherty P, Williams G (2020). Transcription-based drug repurposing for COVID-19. Virus Res, 290 Abstract. Author URL.
Killick R, Ballard C, Doherty P, Williams G (2020). Using the SARS Infection Transcriptional Signature to Identify Potential Treatments for Covid-19. Abstract.
O'Brien J, Taylor JP, Ballard C, Barker RA, Bradley C, Burns A, Collerton D, Dave S, Dudley R, Francis P, et al (2020). Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. J Neurol Neurosurg Psychiatry, 91(5), 512-519. Abstract. Author URL.
Guskey M, Norton J, Coate B, Owen R, Stankovic S, Ballard C (2019). A POST HOC ANALYSIS OF STUDY ACP-103-019 EVALUATING THE IMPACT OF a REDUCTION IN PSYCHOSIS ON THE SEVERITY OF AGITATION AND AGGRESSION IN PATIENTS WITH ALZHEIMER'S DISEASE. American Journal of Geriatric Psychiatry, 27(3).
Vik-Mo AO, Bencze J, Ballard C, HortobĂĄgyi T, Aarsland D (2019). Advanced cerebral amyloid angiopathy and small vessel disease are associated with psychosis in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 90(6), 728-730.
Clarke E, Jantrachotechatchawan C, Buhidma Y, Broadstock M, Yu L, Howlett D, Aarsland D, Ballard C, Francis PT (2019). Age-related neurochemical and behavioural changes in D409V/WT GBA1 mouse: Relevance to lewy body dementia. Neurochem Int, 129 Abstract. Author URL.
Gatt A, Whitfield DR, Ballard C, Doherty P, Williams G (2019). Alzheimer's Disease Progression in the 5×FAD Mouse Captured with a Multiplex Gene Expression Array. J Alzheimers Dis, 72(4), 1177-1191. Abstract. Author URL.
Brooker H, Wesnes KA, Ballard C, Hampshire A, Aarsland D, Khan Z, Stenton R, McCambridge L, Corbett A (2019). An online investigation of the relationship between the frequency of word puzzle use and cognitive function in a large sample of older adults. Int J Geriatr Psychiatry, 34(7), 921-931. Abstract. Author URL.
Erdal A, Ballard C, Vahia IV, Husebo BS (2019). Analgesic treatments in people with dementia - how safe are they? a systematic review. Expert Opinion on Drug Safety, 18(6), 511-522. Abstract.
Creese B, Vassos E, Bergh S, Athanasiu L, Johar I, Rongve A, Medbøen IT, Da Silva MV, Aakhus E, Andersen F, et al (2019). Association between schizophrenia polygenic score and psychotic symptoms in Alzheimer’s disease: meta-analysis of 11 cohort studies. Abstract.
Ballard C, Corbett A (2019). Commentary: Opportunities for Combination Trials. J Prev Alzheimers Dis, 6(3), 177-178. Author URL.
Koychev I, Lawson J, Chessell T, Mackay C, Gunn R, Sahakian B, Rowe JB, Thomas AJ, Rochester L, Chan D, et al (2019). Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. BMJ Open, 9(3). Abstract.
Williams G, Gatt A, Clarke E, Corcoran J, Doherty P, Chambers D, Ballard C (2019). Drug repurposing for Alzheimer's disease based on transcriptional profiling of human iPSC-derived cortical neurons. Transl Psychiatry, 9(1). Abstract. Author URL.
Ballard C, Atri A, Boneva N, Cummings JL, FrĂślich L, Molinuevo JL, Tariot PN, Raket LL (2019). Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 5, 164-174. Abstract.
Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, Lawrence R, McFarlane B, Tadros G, Ridha BH, et al (2019). Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: Study protocol for a randomised controlled trial (ELAD study). Trials, 20(1). Abstract.
Creese B, Ballard C, Vasconcelos Da Silva M (2019). Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer’s disease. Translational Psychiatry
Gatt A, Lee H, Williams G, Thuret S, Ballard C (2019). Expression of neurogenic markers in Alzheimer's disease: a systematic review and metatranscriptional analysis. Neurobiology of Aging, 76, 166-180. Abstract.
Ballard C, Creese B, Gatt A, Doherty P, Francis PT, Whitfield D, Corbett A, Corcoran J, Hanger D, Thuret S, et al (2019). Identifying Novel Candidates for Re-Purposing as Potential Therapeutic Agents for Alzheimer’s disease. Abstract.
Aman Y, Pitcher T, Ballard C, Malcangio M (2019). Impaired chronic pain-like behaviour and altered opioidergic system in the TASTPM mouse model of Alzheimer's disease. European Journal of Pain (United Kingdom), 23(1), 91-106. Abstract.
Romeo R, Zala D, Knapp M, Orrell M, Fossey J, Ballard C (2019). Improving the quality of life of care home residents with dementia: Cost-effectiveness of an optimized intervention for residents with clinically significant agitation in dementia. Alzheimers Dement, 15(2), 282-291. Abstract. Author URL.
Eraydin IE, Mueller C, Corbett A, Ballard C, Brooker H, Wesnes K, Aarsland D, Huntley J (2019). Investigating the relationship between age of onset of depressive disorder and cognitive function. Int J Geriatr Psychiatry, 34(1), 38-46. Abstract. Author URL.
Sabatini S, Silarova B, Martyr A, Collins R, Ballard C, Anstey KJ, Kim S, Clare L (2019). META-ANALYSIS OF AARC AND EMOTIONAL AND PHYSICAL WELL-BEING. Innovation in Aging, 3(Supplement_1), S384-S385. Abstract.
Sabatini S, Silarova B, Martyr A, Collins R, Ballard C, Anstey KJ, Kim S, Clare L (2019). META-ANALYSIS OF AARC AND EMOTIONAL AND PHYSICAL WELL-BEING. Innovation in aging, 3(Suppl 1), S384-S385. Abstract.
Kales HC, Lyketsos CG, Miller EM, Ballard C (2019). Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus. International Psychogeriatrics, 31(1), 83-90. Abstract.
Sultana J, Fontana A, Giorgianni F, Tillati S, Cricelli C, Pasqua A, Patorno E, Ballard C, Sturkenboom M, Trifirò G, et al (2019). Measuring the Effectiveness of Safety Warnings on the Risk of Stroke in Older Antipsychotic Users: a Nationwide Cohort Study in Two Large Electronic Medical Records Databases in the United Kingdom and Italy. Drug Safety, 42(12), 1471-1485. Abstract.
Da Silva MV, Creese B, Johar I, Bergh S, Aarsland D, Rongve A, Medboen IT, Aakhus E, Andersen F, Braekhus A, et al (2019). O2â11â06: THE COURSE OF APATHY IN PEOPLE WITH DEMENTIA. Alzheimer's & Dementia, 15(7S_Part_11), p570-p570.
FrĂślich L, Atri A, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Geist MA, Raket LL, Cummings JL (2019). Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease. Journal of Alzheimer's Disease, 67(1), 303-313. Abstract.
Da Silva MV, Creese B, Johar I, Aarsland D, Bergh S, Athanasiu L, Rongve A, Medboen IT, Aakhus E, Andersen F, et al (2019). P1â131: GENOME WIDE ASSOCIATION STUDY: IDENTIFYING GENETIC MARKERS IN APATHY IN PEOPLE WITH ALZHEIMER'S DISEASE. Alzheimer's & Dementia, 15(7S_Part_5), p286-p286.
Brooker H, Ballard C, Aarsland D, Khan Z, Wesnes K, Corbett A (2019). P1â459: INFORMANTâ AND PARTICIPANTâREPORTED COGNITIVE FUNCTION USING THE IQCODE MEASURE IS a ROBUST INDICATOR OF COGNITIVE HEALTH. Alzheimer's & Dementia, 15(7S_Part_8), p443-p444.
Creese B, Brooker H, Wesnes K, Corbett A, Aarsland D, Ismail Z, Ballard C (2019). P1â468: CHARACTERISING THE COGNITIVE PROFILE ASSOCIATED WITH INDIVIDUAL DOMAINS OF MID BEHAVIOURAL IMPAIRMENT IN THE COGNITIVELY NORMAL POPULATION. Alzheimer's & Dementia, 15(7S_Part_8), p447-p448.
Ballard C, Creese B, Chambers D, Williams G (2019). P2â110: a NEURONAL CONNECTIVITY MAP (NMAP) DATABASE TO ESTABLISH a DRUGâSCREENING PLATFORM FOR AD. Alzheimer's & Dementia, 15(7S_Part_12), p614-p614.
Johar I, Creese B, Bergh S, Athanasiu L, Medboen IT, Da Silva MV, Rongve A, Aakhus E, Anderson F, Bettella F, et al (2019). P2â129: GENOMEâWIDE ASSOCIATION OF ALZHEIMER'S DISEASE WITH DYSPHORIA AND EVALUATION OF GENETIC OVERLAP WITH MAJOR DEPRESSIVE DISORDER. Alzheimer's & Dementia, 15(7S_Part_12), p621-p622.
Brooker H, Ballard C, Aarsland D, Khan Z, Wesnes K, Corbett A (2019). P2â584: ASSOCIATION OF SELFâREPORTED PHYSICAL EXERCISE FREQUENCY AND COGNITIVE TRAJECTORY IN OLDER ADULTS. Alzheimer's & Dementia, 15(7S_Part_16), p847-p847.
Brooker H, Severin J, Sander M, Corbett A, Aarsland D, Wesnes K, Ballard C (2019). P2â607: USE OF HEARING AIDS IN OLDER ADULTS WITH HEARING LOSS IS ASSOCIATED WITH IMPROVED COGNITIVE TRAJECTORY. Alzheimer's & Dementia, 15(7S_Part_16), p857-p858.
Gatt A, Whitfield D, Creese B, Ballard C (2019). P3â228: a MULTIPLEX BIOMARKER ASSAY FOR MEASURING TRANSCRIPTIONAL CHANGES IN THE 5XFAD MOUSE MODEL OF AD. Alzheimer's & Dementia, 15(7S_Part_19), p1019-p1019.
Creese B, Brooker H, Corbett A, Aarsland D, Ballard C (2019). P3â319: FAMILY HISTORY OF DEMENTIA WITH PSYCHOTIC SYMPTOMS IN THE COGNITIVELY NORMAL POPULATION: FEASIBILITY OF MEASUREMENT AND INITIAL CLINICAL AND GENETIC ASSOCIATIONS. Alzheimer's & Dementia, 15(7S_Part_20), p1059-p1059.
Corbett A, Brooker H, Aarsland D, Wesnes K, Ballard C (2019). P3â484: CHRONIC PAIN IS ASSOCIATED WITH POOR COGNITIVE TRAJECTORY IN OLDER ADULTS. Alzheimer's & Dementia, 15(7S_Part_22), p1153-p1153.
Velayudhan L, Ugochukwu A, Wesnes K, Brooker H, Corbett A, Aarsland D, Ballard C, Proitsi P (2019). P3â555: AN ONLINE ASSESSMENT OF THE INFLUENCE OF VASCULAR RISK FACTORS ON COGNITIVE FUNCTION IN HEALTHY ADULTS AGED 50 AND ABOVE. Alzheimer's & Dementia, 15(7S_Part_22), p1187-p1187.
Creese B, Brooker H, Corbett A, Ismail Z, Aarsland D, Ballard C (2019). P4â248: EVALUATING SHARED GENETIC LIABILITY FOR LATEâLIFE ABNORMAL THOUGHTS AND PERCEPTION (MILD BEHAVIORAL IMPAIRMENT), AND NEUROLOGICAL AND PSYCHIATRIC CONDITIONS. Alzheimer's & Dementia, 15(7S_Part_26), p1374-p1374.
Fox C, Howard RJ, Ballard C, Cross J, Poland F, Knapp MRJ, Henderson C, Teale E, Penhale B, Sahota O, et al (2019). P4â386: PERIâOPERATIVE ENHANCED RECOVERY HIP FRACTURE CARE OF PATIENTS WITH DEMENTIA (PERFECTED): RCT RESULTS. Alzheimer's & Dementia, 15(7S_Part_28), p1448-p1448.
Corbett A, Slowinski P, Ballard C, Aarsland D, Wesnes K, Brooker H (2019). P4â428: COGNITIVE TRAJECTORIES OF HEALTHY OLDER ADULTS OVER THREE YEARS: a LARGEâSCALE LONGITUDINAL ANALYSIS. Alzheimer's & Dementia, 15(7S_Part_28), p1466-p1467.
Fox C, Hammond SP, Shepstone L, Poland F, MacLullich A, Cross J, Knapp MRJ, Henderson C, Sahota O, Penhale B, et al (2019). P4â622: DEMENTIA HOSPITAL CARE RESEARCH PROGRAMME: PERIâOPERATIVE ENHANCED RECOVERY HIP FRACTURE CARE OF PATIENTS WITH DEMENTIA (PERFECTED)—CLUSTER RANDOMISED CONTROL TRIAL RESULTS. Alzheimer's & Dementia, 15(7S_Part_30), p1565-p1565.
McDermid J, Ballard C (2019). P4â627: NO IMPROVEMENT IN NURSING HOME CARE FOR PEOPLE WITH DEMENTIA SINCE THE MILLENNIUM. Alzheimer's & Dementia, 15(7S_Part_30), p1568-p1568.
Corbett A, Brooker H, Hampshire A, Williams G, Wesnes K, Aarsland D, Ballard C (2019). P4â658: INTENSIVE SHORTâTERM ONLINE COGNITIVE TRAINING IN GRAMMATICAL REASONING CONFERS BENEFITS TO COGNITION AND FUNCTION IN OLDER ADULTS: OUTCOMES FROM THE START RANDOMISED CONTROLLED TRIAL. Alzheimer's & Dementia, 15(7S_Part_30), p1583-p1583.
Ballard C, Youakim JM, Coate B, Stankovic S (2019). Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. The journal of prevention of Alzheimer's disease, 6(1), 27-33. Abstract.
Creese BA, Griffiths A, Brooker H, Corbett A, Aarsland D, Ballard C, Ismail Z (2019). Profile of Mild Behavioral Impairment and Factor Structure of the Mild Behavioral Impairment Checklist in Cognitively Normal Older Adults. International Psychogeriatrics
Creese B, Griffiths A, Brooker H, Corbett A, Aarsland D, Ballard C, Ismail Z (2019). Profile of mild behavioral impairment and factor structure of the Mild Behavioral Impairment Checklist in cognitively normal older adults. International Psychogeriatrics, 32(6), 705-717. Abstract.
Leavey N, Hammond SP, Shepstone L, Cross J, Zetterberg H, Cunningham C, MacLullich A, Leiv Otto Watne, Minihane AM, Ballard C, et al (2019). Study protocol: ASCRIBED: the impact of Acute SystematiC inflammation upon cerebRospinal fluId and blood BiomarkErs of brain inflammation and injury in dementia: a study in acute hip fracture patients. BMC Neurology, 19(1). Abstract.
Mueller C, Soysal P, Rongve A, Isik AT, Thompson T, Maggi S, Smith L, Basso C, Stewart R, Ballard C, et al (2019). Survival time and differences between dementia with Lewy bodies and Alzheimer's disease following diagnosis: a meta-analysis of longitudinal studies. Ageing Res Rev, 50, 72-80. Abstract. Author URL.
Husebø BS, Ballard C, Aarsland D, Selbaek G, Slettebo DD, Gulla C, Aasmul I, Habiger T, Elvegaard T, Testad I, et al (2019). The Effect of a Multicomponent Intervention on Quality of Life in Residents of Nursing Homes: a Randomized Controlled Trial (COSMOS). J Am Med Dir Assoc, 20(3), 330-339. Abstract. Author URL.
FitzGerald JM, Perera G, Chang-Tave A, Price A, Rajkumar AP, Bhattarai M, O'Brien JT, Ballard C, Aarsland D, Stewart R, et al (2019). The Incidence of Recorded Delirium Episodes Before and After Dementia Diagnosis: Differences Between Dementia with Lewy Bodies and Alzheimer's Disease. J Am Med Dir Assoc, 20(5), 604-609. Abstract. Author URL.
Brooker H, Wesnes KA, Ballard C, Hampshire A, Aarsland D, Khan Z, Stenton R, Megalogeni M, Corbett A (2019). The relationship between the frequency of number-puzzle use and baseline cognitive function in a large online sample of adults aged 50 and over. Int J Geriatr Psychiatry, 34(7), 932-940. Abstract. Author URL.
El-Hayek YH, Wiley RE, Khoury CP, Daya RP, Ballard C, Evans AR, Karran M, Molinuevo JL, Norton M, Atri A, et al (2019). Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders. Journal of Alzheimer's Disease, 70(2), 321-339. Abstract.
Cummings JL, Tong G, Ballard C (2019). Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. Journal of Alzheimer's Disease, 67(3), 779-794. Abstract.
sabatini S, Ukoumunne O, Ballard C, Brothers A, Kaspar R, Collins R, Kim S, Corbett A, Aarsland D, Hampshire A, et al (2019). UK Validation of Two Measures of Awareness of Age-Related Change (AARC). Abstract.
Fossey J, Garrod L, Tolbol Froiland C, Ballard C, Lawrence V, Testad I (2019). What influences the sustainability of an effective psychosocial intervention for people with dementia living in care homes? a 9 to 12-month follow-up of the perceptions of staff in care homes involved in the WHELD randomised controlled trail. Int J Geriatr Psychiatry, 34(5), 674-682. Abstract. Author URL.
Becker RE, Greig NH, Lahiri DK, Bledsoe J, Majercik S, Ballard C, Aarsland D, Schneider LS, Flanagan D, Govindarajan R, et al (2018). (-)-phenserine and inhibiting pre-programmed cell death: in pursuit of a novel intervention for Alzheimer’s disease. Current Alzheimer Research, 15(9), 883-891. Abstract.
Weintraub D, Norton J, Coate B, Andersson C, Fredericks D, Ballard C (2018). 122 Use of Pimavanserin in Patients with Parkinson’s Disease Psychosis: Subgroup Analysis of Efficacy and Safety in Patients with and Without Cognitive Impairment. CNS Spectrums, 23(1), 77-77.
Pickett J, Bird C, Ballard C, Banerjee S, Brayne C, Cowan K, Clare L, Comas-Herrera A, Corner L, Daley S, et al (2018). A roadmap to advance dementia research in prevention, diagnosis, intervention, and care by 2025. Int J Geriatr Psychiatry, 33(7), 900-906. Abstract. Author URL.
Elliott C, Rojo AI, Ribe E, Broadstock M, Xia W, Morin P, Semenov M, Baillie G, Cuadrado A, Al-Shawi R, et al (2018). A role for APP in Wnt signalling links synapse loss with β-amyloid production. Transl Psychiatry, 8(1). Abstract. Author URL.
Ballard C, Lang I (2018). Alcohol and dementia: a complex relationship with potential for dementia prevention. The Lancet Public Health, 3(3), e103-e104.
Whitfield DR, Francis PT, Ballard C, Williams G (2018). Associations between ZnT3, tau pathology, agitation, and delusions in dementia. Int J Geriatr Psychiatry, 33(8), 1146-1152. Abstract. Author URL.
Vik-Mo AO, Giil LM, Ballard C, Aarsland D (2018). Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study. International Journal of Geriatric Psychiatry, 33(10), 1361-1369. Abstract.
Ballard C (2018). Diagnostic Criteria for Functional Psychosis (2nd edn). By P. Berner, E. Gabriel, H. Katschnig, W. Kieffer, K. Koehler, G. Lenz, D. Nutzinger, H. Schanda and C. Simbandl Cambridge: Cambridge University Press. 1992. 268 pp. £45.00. The British Journal of Psychiatry, 162(2), 291-292.
Erdal A, Flo E, Aarsland D, Ballard C, Slettebo DD, Husebo BS (2018). Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM). Drugs and Aging, 35(6), 545-558. Abstract.
Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, Youakim JM, Owen R, Stankovic S, Tomkinson EB, et al (2018). Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. The Lancet Neurology, 17(3), 213-222. Abstract.
Ballard C, Fossey J, Romeo R, McDermid J (2018). F3â03â01: EFFICACY, COSTâEFFECTIVENESS AND SUSTAINED ENGAGEMENT OF THE IMPROVING WELLâBEING AND HEALTH FOR PEOPLE WITH DEMENTIA (WHELD) PERSONâCENTERED CARE TRAINING PROGRAMME. Alzheimer's & Dementia, 14(7S_Part_18), p999-p999.
Devanand DP, Cummings JL, Ballard C, Foff E, Youakim J, Owen R, Knowles M, Tariot PN, Stankovic S (2018). F4â03â04: a SUMMARY OF THE RATIONALE AND DESIGN OF THE HARMONY STUDY: a PHASE 3 STUDY TO EVALUATE PIMAVANSERIN FOR THE TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH DEMENTIAâRELATED PSYCHOSIS. Alzheimer's & Dementia, 14(7S_Part_26), p1387-p1387.
Petyaeva A, Kajander M, Lawrence V, Clifton L, Thomas AJ, Ballard C, Leroi I, Briggs M, Closs J, Dening T, et al (2018). Feasibility of a staff training and support programme to improve pain assessment and management in people with dementia living in care homes. Int J Geriatr Psychiatry, 33(1), 221-231. Abstract. Author URL.
Chen C, Li X, Ge G, Liu J, Biju KC, Laing SD, Qian Y, Ballard C, He Z, Masliah E, et al (2018). GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice. Sci Rep, 8(1). Abstract. Author URL.
Creese B, Bell E, Johar I, Francis P, Ballard C, Aarsland D (2018). Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analyses. Am J Med Genet B Neuropsychiatr Genet, 177(2), 232-241. Abstract. Author URL.
Mueller C, Perera G, Rajkumar AP, Bhattarai M, Price A, O'Brien JT, Ballard C, Stewart R, Aarsland D (2018). Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 10, 143-152. Abstract.
Ballard C, Corbett A, Orrell M, Williams G, Moniz-Cook E, Romeo R, Woods B, Garrod L, Testad I, Woodward-Carlton B, et al (2018). Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: a cluster-randomised controlled trial. PLoS Med, 15(2). Abstract. Author URL.
Cummings JL, Atri A, Ballard C, Boneva N, FrĂślich L, Molinuevo JL, Raket LL, Tariot PN (2018). Insights into globalization: Comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program. Alzheimer's Research and Therapy, 10(1). Abstract.
Ballard CG, Mohan RNC, Handy S, Dodwell D (2018). Medication compliance and dispensing among psychogeriatric patients. BJPsych Bulletin, 15(10), 624-625.
Surr C, Holloway I, Walwyn RE, Griffiths AW, Meads D, Kelley R, Martin A, McLellan V, Ballard C, Fossey J, et al (2018). O3â08â06: RESULTS OF a PRAGMATIC, CLUSTER RANDOMISED, CONTROLLED TRIAL OF THE EFFECTIVENESS AND COSTâEFFECTIVENESS OF DEMENTIA CARE MAPPING (DCM) IN UK CARE HOMES (DCM EPIC TRIAL). Alzheimer's & Dementia, 14(7S_Part_19), p1035-p1035.
McDermid J, Fossey J, Da Silva MV, Ballard C (2018). O4â03â06: a RANDOMIZED CONTROLLED TRIAL EVALUATING THE IMPACT OF AN EâLEARNING INTERVENTION BASED ON THE IMPROVING WELLâBEING AND HEALTH FOR PEOPLE WITH DEMENTIA (WHELD) PERSONâCENTRED CARE TRAINING PROGRAMME. Alzheimer's & Dementia, 14(7S_Part_26), p1406-p1406.
Ballard C, Romeo R, Knapp MRJ, Testad I, Fossey J (2018). O5â07â05: HEALTH ECONOMIC ANALYSIS OF THE IMPROVING WELLâBEING AND HEALTH FOR PEOPLE WITH DEMENTIA (WHELD) PERSONâCENTRED CARE TRAINING FOR THE TREATMENT OF AGITATION IN PEOPLE WITH DEMENTIA: a CLUSTER RANDOMIZED CONTROLLED TRIAL. Alzheimer's & Dementia, 14(7S_Part_31), p1663-p1664.
Huntley J, Corbett A, Wesnes K, Brooker H, Stenton R, Hampshire A, Ballard C (2018). Online assessment of risk factors for dementia and cognitive function in healthy adults. Int J Geriatr Psychiatry, 33(2), e286-e293. Abstract. Author URL.
Creese B, Bergh S, Aarsland D, Andersen F, Brooker H, Corbett A, Khan Z, Megalogeni M, Rongve A, Stordal E, et al (2018). P1â151: GENETIC OVERLAP BETWEEN PSYCHOTIC SYMPTOMS ACROSS THE LIFESPAN: FINDINGS FROM SCHIZOPHRENIA, COGNITIVELY NORMAL OLDER ADULTS AND ALZHEIMER'S DISEASE. Alzheimer's & Dementia, 14(7S_Part_6).
Brooker H, Creese B, Ismail Z, Khan Z, Megalogeni M, Corbett A, Hampshire A, Aarsland D, Ballard C, Wesnes K, et al (2018). P1â523: THE RELATIONSHIP BETWEEN THE MILD BEHAVIOURAL IMPAIRMENT CHECKLIST (MBIâC) TOTAL SCORE AND CORE ASPECTS OF COGNITIVE FUNCTION IN OLDER ADULTS. Alzheimer's & Dementia, 14(7S_Part_9).
Ballard C, Brooker H, Khan Z, Corbett A, Aarsland D, Wesnes K (2018). P1â658: REPEATED COGNITIVE TESTING REDUCES SAMPLE SIZE NECESSARY TO DETECT CLINICALLY RELEVANT EFFECTS. Alzheimer's & Dementia, 14(7S_Part_10), p595-p595.
Aman Y, Troakes C, Ballard C, Malcangio M (2018). P2â010: INVOLVEMENT OF ELEVATED NEUROINFLAMMATION IN KEY REGIONS OF THE PAIN PATHWAY IN NOCICEPTIVE PROCESSING IN ALZHEIMER'S DISEASE. Alzheimer's & Dementia, 14(7S_Part_12), p668-p668.
Creese B, Pishva E, Proitsi P, Smith RG, Ballard C, van den Hove DLA, Mill J, Lunnon K (2018). P2â143: PSYCHOSISâASSOCIATED EPIGENETIC VARIATION IN PATIENTS WITH ALZHEIMER'S DISEASE ACROSS CORTICAL BRAIN REGIONS. Alzheimer's & Dementia, 14(7S_Part_13), p723-p723.
Wesnes K, Brooker H, Creese B, Khan Z, Megalogeni M, Corbett A, Davis K, Hotopf M, Aarsland D, Ballard C, et al (2018). P2â483: DEPRESSION IS ASSOCIATED WITH IMPAIRMENT IN COGNITIVE FUNCTION IN ADULTS AGED 50 AND OVER. Alzheimer's & Dementia, 14(7S_Part_16).
Erdal A, Flo E, Aarsland D, Ballard C, Husebø BS (2018). P3â001: a RANDOMIZED, PLACEBOâCONTROLLED TRIAL TO INVESTIGATE SAFETY OF BUPRENORPHINE TRANSDERMAL SYSTEM FOR PAIN MANAGEMENT IN PEOPLE WITH DEMENTIA. Alzheimer's & Dementia, 14(7S_Part_19), p1062-p1062.
Ballard C, Youakim J, Coate B, Stankovic S (2018). P3â002: PIMAVANSERIN IN ALZHEIMER'S DISEASE PSYCHOSIS: SUBGROUP ANALYSIS OF THE MORE SEVERE POPULATION. Alzheimer's & Dementia, 14(7S_Part_19), p1062-p1062.
Ballard C, Atri A, Boneva N, Cummings JL, FrĂślich L, Molinuevo JL, Raket LL, Tariot PN (2018). P3â003: IDENTIFYING ENRICHMENT FACTORS THAT PREDICT ALZHEIMER'S DISEASE PROGRESSION: AN ANALYSIS OF THREE RANDOMIZED, CONTROLLED TRIALS. Alzheimer's & Dementia, 14(7S_Part_19), p1062-p1063.
Fox C, Arthur A, Ballard C, Howard RJ, Maidment ID, Pakpahan E, Richardson K, Boyd P, Aldus C, Loke Y, et al (2018). P3â023: BEYOND ANTIPSYCHOTICS: EXPLORING EFFICACY AND HARMS OF ZâDRUGS FOR SLEEP DISTURBANCE ON THE PROGRESSION OF KEY DEMENTIA OUTCOMES. Alzheimer's & Dementia, 14(7S_Part_20), p1072-p1073.
Femminella GD, Fan Z, Frangou E, Love S, Calsolaro V, Holmes C, Ritchie CW, Lawrence RM, McFarlane B, Tadros G, et al (2018). P3â225: PERIPHERAL INSULIN RESISTANCE DOES NOT CORRELATE WITH CEREBRAL GLUCOSE METABOLIC RATE IN NONâDIABETIC ALZHEIMER'S PATIENTS. Alzheimer's & Dementia, 14(7S_Part_22), p1157-p1158.
Creese B, Brooker H, Ismail Z, Aarsland D, Corbett A, Khan Z, Megalogeni M, Ballard C, Wesnes K (2018). P3â554: PROFILE OF MILD BEHAVIOURAL IMPAIRMENT IN a POPULATIONâBASED SAMPLE OF ADULTS AGED 50 AND OVER: INITIAL FINDINGS FROM THE PROTECT STUDY. Alzheimer's & Dementia, 14(7S_Part_25).
Ballard C, Murphy C (2018). P4â017: CLINICAL TRIAL PIPELINES FOR ALZHEIMER'S DISEASE POSE CHALLENGES FOR FUTURE EFFECTIVE TREATMENT AND THERAPIES. Alzheimer's & Dementia, 14(7S_Part_27), p1439-p1439.
Aman Y, Pitcher T, Ballard C, Malcangio M (2018). P4â018: IMPAIRED CHRONIC PAINâLIKE BEHAVIOUR AND DISRUPTION OF OPIOIDERGIC SYSTEM IN TASTPM MODEL OF ALZHEIMER'S DISEASE. Alzheimer's & Dementia, 14(7S_Part_27), p1439-p1440.
Ballard C, Gatt A (2018). P4â026: a TRIAGE SYSTEM FOR IDENTIFYING CANDIDATE COMPOUNDS FOR REPURPOSING AS POTENTIAL THERAPEUTICS FOR AD (GATT). Alzheimer's & Dementia, 14(7S_Part_27), p1443-p1443.
Richardson K, Loke Y, Savva GM, Howard RJ, Boyd P, Aldus C, Maidment ID, Steel N, Arthur A, Ballard C, et al (2018). P4â387: UNINTENDED EFFECTS OF ZâDRUGS (ZOLPIDEM, ZOPICLONE AND ZALEPLON) IN PEOPLE LIVING WITH DEMENTIA. Alzheimer's & Dementia, 14(7S_Part_31), p1622-p1622.
Espay AJ, Guskey MT, Norton JC, Coate B, Vizcarra JA, Ballard C, Factor SA, Friedman JH, Lang AE, Larsen NJ, et al (2018). Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. Mov Disord, 33(11), 1769-1776. Abstract. Author URL.
Cummings J, Ballard C, Tariot P, Owen R, Foff E, Youakim J, Norton J, Stankovic S (2018). Pimavanserin: Potential Treatment for Dementia-Related Psychosis. The journal of prevention of Alzheimer's disease, 5(4), 253-258. Abstract.
Duncan OF, Granat L, Ranganathan R, Singh VK, Mazaud D, Fanto M, Chambers D, Ballard CG, Bateman JM (2018). Ras-ERK-ETS inhibition alleviates neuronal mitochondrial dysfunction by reprogramming mitochondrial retrograde signaling. PLoS Genet, 14(7). Abstract. Author URL.
Simpkin AJ, Simkovic F, Thomas JMH, Savko M, Lebedev A, Uski V, Ballard C, Wojdyr M, Wu R, Sanishvili R, et al (2018). SIMBAD: a sequence-independent molecular-replacement pipeline. Acta Crystallogr D Struct Biol, 74(Pt 7), 595-605. Abstract. Author URL.
Bereczki E, Branca RM, Francis PT, Pereira JB, Baek JH, HortobĂĄgyi T, Winblad B, Ballard C, LehtiĂś J, Aarsland D, et al (2018). Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. Brain, 141(2), 582-595. Abstract.
Ballard C, Testad I (2018). TIME in the Context of Emerging Evidence Regarding Training Interventions for Dementia in Nursing Homes. Am J Geriatr Psychiatry, 26(1), 39-41. Author URL.
Creese B, Da Silva MV, Johar I, Ballard C (2018). The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease. Expert Rev Neurother, 18(6), 461-467. Abstract. Author URL.
Erdal A, Flo E, Aarsland D, Selbaek G, Ballard C, Slettebo DD, Husebo BS (2018). Tolerability of buprenorphine transdermal system in nursing home patients with advanced dementia: a randomized, placebo-controlled trial (DEP.PAIN.DEM). Clinical Interventions in Aging, 13, 935-946. Abstract.
Skogseth R, HortobĂĄgyi T, Soennesyn H, Chwiszczuk L, Ffytche D, Rongve A, Ballard C, Aarsland D (2017). Accuracy of clinical diagnosis of dementia with lewy bodies versus neuropathology. Journal of Alzheimer's Disease, 59(4), 1139-1152. Abstract.
Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C (2017). Cognitive decline in Parkinson disease. Nat Rev Neurol, 13(4), 217-231. Abstract. Author URL.
Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, Banerjee S, Woods B, Perneczky R, Lafortune L, et al (2017). Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. PLoS One, 12(6). Abstract. Author URL.
Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, Banerjee S, Barber R, Bentham P, Brown RG, et al (2017). Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). International Journal of Geriatric Psychiatry, 32(12), 1205-1216. Abstract.
Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, et al (2017). Dementia prevention, intervention, and care. The Lancet, 390(10113), 2673-2734.
Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, Banerjee S, Woods B, Perneczky R, Lafortune L, et al (2017). Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technol Assess, 21(26), 1-192. Abstract. Author URL.
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, et al (2017). Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium. NEUROLOGY, 89(1), 88-100. Author URL.
Khan A, Corbett A, Ballard C (2017). Emerging amyloid and tau targeting treatments for Alzheimer's disease. Expert Rev Neurother, 17(7), 697-711. Abstract. Author URL.
Khan A, Corbett A, Ballard C (2017). Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets. Expert Rev Neurother, 17(7), 683-695. Abstract. Author URL.
Rajkumar AP, Ballard C, Fossey J, Orrell M, Moniz-Cook E, Woods RT, Murray J, Whitaker R, Stafford J, Knapp M, et al (2017). Epidemiology of Pain in People with Dementia Living in Care Homes: Longitudinal Course, Prevalence, and Treatment Implications. J Am Med Dir Assoc, 18(5), 453.e1-453.e6. Abstract. Author URL.
Mueller C, Ballard C, Corbett A, Aarsland D (2017). Historical landmarks in dementia with Lewy bodies. Lancet Neurol, 16(5). Author URL.
Ballard C, Orrell M, Sun Y, Moniz-Cook E, Stafford J, Whitaker R, Woods B, Corbett A, Banerjee S, Testad I, et al (2017). Impact of antipsychotic review and non-pharmacological intervention on health-related quality of life in people with dementia living in care homes: WHELD-a factorial cluster randomised controlled trial. Int J Geriatr Psychiatry, 32(10), 1094-1103. Abstract. Author URL.
Gatt A, Ekonomou A, Somani A, Thuret S, Howlett D, Corbett A, Johnson M, Perry E, Attems J, Francis P, et al (2017). Importance of Proactive Treatment of Depression in Lewy Body Dementias: the Impact on Hippocampal Neurogenesis and Cognition in a Post-Mortem Study. Dement Geriatr Cogn Disord, 44(5-6), 283-293. Abstract. Author URL.
Chong JR, Chai YL, Lee JH, Howlett D, Attems J, Ballard CG, Aarsland D, Francis PT, Chen CP, Lai MKP, et al (2017). Increased transforming growth factor β2 in the neocortex of Alzheimer's disease and dementia with lewy bodies is correlated with disease severity and soluble Aβ<inf>42</inf> load. Journal of Alzheimer's Disease, 56(1), 157-166. 42 load' data-abstract='Background: of the three transforming growth factor (TGF)-β isoforms known, TGFβ1 deficits have been widely reported in Alzheimer's disease (AD) and studied as a potential therapeutic target. In contrast, the status of TGFβ2, which has been shown to mediate amyloid-β (Aβ)-mediated neuronal death, are unclear both in AD and in Lewy body dementias (LBD) with differential neuritic plaque and neurofibrillary tangle burden. Objective: to measure neocortical TGFβ2 levels and their correlations with neuropathological and clinical markers of disease severity in a well-characterized cohort of AD as well as two clinical subtypes of LBD, dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), known to manifest relatively high and low Aβ plaque burden, respectively. Methods: Postmortem samples from temporal cortex (BA21) were measured for TGFβ2 using a Luminex-based platform, and correlated with scores for neuritic plaques, neurofibrillary tangles, α-synuclein pathology, dementia severity (as measured by annual decline of Mini-Mental State Examination scores) as well as soluble and total fractions of brain Aβ42. Results: TGFβ2 was significantly increased in AD and DLB, but not in PDD. TGFβ2 also correlated with scores for neurofibrillary tangles, Lewy bodies (within the LBD group), dementia severity, and soluble Aβ42 concentration, but not with neuritic plaque scores, total Aβ42, or monomeric α-synuclein immunoreactivity. Conclusions: TGFβ2 is increased in the temporal cortex of AD and DLB, and its correlations with neuropathological and clinical markers of disease severity as well as with soluble Aβ42 load suggest a potential pathogenic role in mediating the neurotoxicity of non-fibrillar Aβ. Our study also indicates the potential utility of targeting TGFβ2 in pharmacotherapeutic approaches to AD and DLB.' onclick='modalCall(this);return false;'>Abstract.
Bath PM, Scutt P, Blackburn DJ, Ankolekar S, Krishnan K, Ballard C, Burns A, Mant J, Passmore P, Pocock S, et al (2017). Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main results from the pilot prevention of Decline in Cognition after Stroke trial' (PODCAST) randomised controlled trial. PLoS ONE, 12(1). Abstract.
Chai YL, Xing H, Chong JR, Francis PT, Ballard CG, Chen CP, Lai MKP (2017). Mitochondrial Translocase of the Outer Membrane Alterations May Underlie Dysfunctional Oxidative Phosphorylation in Alzheimer's Disease. Journal of Alzheimer's Disease, 61(2), 793-801. Abstract.
LanctĂ´t KL, Amatniek J, Ancoli-Israel S, Arnold SE, Ballard C, Cohen-Mansfield J, Ismail Z, Lyketsos C, Miller DS, Musiek E, et al (2017). Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 3(3), 440-449. Abstract.
Velayudhan L, Ffytche D, Ballard C, Aarsland D (2017). New Therapeutic Strategies for Lewy Body Dementias. Current Neurology and Neuroscience Reports, 17(9). Abstract.
Hammond SP, Cross JL, Shepstone L, Backhouse T, Henderson C, Poland F, Sims E, MacLullich A, Penhale B, Howard R, et al (2017). PERFECTED enhanced recovery (PERFECT-ER) care versus standard acute care for patients admitted to acute settings with hip fracture identified as experiencing confusion: study protocol for a feasibility cluster randomized controlled trial. Trials, 18(1). Abstract. Author URL.
Alghamdi A, Vallortigara J, Howlett DR, Broadstock M, HortobĂĄgyi T, Ballard C, Thomas AJ, O'Brien JT, Aarsland D, Attems J, et al (2017). Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. J Alzheimers Dis, 57(2), 373-386. Abstract. Author URL.
Ffytche DH, Pereira JB, Ballard C, Chaudhuri KR, Weintraub D, Aarsland D (2017). Risk factors for early psychosis in PD: Insights from the Parkinson's Progression markers initiative. Journal of Neurology, Neurosurgery and Psychiatry, 88(4), 325-331. Abstract.
Bereczki E, Bogstedt A, HĂśglund K, Tsitsi P, Brodin L, Ballard C, Svenningsson P, Aarsland D (2017). Synaptic proteins in CSF relate to Parkinson's disease stage markers. NPJ Parkinsons Dis, 3 Abstract. Author URL.
Husebø BS, Ballard C, Cohen-Mansfield J, Aarsland D (2017). THE RESPONSE OF AGITATED BEHAVIOR TO PAIN MANAGEMENT IN PERSONS WITH DEMENTIA. RCT TRIAL. Innovation in Aging, 1(suppl_1), 21-22.
Husebø BS, Ballard C, Cohen-Mansfield J, Aarsland D (2017). THE RESPONSE OF AGITATED BEHAVIOR TO PAIN MANAGEMENT IN PERSONS WITH DEMENTIA. RCT TRIAL. Innovation in aging, 1(Suppl 1), 21-22. Abstract.
Romeo R, Knapp M, Salverda S, Orrell M, Fossey J, Ballard C (2017). The cost of care homes for people with dementia in England: a modelling approach. International Journal of Geriatric Psychiatry, 32(12), 1466-1475. Abstract.
Mueller C, Ballard C, Corbett A, Aarsland D (2017). The prognosis of dementia with Lewy bodies. Lancet Neurol, 16(5), 390-398. Abstract. Author URL.
Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D (2017). The psychosis spectrum in Parkinson disease. Nat Rev Neurol, 13(2), 81-95. Abstract. Author URL.
Wesnes KA, Brooker H, Ballard C, McCambridge L, Stenton R, Corbett A (2017). Utility, reliability, sensitivity and validity of an online test system designed to monitor changes in cognitive function in clinical trials. Int J Geriatr Psychiatry, 32(12), e83-e92. Abstract. Author URL.
Atri A, FrĂślich L, Ballard C, Tariot P, Molinuevo JL, Boneva N, Windfeld K, Cummings JL (2017). [DTâ02–02]: IDALOPIRDINE, a 5âHT6 ANTAGONIST, AS ADJUNCTIVE THERAPY TO ACETYLCHOLINESTERASE INHIBITORS IN PATIENTS WITH MILDâMODERATE ALZHEIMER's DISEASE: KEY OUTCOMES FROM THE STAR PHASE III PROGRAM. Alzheimer's & Dementia, 13(7S_Part_30), p1476-p1477.
Ballard C, Fossey J, Corbett A, Orrell M, Romeo R, MonizâCook E, Woods B, Whitaker R (2017). [F1–01–01]: IMPACT OF WHELD INTERVENTION ON NEUROPSYCHIATRIC SYMPTOMS, ANTIPSYCHOTIC USE AND QUALITY OF LIFE IN PEOPLE WITH DEMENTIA LIVING IN NURSING HOMES: a CLUSTERâRANDOMIZED TRIAL. Alzheimer's & Dementia, 13(7S_Part_3), p171-p171.
Buttery AK, Hopper A, Ballard C, Kinirons M, Sauer J, Lawrence RM, Saiz AB, Martin FC (2017). [O4–05–03]: OPTIMISING FALLS RISK ASSESSMENT IN MEMORY SERVICES: INVESTIGATING SYSTEMâWIDE INTEGRATION OF FALL PREVENTION EVIDENCE INTO PRACTICE. Alzheimer's & Dementia, 13(7S_Part_25), p1239-p1239.
Hortobagyi T, Alghamdi A, Vallortigara J, Whitfield D, Howlett D, Broadstock M, Ballard C, Attems J, Aarsland D, Francis PT, et al (2017). [P1–235]: RELATIONSHIP BETWEEN PATHOLOGY SCORES, CLINICAL DATA AND EXPRESSION LEVELS OF PROTEASOME SUBâUNITS IN ALZHEIMER's DISEASE AND LEWY BODY DEMENTIAS. Alzheimer's & Dementia, 13(7S_Part_7).
Creese B, Ballard C, Aarsland D, Bergh S, Rongve A, Selbaek G (2017). [P1–299]: AN EVALUATION OF PREDICTORS AND COGNITIVE DECLINE ASSOCIATED WITH PERSISTENT AND TRANSIENT PSYCHOTIC SYMPTOMS IN ALZHEIMER's DISEASE. Alzheimer's & Dementia, 13(7S_Part_7), p367-p367.
Johar I, Aarsland D, Ballard C, Bergh S, Fossey J, Kirkevold Ă, Medboen IT, Orrell M, Rongve A, Selbaek G, et al (2017). [P1–309]: PREVALENCE AND COâMORBIDITY OF APATHY AND DEPRESSION IN ALZHEIMER's DISEASE. Alzheimer's & Dementia, 13(7S_Part_7), p371-p372.
Rajamani APR, Ballard C, Fossey J, Orrell M, MonizâCook E, Woods R, Murray J, Whitaker R, Stafford J, Knapp MRJ, et al (2017). [P1–562]: EPIDEMIOLOGY OF PAIN IN PEOPLE WITH DEMENTIA LIVING IN CARE HOMES: LONGITUDINAL COURSE, PREVALENCE AND TREATMENT IMPLICATIONS. Alzheimer's & Dementia, 13(7S_Part_10), p509-p510.
Mueller C, Perera G, Rajamani A, Bhattarai M, Stewart R, Ballard C, Aarsland D (2017). [P1–564]: RISK AND DURATION OF HOSPITALIZATION IN DEMENTIA WITH LEWY BODIES. Alzheimer's & Dementia, 13(7S_Part_10), p510-p511.
Corbett A, Ballard C, Brooker H, Hampshire A, Stenton R, McCambridge L, Wesnes K (2017). [P1–599]: ONLINE COGNITIVE TRAINING INCREASES NEUROGENESIS AND IMPROVES COGNITIVE PERFORMANCE IN ADULTS OVER 50. Alzheimer's & Dementia, 13(7S_Part_10), p525-p525.
Brooker H, Wesnes K, McCambridge L, Ballard C, Corbett A (2017). [P1–612]: THE RELATIONSHIP BETWEEN SELFâREPORTED MONTHLY PHYSICAL EXERCISE FREQUENCY AND COGNITIVE FUNCTION. Alzheimer's & Dementia, 13(7S_Part_10), p531-p531.
Wesnes K, Brooker H, Corbett A, McCambridge L, Ballard C (2017). [P1–614]: THE ASSOCIATION BETWEEN COGNITIVE FUNCTION AND ACTIVITIES OF DAILY LIVING IN HEALTHY ADULTS AGED 50 AND OVER. Alzheimer's & Dementia, 13(7S_Part_10), p532-p532.
Hortobagyi T, Alghamdi A, Whitfield D, Vallortigara J, Howlett D, Broadstock M, Ballard C, Thomas A, Attems J, Aarsland D, et al (2017). [P2–204]: RPT6, 20S αâ6 AND αâ3 PROTEASOME SUBUNIT LEVELS AND ASSOCIATION WITH COGNITIVE DECLINE IN ALZHEIMER's DISEASE AND LEWY BODY DEMENTIAS. Alzheimer's & Dementia, 13(7S_Part_14), p684-p684.
Wesnes K, Brooker H, Corbett A, McCambridge L, Ballard C (2017). [P2–581]: THE RELATIONSHIP BETWEEN THE FREQUENCY OF WORD PUZZLE USE AND COGNITIVE FUNCTION IN a LARGE SAMPLE OF ADULTS AGED 50 TO 96 YEARS. Alzheimer's & Dementia, 13(7S_Part_17).
Alwesmi M, Ballard C, Francis PT (2017). [P3–180]: THE RELATIONSHIP OF SYNAPTIC PROTEINS WITH AGE IN DOWN SYNDROME. Alzheimer's & Dementia, 13(7S_Part_21), p1003-p1003.
Huntley JD, Corbett A, Wesnes K, Hampshire A, Ballard C (2017). [P3–563]: RISK FACTORS FOR DEMENTIA AND COGNITIVE FUNCTION IN HEALTHY ADULTS. Alzheimer's & Dementia, 13(7S_Part_24), p1194-p1195.
Wesnes K, Brooker H, Corbett A, Ballard C (2017). [P3–582]: CAN INCREASING THE DIFFICULTY OF A NEUROGENESISâSENSITIVE TASK ENHANCE ITS SENSITIVITY TO DETECTING AGEâRELATED DECLINES IN VOLUNTEERS AGED 50 TO 96?. Alzheimer's & Dementia, 13(7S_Part_25).
Webster LA, Groskreutz D, GrinbergsâSaull A, Howard RJ, O'Brien JT, Mountain G, Banerjee S, Woods B, Perneczky R, Lafortune L, et al (2017). [P4–019]: a CORE OUTCOME SET FOR DISEASE MODIFICATION TRIALS IN MILDâTOâMODERATE DEMENTIA: a SYSTEMATIC REVIEW AND CONSENSUS RECOMMENDATIONS. Alzheimer's & Dementia, 13(7S_Part_26), p1261-p1262.
Greenan C, Murphy L, Yu LM, Kehoe PG, Coulthard E, Bath P, Stewart R, Jones R, Corbett A, Thomas A, et al (2016). A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine for the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): Study protocol. Trials, 17(1). Abstract.
Enache D, Fereshtehnejad SM, KĂĽreholt I, Cermakova P, Garcia-Ptacek S, Johnell K, Religa D, Jelic V, Winblad B, Ballard C, et al (2016). Antidepressants and mortality risk in a dementia cohort: data from SveDem, the Swedish Dementia Registry. Acta Psychiatrica Scandinavica, 134(5), 430-440. Abstract.
SelbĂŚk G, Aarsland D, Ballard C, Engedal K, Langballe EM, Benth JĹ , Bergh S (2016). Antipsychotic Drug Use is Not Associated with Long-Term Mortality Risk in Norwegian Nursing Home Patients. Journal of the American Medical Directors Association, 17(5), 464.e1-464.e7. Abstract.
Rajkumar AP, Ballard C, Fossey J, Corbett A, Woods B, Orrell M, Prakash R, Moniz-Cook E, Testad I (2016). Apathy and its Response to Antipsychotic Review and Nonpharmacological Interventions in People with Dementia Living in Nursing Homes: WHELD, a Factorial Cluster Randomized Controlled Trial. Journal of the American Medical Directors Association, 17(8), 741-747. Abstract.
Lovestone S, Rossor M, Gallacher J, Ritchie C, Burn D, Hyslop PSG, Mackay C, Matthews PM, Ballard C, Georges J, et al (2016). Better together for better dementia research and care. The Lancet Psychiatry, 3(6), 503-504.
Rongve A, Soennesyn H, Skogseth R, Oesterhus R, HortobĂĄgyi T, Ballard C, Auestad BH, Aarsland D (2016). Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study. BMJ Open, 6(2). Abstract.
Vallortigara J, Whitfield D, Quelch W, Alghamdi A, Howlett D, HortobĂĄgyi T, Johnson M, Attems J, O'Brien JT, Thomas A, et al (2016). Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. Journal of Alzheimer's Disease, 50(1), 101-110. Abstract.
Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, et al (2016). Defeating Alzheimer's disease and other dementias: a priority for European science and society. The Lancet Neurology, 15(5), 455-532.
Ballard C, Mobley W, Hardy J, Williams G, Corbett A (2016). Dementia in Down's syndrome. Lancet Neurol, 15(6), 622-636. Abstract. Author URL.
Gatt AP, Duncan OF, Attems J, Francis PT, Ballard CG, Bateman JM (2016). Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency. Movement Disorders, 31(3), 352-359. Abstract.
Corbett A, Ballard C (2016). Dextromethorphan and quinidine are suitable for off-label short-term treatment of agitation in people with Alzheimer's disease following first-line non-drug approaches. Evid Based Med, 21(1). Author URL.
Surr CA, Walwyn REA, Lilley-Kelly A, Cicero R, Meads D, Ballard C, Burton K, Chenoweth L, Corbett A, Creese B, et al (2016). Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial. Trials, 17(1). Abstract. Author URL.
Winblad B, Qiu C, Ballard C, Johansson G (2016). Evidence-based prevention and treatment of dementia – Authors' reply. The Lancet Neurology, 15(10), 1007-1008.
Brooker DJ, Latham I, Evans SC, Jacobson N, Perry W, Bray J, Ballard C, Fossey J, Pickett J (2016). FITS into practice: Translating research into practice in reducing the use of anti-psychotic medication for people with dementia living in care homes. Aging and Mental Health, 20(7), 709-718. Abstract.
Lawrence V, Fossey J, Ballard C, Ferreira N, Murray J (2016). Helping staff to implement psychosocial interventions in care homes: Augmenting existing practices and meeting needs for support. International Journal of Geriatric Psychiatry, 31(3), 284-293. Abstract.
Ballard C, Orrell M, YongZhong S, Moniz-Cook E, Stafford J, Whittaker R, Woods B, Corbett A, Garrod L, Khan Z, et al (2016). Impact of Antipsychotic Review and Nonpharmacological Intervention on Antipsychotic Use, Neuropsychiatric Symptoms, and Mortality in People with Dementia Living in Nursing Homes: a Factorial Cluster-Randomized Controlled Trial by the Well-Being and Health for People with Dementia (WHELD) Program. Am J Psychiatry, 173(3), 252-262. Abstract. Author URL.
Mills R, Ballard C, Isaacson S, Williams H, Corbett A, Coate B, Pahwa R, Rascol O, Burn D (2016). Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson’s disease psychosis (PDP). Parkinsonism & Related Disorders, 22, e91-e92.
Xing H, Lim YA, Chong JR, Lee JH, Aarsland D, Ballard CG, Francis PT, Chen CP, Lai MKP (2016). Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias. Molecular Brain, 9(1). Abstract.
Lee JH, Francis PT, Ballard CG, Aarsland D, Kalaria RN, Wong PTH, Chen CP, Lai MKP (2016). Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson's Disease Dementia. Journal of Parkinson's Disease, 6(4), 733-739. Abstract.
Rongve A, Ballard C, Aarsland D (2016). Non-Alzheimer Dementias. Journal of Geriatric Psychiatry and Neurology, 29(5), 247-248.
Khan Z, Ballard C (2016). O3â01â01: Nonverbal Communication and Quality of Life of People with Dementia. Alzheimer's & Dementia, 12(7), p279-p279.
Aarsland D, Skogseth RE, Chwiszczuk LJ, Sonnesyn H, Rongve A, Ballard C, Hortobagyi T (2016). O3â04â02: ClinicoâPathologic Correlations in Dementia with Lewy Bodies (DLB): a Prospective Cohort Study. Alzheimer's & Dementia, 12(7S_Part_6), p291-p291.
Ballard C, Fossey J, Group WR (2016). P1â428: Wheld: an RCT of an Optimized NonâPharmacological Intervention to Improve Agitation and Quality of Life in 1006 People with Dementia Living in Nursing Homes. Alzheimer's & Dementia, 12(7S_Part_12), p599-p599.
Puangmalai N, Thangnipon W, Somani A, Ballard C, Broadstock M (2016). P3â136: a Genetically Immortalized Human Stem Cell Line: a Promising New Tool for Alzheimer’s Disease Therapy. Alzheimer's & Dementia, 12(7S_Part_18), p871-p871.
Aman Y, Pitcher T, Simeoli R, Ballard C, Malcangio M (2016). Reduced thermal sensitivity and increased opioidergic tone in the TASTPM mouse model of Alzheimer's disease. Pain, 157(10), 2285-2296. Abstract.
Bereczki E, Francis PT, Howlett D, Pereira JB, HĂśglund K, Bogstedt A, Cedazo-Minguez A, Baek JH, HortobĂĄgyi T, Attems J, et al (2016). Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. Alzheimer's and Dementia, 12(11), 1149-1158. Abstract.
Sultana J, Fontana A, Giorgianni F, Pasqua A, Cricelli C, Spina E, Gambassi G, Ivanovic J, Ferrajolo C, Molokhia M, et al (2016). The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: a Population-Based Study. CNS Drugs, 30(11), 1097-1109. Abstract.
Baek JH, Whitfield D, Howlett D, Francis P, Bereczki E, Ballard C, HortobĂĄgyi T, Attems J, Aarsland D (2016). Unfolded protein response is activated in Lewy body dementias. Neuropathology and Applied Neurobiology, 42(4), 352-365. Abstract.
Khan A, Kalaria RN, Corbett A, Ballard C (2016). Update on Vascular Dementia. J Geriatr Psychiatry Neurol, 29(5), 281-301. Abstract. Author URL.
Ballard C, Thomas A, Gerry S, Yu L-M, Aarsland D, Merritt C, Corbett A, Davison C, Sharma N, Khan Z, et al (2015). A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People with Alzheimer's Disease (MAIN-AD). JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 16(4), 316-322. Author URL.
Zuidema SU, Johansson A, Selbaek G, Murray M, Burns A, Ballard C, Koopmans RTCM (2015). A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practice. International Psychogeriatrics, 27(11), 1849-1859. Abstract.
Puangmalai N, Somani A, Thangnipon W, Ballard C, Broadstock M (2015). A genetically immortalized human stem cell line: a promising new tool for Alzheimer’s disease therapy. EXCLI Journal, 14, 1135-1144. Abstract.
Livingston G, Frankish H (2015). A global perspective on dementia care: a Lancet Commission. The Lancet, 386(9997), 933-934.
Ferreira N, Owen A, Mohan A, Corbett A, Ballard C (2015). Associations between cognitively stimulating leisure activities, cognitive function and age-related cognitive decline. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 30(4), 422-430. Author URL.
Scutt P, Blackburn D, Krishnan K, Ballard C, Burns A, Ford GA, Mant J, Passmore P, Pocock S, Reckless J, et al (2015). Baseline characteristics, analysis plan and report on feasibility for the Prevention of Decline in Cognition After Stroke Trial (PODCAST). Trials, 16(1). Abstract.
Husebo BS, Flo E, Aarsland D, Selbaek G, Testad I, Gulla C, Aasmul I, Ballard C (2015). COSMOS--improving the quality of life in nursing home patients: protocol for an effectiveness-implementation cluster randomized clinical hybrid trial. Implement Sci, 10 Abstract. Author URL.
Whitfield DR, Vallortigara J, Alghamdi A, HortobĂĄgyi T, Ballard C, Thomas AJ, O'Brien JT, Aarsland D, Francis PT (2015). Depression and synaptic zinc regulation in alzheimer disease, dementia with lewy bodies, and parkinson disease dementia. American Journal of Geriatric Psychiatry, 23(2), 141-148. Abstract.
Green D, Ballard C, Kunst G (2015). Depth of anaesthesia optimisation and postoperative cognitive dysfunction. British Journal of Anaesthesia, 114(2), 343-344.
Ballard C, Sharp S, Corbett A (2015). Dextromethorphan and Quinidine for Treating Agitation in Patients with Alzheimer Disease Dementia. JAMA, 314(12), 1233-1235. Author URL.
Corbett A, Williams G, Ballard C (2015). Drug repositioning in Alzheimer's disease. Front Biosci (Schol Ed), 7(1), 184-188. Abstract. Author URL.
Creese B, Corbett A, DPhil EJ, Fox C, Ballard C (2015). Erratum to [Role of the Extended MAPT Haplotype in the Worsening of Psychotic Symptoms and Treatment Response in Alzheimer Disease, J Am Med Dir Assoc, 15, 12, (2014), 934-937], DOI: 10.1016/j.jamda.2014.08.011. Journal of the American Medical Directors Association, 16(3).
Ballard C, Isaacson S, Mills R, Williams H, Corbett A, Coate B, Pahwa R, Rascol O, Burn DJ (2015). Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People with Parkinson Disease Psychosis. J Am Med Dir Assoc, 16(10), 898.e1-898.e7. Abstract. Author URL.
Enache D, Cavallin L, Lindberg O, Farahmand B, Kramberger MG, Westman E, Jelic V, Eriksdotter M, Ballard C, Winblad B, et al (2015). Medial temporal lobe atrophy and depressive symptoms in elderly patients with and without alzheimer disease. Journal of Geriatric Psychiatry and Neurology, 28(1), 40-48. Abstract.
Soto M, Andrieu S, Nourhashemi F, Ousset PJ, Ballard C, Robert P, Vellas B, Lyketsos CG, Rosenberg PB (2015). Medication development for agitation and aggression in Alzheimer disease: Review and discussion of recent randomized clinical trial design. International Psychogeriatrics, 27(2), 181-197. Abstract.
Wesnes KA, Aarsland D, Ballard C, Londos E (2015). Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry, 30(1), 46-54. Abstract. Author URL.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, et al (2015). Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: Secondary and post-hoc analyses. The Lancet Neurology, 14(12), 1171-1181. Abstract.
Howlett DR, Whitfield D, Johnson M, Attems J, O'Brien JT, Aarsland D, Lai MKP, Lee JH, Chen C, Ballard C, et al (2015). Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. Brain Pathology, 25(4), 401-408. Abstract.
Ekonomou A, Savva GM, Brayne C, Forster G, Francis PT, Johnson M, Perry EK, Attems J, Somani A, Minger SL, et al (2015). Stage-specific changes in neurogenic and glial markers in Alzheimer's disease. Biological Psychiatry, 77(8), 711-719. Abstract.
Bradley P, Akehurst R, Ballard C, Banerjee S, Blennow K, Bremner J, Broich K, Cummings J, Dening K, Dubois B, et al (2015). Taking stock: a multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. Alzheimer's and Dementia, 11(4), 455-461. Abstract.
Corbett A, Owen A, Hampshire A, Grahn J, Stenton R, Dajani S, Burns A, Howard R, Williams N, Williams G, et al (2015). The Effect of an Online Cognitive Training Package in Healthy Older Adults: an Online Randomized Controlled Trial. Journal of the American Medical Directors Association, 16(11), 990-997. Author URL.
Ballard C, Corbett A, Sharp S (2014). Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer’s disease. Expert Review of Neurotherapeutics, 11(3), 327-329.
Whitfield DR, Vallortigara J, Alghamdi A, Howlett D, HortobĂĄgyi T, Johnson M, Attems J, Newhouse S, Ballard C, Thomas AJ, et al (2014). Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: Association with cognitive impairment. Neurobiology of Aging, 35(12), 2836-2844. Abstract.
Sultana J, Chang CK, Hayes RD, Broadbent M, Stewart R, Corbett A, Ballard C (2014). Associations between risk of mortality and atypical antipsychotic use in vascular dementia: a clinical cohort study. International Journal of Geriatric Psychiatry, 29(12), 1249-1254. Abstract.
Kurian M, George S, Ballard CG, Mohan RN, Cumella S (2014). Audit of new long-stay patients in a district general hospital. Irish Journal of Psychological Medicine, 11(1), 42-43.
Khan Z, Corbett A, Ballard C (2014). Cognitive stimulation therapy: training, maintenance and implementation in clinical trials. Pragmat Obs Res, 5, 15-19. Abstract. Author URL.
Creese B, Ballard C, Aarsland D, Londos E, Sharp S, Jones E (2014). Corrigendum to "No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias" [Neurosci. Lett. 531 (1) (2012) 1-4]. Neuroscience Letters, 580
Gatt AP, Jones EL, Francis PT, Ballard C, Bateman JM (2014). Corrigendum to Association of a polymorphism in mitochondrial transcription factor a (TFAM) with Parkinson's disease dementia but not dementia with Lewy bodies [Neurosci. Lett. 557, (2013), 177-180]. Neuroscience Letters, 563
Lebedev AV, Beyer MK, Fritze F, Westman E, Ballard C, Aarsland D (2014). Cortical changes associated with depression and antidepressant use in alzheimer and lewy body dementia: an MRI surface-based morphometric study. American Journal of Geriatric Psychiatry, 22(1). Abstract.
Stewart R, Hotopf M, Dewey M, Ballard C, Bisla J, Calem M, Fahmy V, Hockley J, Kinley J, Pearce H, et al (2014). Current prevalence of dementia, depression and behavioural problems in the older adult care home sector: the South East London care home survey. Age and Ageing, 43(4), 562-567. Abstract.
Mohamed NE, Howlett DR, Ma L, Francis PT, Aarsland D, Ballard CG, McKeith IG, Chen CP, Lai MKP (2014). Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias. Journal of Neural Transmission, 121(1), 71-78. Abstract.
Mahmood A, Brennan A, Stanley A, Ballard CG, Malik A, Mohan RNC (2014). Delusional disorder in tropical spastic paraparesis. Irish Journal of Psychological Medicine, 11(1), 30-31.
Creese B, Ballard C, Aarsland D, Londos E, Sharp S, Jones E (2014). Determining the Association of the 5HTTLPR Polymorphism with Delusions and Hallucinations in Lewy Body Dementias. The American Journal of Geriatric Psychiatry, 22(6), 580-586.
Corbett A, Burns A, Ballard C (2014). Don't use antipsychotics routinely to treat agitation and aggression in people with dementia. BMJ, 349 Author URL.
Mulugeta E, Vallortigara J, Francis PT, Hye A, Kalaria RN, Perry EK, Lovestone S, Ballard CG (2014). Dynamin protein in stroke and vascular dementia. Neuroscience Letters, 563, 118-122. Abstract.
Vallortigara J, Rangarajan S, Whitfield D, Alghamdi A, Howlett D, HortobĂĄgyi T, Johnson M, Attems J, Ballard C, Thomas A, et al (2014). Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. F1000Research, 3 Abstract.
Vallortigara J, Rangarajan S, Whitfield D, Alghamdi A, Howlett D, HortobĂĄgyi T, Johnson M, Attems J, Ballard C, Thomas A, et al (2014). Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. F1000Research
Husebo BS, Ballard C, Fritze F, Sandvik RK, Aarsland D (2014). Efficacy of pain treatment on mood syndrome in patients with dementia: a randomized clinical trial. International Journal of Geriatric Psychiatry, 29(8), 828-836. Abstract.
Ruiz A, HernĂĄndez I, Ronsende-Roca M, GonzĂĄlez-PĂŠrez A, Rodriguez-Noriega E, RamĂrez-Lorca R, MauleĂłn A, Moreno-Rey C, Boswell L, Tune L, et al (2014). Erratum to "Exploratory analysis of seven Alzheimer's disease genes: Disease progression" [Neurobiol. Aging 34, (2013), 1310.e1-1310.e7], doi:10.1016/j.neurobiolaging.2012.08.014. Neurobiology of Aging, 35(11).
Mok KY, Jones EL, Hanney M, Harold D, Sims R, Williams J, Ballard C, Hardy J (2014). Erratum to "Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome" [Neurobiol. Aging 35 (2014) 1513.e1-1513.e5]. Neurobiology of Aging, 35(12).
Mok KY, Jones EL, Hanney M, Harold D, Sims R, Williams J, Ballard C, Hardy J (2014). Erratum to "Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome" [Neurobiol. Aging 35, (2014), 1513.e1-1513.e5], doi:10.1016/j.neurobiolaging.2013.12.022. Neurobiology of Aging, 35(11).
Ballard C, Aarsland D, Francis P, Corbett A (2014). Erratum to: Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: Pathophysiology, clinical features, and pharmacological management (Drugs Aging (2013) 30, (603-611) DOI: 10.1007/s40266-013-0092-x). Drugs and Aging, 31(8).
Lawrence V, Pickett J, Ballard C, Murray J (2014). Erratum: Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment. International Journal of Geriatric Psychiatry, 29(12).
Testad I, Corbett A, Aarsland D, Lexow KO, Fossey J, Woods B, Ballard C (2014). Erratum: the value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review (International Psychogeriatrics (2014) DOI; 10.1017/S1041610214000131)). International Psychogeriatrics, 26(7).
Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW, Jonsson L, Khachaturian AS, Kramberger M (2014). Health economic evaluation of treatments for Alzheimer′s disease: Impact of new diagnostic criteria. Journal of Internal Medicine, 275(3), 304-316. Abstract.
Zuidema SU, Johansson A, SelbĂŚk G, Ballard C, Koopmans RTCM (2014). IS1.07: a consensus guideline for antipsychotic drug use for dementia in long-term care. Collecting expert opinion through Delphi-consensus and focus groups. European Geriatric Medicine, 5
Sandvik RK, Selbaek G, Seifert R, Aarsland D, Ballard C, Corbett A, Husebo BS (2014). Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial. Eur J Pain, 18(10), 1490-1500. Abstract. Author URL.
Whitaker R, Fossey J, Ballard C, Orrell M, Moniz-Cook E, Woods RT, Murray J, Stafford J, Knapp M, Romeo R, et al (2014). Improving Well-being and Health for People with Dementia (WHELD): study protocol for a randomised controlled trial. Trials, 15 Abstract. Author URL.
Broadstock M, Ballard C, Corbett A (2014). Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. Expert Opin Pharmacother, 15(13), 1797-1810. Abstract. Author URL.
Oesterhus R, Soennesyn H, Rongve A, Ballard C, Aarsland D, Vossius C (2014). Long-term mortality in a Cohort of home-dwelling elderly with mild Alzheimer's disease and Lewy body dementia. Dementia and Geriatric Cognitive Disorders, 38(3-4), 161-169. Abstract.
McIntyre N, Ballard C, Bruen M, Bulygina N, Buytaert W, Cluckie I, Dunn S, Ehret U, Ewen J, Gelfan A, et al (2014). Modelling the hydrological impacts of rural land use change. Hydrology Research, 45(6), 737-754. Abstract.
Corbett A, Smith J, Ballard C (2014). New and emerging treatments for Alzheimer’s disease. Expert Review of Neurotherapeutics, 12(5), 535-543.
Broadstock M, Ballard C, Corbett A (2014). Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease. Expert Rev Clin Pharmacol, 7(6), 779-786. Abstract. Author URL.
Bereczki E, Hoglund K, Svenningsson P, CedazoâMinguez A, Francis P, Ballard CG, Aarsland D (2014). P2â123: BIOMARKERS FOR COGNITIVE DECLINE OF EARLY PARKINSON's DISEASE. Alzheimer's & Dementia, 10(4S_Part_13), p516-p516.
Somani AA, Jones E, Rasmussen J, Ballard CG (2014). P4â008: APP INTRON 7 POLYMORPHISM AND PLASMA AMYLOIDâBETA PEPTIDE LEVELS CAN PREDICT THE ONSET OF DEMENTIA IN DOWN's SYNDROME. Alzheimer's & Dementia, 10(4S_Part_21), p786-p786.
Lawrence V, Pickett J, Ballard C, Murray J (2014). Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment. International Journal of Geriatric Psychiatry, 29(1), 22-31. Abstract.
Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C (2014). Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet, 383(9916), 533-540. Abstract. Author URL.
Mok KY, Jones EL, Hanney M, Harold D, Sims R, Williams J, Ballard C, Hardy J (2014). Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome. Neurobiology of Aging, 35(6), 1513.e1-1513.e5. Abstract.
Ballard C, Corbett A, Howard R (2014). Prescription of antipsychotics in people with dementia. Br J Psychiatry, 205(1), 4-5. Author URL.
Ballard C, Francis P, Corbett A (2014). Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies - ADDENDUM. Int Psychogeriatr Author URL.
Creese B, Corbett A, Jones E, Fox C, Ballard C (2014). Role of the Extended MAPT Haplotype in the Worsening of Psychotic Symptoms and Treatment Response in Alzheimer Disease. Journal of the American Medical Directors Association, 15(12), 934-937.
Ballard C, Corbett A (2014). Screening for dementia: an opportunity for debate. Expert Review of Neurotherapeutics, 11(10), 1347-1349.
Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, SelbĂŚk G (2014). Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. American Journal of Geriatric Psychiatry, 22(4), 321-331. Abstract.
Fossey J, Masson S, Stafford J, Lawrence V, Corbett A, Ballard C (2014). The disconnect between evidence and practice: a systematic review of person-centred interventions and training manuals for care home staff working with people with dementia. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 29(8), 797-807. Author URL.
Marshall MR, Ballard CE, Frogbrook ZL, Solloway I, Mcintyre N, Reynolds B, Wheater HS (2014). The impact of rural land management changes on soil hydraulic properties and runoff processes: Results from experimental plots in upland UK. Hydrological Processes, 28(4), 2617-2629. Abstract.
Husebo BS, Ballard C, Cohen-Mansfield J, Seifert R, Aarsland D (2014). The response of agitated behavior to pain management in persons with dementia. American Journal of Geriatric Psychiatry, 22(7), 708-717. Abstract.
Testad I, Corbett A, Aarsland D, Lexow KO, Fossey J, Woods B, Ballard C (2014). The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review. INTERNATIONAL PSYCHOGERIATRICS, 26(7), 1083-1098. Author URL.
Corbett A, Ballard C (2014). The value of vitamin E as a treatment for Alzheimer's disease remains unproven despite functional improvement, due to a lack of established effect on cognition or other outcomes from RCTs. Evidence Based Medicine, 19(4), 140-140.
Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E (2014). Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. BMJ Open, 4(7). Abstract.
Siepel FJ, Rongve A, Buter TC, Beyer MK, Ballard CG, Booij J, Aarsland D (2013). (<sup>123</sup>I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. BMJ Open, 3(4). Abstract.
Nordberg A, Ballard C, Bullock R, Darreh-Shori T, Somogyi M (2013). A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease. Primary Care Companion to the Journal of Clinical Psychiatry, 15(2). Abstract.
Ballard C, Corbett A (2013). Agitation and aggression in people with Alzheimer's disease. Current Opinion in Psychiatry, 26(3), 252-259.
Ballard C, O'Sullivan MJ (2013). Alzheimer disease and stroke: Cognitive and neuroimaging predictors of AD and stroke. Nature Reviews Neurology, 9(11), 605-606.
Jones EL, Gauge N, Nilsen OB, Lowery D, Wesnes K, Katsaiti E, Arden J, Amoako D, Prophet N, Purushothaman B, et al (2013). Analysis of neuron-specific enolase and S100B as biomarkers of cognitive decline following surgery in older people. Dementia and Geriatric Cognitive Disorders, 34(5-6), 307-311. Abstract.
Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Dhall R, Ballard C (2013). Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson's Disease psychosis (Acp-103-020). Journal of the Neurological Sciences, 333, e119-e120.
Gatt AP, Jones EL, Francis PT, Ballard C, Bateman JM (2013). Association of a polymorphism in mitochondrial transcription factor a (TFAM) with Parkinson's disease dementia but not dementia with Lewy bodies. Neuroscience Letters, 557(PB), 177-180. Abstract.
Creese B, Ballard C, Jones E (2013). Cognitive Impairment in Studies of 5HTTLPR and Psychosis in Alzheimer’s Disease: a Systematic Review. Dementia and Geriatric Cognitive Disorders, 35(3-4), 155-164. Abstract.
Corbett A, Husebo B, Malcangio M, Staniland A, Cohen-Mansfield J, Aarsland D, Ballard C (2013). Correction: Assessment and treatment of pain in people with dementia. Nature Reviews Neurology, 9(7), 358-358.
Ballard C, Jones E, Gauge N, Aarsland D, Nilsen OB, Saxby BK, Lowery D, Corbett A, Wesnes K, Katsaiti E, et al (2013). Correction: Optimised Anaesthesia to Reduce Post Operative Cognitive Decline (POCD) in Older Patients Undergoing Elective Surgery, a Randomised Controlled Trial. PLoS ONE, 8(9).
Romeo R, Knapp M, Hellier J, Dewey M, Ballard C, Baldwin R, Bentham P, Burns A, Fox C, Holmes C, et al (2013). Cost-effectiveness analyses for mirtazapine and sertraline in dementia: Randomised controlled trial. British Journal of Psychiatry, 202(2), 121-128. Abstract.
Corbett A, Williams G, Ballard C (2013). Drug Repositioning: an Opportunity to Develop Novel Treatments for Alzheimer’s Disease. Pharmaceuticals, 6(10), 1304-1321.
Corbett A, Smith J, Ballard C (2013). Erratum: New and emerging treatments for Alzheimer's disease (Expert Review of Neurotherapeutics (2012) 12:5 (533-543) DOI: 10.1586/ern.12.43). Expert Review of Neurotherapeutics, 13(7).
Corbett A, Smith J, Ballard C (2013). Erratum: New and emerging treatments for Alzheimer's disease (Expert Review of Neurotherapeutics (2012) 12:5 (535-543)). Expert Review of Neurotherapeutics, 13(6).
Bajic N, Jenner P, Ballard CG, Francis PT (2013). Erratum: Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture (Journal of Neural Transmission (2012) 119 (1467-1476) DOI:10.1007/s00702-012-0816-9). Journal of Neural Transmission, 120(7).
Jones EL, Mok K, Hanney M, Harold D, Sims R, Williams J, Ballard C (2013). Evidence that PICALM affects age at onset of alzheimer's dementia in down syndrome. Neurobiology of Aging, 34(10), 2441.e1-2441.e5. Abstract.
Ruiz A, HernĂĄndez I, Ronsende-Roca M, GonzĂĄlez-PĂŠrez A, Rodriguez-Noriega E, RamĂrez-Lorca R, MauleĂłn A, Moreno-Rey C, Boswell L, Tune L, et al (2013). Exploratory analysis of seven Alzheimer's disease genes: Disease progression. Neurobiology of Aging, 34(4), 1310.e1-1310.e7. Abstract.
Whitaker R, Ballard C, Stafford J, Orrell M, Moniz-Cook E, Woods RT, Murray J, Knapp M, Carlton BW, Fossey J, et al (2013). Feasibility study of an optimised person-centred intervention to improve mental health and reduce antipsychotics amongst people with dementia in care homes: Study protocol for a randomised controlled trial. Trials, 14(1). Abstract.
Ballard C, Grimmer T (2013). Improving diagnosis of possible DLB: is there a role for MIBG myocardial scintigraphy?. Neurology, 81(20), 1730-1731.
Corbett A, Ballard C (2013). Is a potential Alzheimer's therapy already in use for other conditions? can medications for hypertension, diabetes and acne help with the symptoms?. Expert Opinion on Investigational Drugs, 22(8), 941-943.
Ballard C, Roversi P, Walden H (2013). Molecular replacements. Acta Crystallographica Section D: Biological Crystallography, 69(11), 2165-2166.
Ballard C, Aarsland D, Francis P, Corbett A (2013). Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management. Drugs & Aging, 30(8), 603-611.
Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, Evans J, Lee M, Porsteinsson A, LanctĂ´t KL, et al (2013). Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. Alzheimer's and Dementia, 9(5), 602-608. Abstract.
Ballard C, Mills R, Williams H, ChiâBurris K, Bahr D, Cummings J (2013). O4–05–04: Antipsychotic efficacy and good tolerability in a Phase III placeboâcontrolled study of pimavanserin in patients with Parkinson's disease psychosis (ACPâ103–020). Alzheimer's & Dementia, 9(4S_Part_17).
Francis P, HortobĂĄgyi T, Attems J, Aarsland D, Ballard C, O'Brein J, Whitfield D, Alghamdi A, Vallortigara J (2013). P3–041: Contribution of Alzheimer's disease and Lewy body pathology to behavior and cognition in Lewy body dementias. Alzheimer's & Dementia, 9(4S_Part_14), p566-p566.
Wesnes K, Aarsland D, Ballard C, Londos E (2013). P4–419: Memantine improves attention and verbal episodic memory in Parkinson's disease dementia and dementia with Lewy bodies: a doubleâblind, placeboâcontrolled multicentre trial. Alzheimer's & Dementia, 9(4S_Part_22), p890-p890.
Blackburn DJ, Krishnan K, Fox L, Ballard C, Burns A, Ford GA, Mant J, Passmore P, Pocock S, Reckless J, et al (2013). Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. Trials, 14(1). Abstract.
Ballard C, Corbett A (2013). Randomised controlled trial: a small proportion of people with dementia and neuropsychiatric symptoms experience clinically significant worsening when antidepressants are discontinued (Evidence-Based Medicine (2013) 18, (27-28)). Evidence-Based Medicine, 18(3).
Ballard C, Francis P, Corbett A (2013). Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies. International Psychogeriatrics, 25(5), 687-689. Abstract.
Corbett A, Francis P, Ballard C (2013). Safety and efficacy of memantine extended-release in the management of alzheimer's disease. Clinical Medicine Insights: Therapeutics, 5, 95-102. Abstract.
Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, et al (2013). Study of the use of antidepressants for depression in dementia: the HTA-SADD trial- a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technology Assessment, 17(7), 1-43. Abstract.
Husebo BS, Ballard C, Cohen-Mansfield J, Seifert R, Aarsland D (2013). The Response of Agitated Behavior to Pain Management in Persons with Dementia. American Journal of Geriatric Psychiatry
Ewen J, O'Donnell G, Bulygina N, Ballard C, O'Connell E (2013). Towards understanding links between rural land management and the catchment flood hydrograph. Quarterly Journal of the Royal Meteorological Society, 139(671), 350-357. Abstract.
Ballard C (2012). 4 Optimal treatment for parkinson patients with cognitive disorders. Neurobiology of Aging, 33, s2-s3.
Jones EL, Aarsland D, Londos E, Ballard C (2012). A pilot study examining associations between DYRK1A and α-synuclein dementias. Neurodegenerative Diseases, 10(1-4), 229-231. Abstract.
Ballard C, Corbett A (2012). A small proportion of people with dementia and neuropsychiatric symptoms experience clinically significant worsening when antidepressants are discontinued. Evidence Based Medicine, 18(1), 27-28.
Corbett A, Ballard C (2012). Antipsychotics and Mortality in Dementia. American Journal of Psychiatry, 169(1), 7-9.
Corbett A, Husebo B, Malcangio M, Staniland A, Cohen-Mansfield J, Aarsland D, Ballard C (2012). Assessment and treatment of pain in people with dementia. Nature Reviews Neurology, 8(5), 264-274. Abstract.
Aarsland D, Ballard CG (2012). Biomarkers for dementia diagnosis: Differentiating DLB and FTD may be difficult. Journal of Neurology, Neurosurgery and Psychiatry, 83(11).
Aarsland D, Ballard C, Rongve A, Broadstock M, Svenningsson P (2012). Clinical trials of dementia with lewy bodies and parkinson's disease dementia. Current Neurology and Neuroscience Reports, 12(5), 492-501. Abstract.
Svenningsson P, Westman E, Ballard C, Aarsland D (2012). Cognitive impairment in patients with Parkinson's disease: Diagnosis, biomarkers, and treatment. The Lancet Neurology, 11(8), 697-707. Abstract.
(2012). Correction: Optimised Anaesthesia to Reduce Post Operative Cognitive Decline (POCD) in Older Patients Undergoing Elective Surgery, a Randomised Controlled Trial. PloS one, 7(9).
Aarsland D, PĂĽhlhagen S, Ballard CG, Ehrt U, Svenningsson P (2012). Depression in Parkinson disease - Epidemiology, mechanisms and management. Nature Reviews Neurology, 8(1), 35-47. Abstract.
Corbett A, Husebo B, Ballard C (2012). Discomfort in dementia: identifying and managing pain. Nursing and Residential Care, 14(9), 462-467.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, et al (2012). Donepezil and memantine for moderate-to-severe Alzheimer's disease. New England Journal of Medicine, 366(10), 893-903. Abstract.
Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, Hagan JJ, Holmes C, Jones E, Katona C, et al (2012). Drug repositioning for Alzheimer's disease. Nature Reviews Drug Discovery, 11(11), 833-846.
Ballard CE, McIntyre N, Wheater HS (2012). Effects of peatland drainage management on peak flows. Hydrology and Earth System Sciences, 16(7), 2299-2310. Abstract.
Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, Ballard C, Boustani M, Katona C, Livingston G, et al (2012). Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS ONE, 7(5). Abstract.
Ballard C, Fossey J, Stafford J, Testad I (2012). F4â02â03: Psychological interventions for neuropsychiatric symptoms in dementia. Alzheimer's & Dementia, 8(4S_Part_17), p609-p609.
Corbett A, Burns A, Ballard C (2012). F4â02â04: Management of behavioural and psychological symptoms of dementia: Development of a best practice guide. Alzheimer's & Dementia, 8(4S_Part_17), p609-p609.
Lawrence V, Fossey J, Ballard C, Moniz-Cook E, Murray J (2012). Improving quality of life for people with dementia in care homes: Making psychosocial interventions work. British Journal of Psychiatry, 201(5), 344-351. Abstract.
Ekonomou A, Johnson M, Perry RH, Perry EK, Kalaria RN, Minger SL, Ballard CG (2012). Increased neural progenitors in individuals with cerebral small vessel disease. Neuropathology and Applied Neurobiology, 38(4), 344-353. Abstract.
Bulygina N, Ballard C, McIntyre N, O'Donnell G, Wheater H (2012). Integrating different types of information into hydrological model parameter estimation: Application to ungauged catchments and land use scenario analysis. Water Resources Research, 48(6). Abstract.
Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, Lawrence D, Yu L-M, Tyrer S, Francis PT, et al (2012). Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. LANCET, 379(9815), 528-536. Author URL.
Perry EK, Johnson M, Ekonomou A, Perry RH, Ballard C, Attems J (2012). Neurogenic abnormalities in Alzheimer's disease differ between stages of neurogenesis and are partly related to cholinergic pathology. Neurobiology of Disease, 47(2), 155-162. Abstract.
Bjoerke-Bertheussen J, Ehrt U, Rongve A, Ballard C, Aarsland D (2012). Neuropsychiatric symptoms in mild dementia with lewy bodies and alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 34(1), 1-6. Abstract.
Corbett A, Ballard C (2012). New and emerging treatments for Alzheimer's disease. Expert Opin Emerg Drugs, 17(2), 147-156. Abstract. Author URL.
Ballard C, Corbett A (2012). New guidelines on disorders associated with dementia. Nature Reviews Neurology, 8(12), 663-664.
Creese B, Ballard C, Aarsland D, Londos E, Sharp S, Jones E (2012). No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. Neuroscience Letters, 531(1), 1-4.
Ballard C, Aarsland D, Walker Z, Thomas A (2012). O4â12â01: a randomized double blind clinical trial comparing memantine and antipsychotics for the prophylaxis of behavioural and psychological symptoms in people with Alzheimer's disease (MAIN AD). Alzheimer's & Dementia, 8(4S_Part_20), s745-s745.
Ballard C, Jones E, Gauge N, Aarsland D, Nilsen OB, Saxby BK, Lowery D, Corbett A, Wesnes K, Katsaiti E, et al (2012). Optimised Anaesthesia to Reduce Post Operative Cognitive Decline (POCD) in Older Patients Undergoing Elective Surgery, a Randomised Controlled Trial. PLoS ONE, 7(6), e37410-e37410.
Lee J, Lai M, Francis P, Aarsland D, Ballard C, Chen C, Wong P (2012). P4â005: Gâprotein coupling to muscarinic M1 receptors is differentially affected in neurodenegerative dementias. Alzheimer's & Dementia, 8(4S_Part_17), p639-p639.
Ruiz A, Hernandez I, RosendeâRoca M, GonzĂĄlezâPĂŠrez A, RodrĂguezâNoriega E, RamirezâLorca R, Mauleon A, MorenoâRey C, Boswell L, Tune L, et al (2012). P4â244: Exploratory analysis of seven confirmed risk factors for Alzheimer's disease with disease progression. Alzheimer's & Dementia, 8(4S_Part_20), p721-p722.
Bajic N, Jenner P, Ballard CG, Francis PT (2012). Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture. Journal of Neural Transmission, 119(12), 1467-1476. Abstract.
Ballard C (2012). S2â03â04: Behavioral alternatives to antiâpsychotic prescribing for people with dementia in residential care settings. Alzheimer's & Dementia, 8(4S_Part_6), p230-p230.
Corbett A, Smith J, Creese B, Ballard C (2012). Treatment of Behavioral and Psychological Symptoms of Alzheimer’s Disease. Current Treatment Options in Neurology, 14(2), 113-125.
Burns A, Perry E, Holmes C, Francis P, Morris J, Howes MJR, Chazot P, Lees G, Ballard C (2011). A double-blind placebo-controlled randomized trial of melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 31(2), 158-164. Abstract.
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011). Alzheimer's disease. LANCET, 377(9770), 1019-1031. Author URL.
Jones EL, Ballard CG, Prasher VP, Arno M, Tyrer S, Moore B, Hanney ML (2011). An intron 7 polymorphism in APP affects the age of onset of dementia in down syndrome. International Journal of Alzheimer's Disease Abstract.
Clarke NA, Hartmann T, Jones EL, Ballard CG, Francis PT (2011). Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid Aβ 40 and tau in patients with intractable unipolar depression. International Journal of Geriatric Psychiatry, 26(12), 1283-1291. Abstract.
Creese B, Ballard C, Corbett A, Aarsland D (2011). Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opinion on Drug Safety, 10, 35-43.
Aarsland D, Husebo B, Ballard C (2011). Authors' reply to McShane and Regnard. BMJ (Online), 343(7821).
Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, Minthon L, Aarsland D (2011). CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 82(2), 160-164. Abstract.
Mulugeta E, Londos E, Hansson O, Ballard C, Skogseth R, Minthon L, Blennow K, Zetterberg H, Aarsland D (2011). Cerebrospinal fluid levels of sAPPα and sAPPβ in Lewy body and Alzheimer's disease: Clinical and neurochemical correlates. International Journal of Alzheimer's Disease Abstract.
Ballard C, Corbett A, Jones EL (2011). Dementia: challenges and promising developments. The Lancet Neurology, 10(1), 7-9.
Ballard C, Corbett A, Pickett J (2011). Depression and dementia. Ment Health Today, 23-25. Author URL.
Fritze F, Ehrt U, Sønnesyn H, Kurz M, Hortobågyi T, Nore SP, Ballard C, Aarsland D (2011). Depression in mild dementia: Associations with diagnosis, APOE genotype and clinical features. International Journal of Geriatric Psychiatry, 26(10), 1054-1061. Abstract.
Fritze F, Ehrt U, Hortobagyi T, Ballard C, Aarsland D (2011). Depressive symptoms in Alzheimer's disease and lewy body dementia: a one-year follow-up study. Dementia and Geriatric Cognitive Disorders, 32(2), 143-149. Abstract.
Howard R, Phillips P, Johnson T, O'Brien J, Sheehan B, Lindesay J, Bentham P, Burns A, Ballard C, Holmes C, et al (2011). Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry, 26(8), 812-817. Abstract.
Auning E, Rongve A, Fladby T, Booij J, HortobĂĄgyi T, Siepel FJ, Ballard C, Aarsland D (2011). Early and presenting symptoms of dementia with Lewy bodies. Dementia and Geriatric Cognitive Disorders, 32(3), 202-208. Abstract.
Johansson C, Ballard C, Hansson O, Palmqvist S, Minthon L, Aarsland D, Londos E (2011). Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. International Journal of Geriatric Psychiatry, 26(2), 206-213. Abstract.
Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D (2011). Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: Cluster randomised clinical trial. BMJ, 343(7816). Abstract.
Jones EL, Kalaria RN, Sharp SI, O'Brien JT, Francis PT, Ballard CG (2011). Genetic associations of autopsy-confirmed vascular dementia subtypes. Dementia and Geriatric Cognitive Disorders, 31(4), 247-253. Abstract.
Ballard CE, McIntyre N, Wheater HS, Holden J, Wallage ZE (2011). Hydrological modelling of drained blanket peatland. Journal of Hydrology, 407(1-4), 81-93. Abstract.
Sharp SI, Aarsland D, Day S, Sønnesyn H, Ballard C (2011). Hypertension is a potential risk factor for vascular dementia: Systematic review. International Journal of Geriatric Psychiatry, 26(7), 661-669. Abstract.
Ăhrfelt A, Zetterberg H, Andersson K, Persson R, Secic D, Brinkmalm G, Wallin A, Mulugeta E, Francis PT, Vanmechelen E, et al (2011). Identification of novel α-synuclein isoforms in human brain tissue by using an online NanoLC-ESI-FTICR-MS method. Neurochemical Research, 36(11), 2029-2042. Abstract.
Ekonomou A, Ballard CG, Pathmanaban ON, Perry RH, Perry EK, Kalaria RN, Minger SL (2011). Increased neural progenitors in vascular dementia. Neurobiology of Aging, 32(12), 2152-2161. Abstract.
Corbett A, Ballard C (2011). Information provision services in dementia care. International Journal of Older People Nursing, 6(3), 217-226. Abstract.
Morris CM, Ballard CG, Allan L, Rowan E, Stephens S, Firbank M, Ford GA, Kenny RA, O'Brien JT, Kalaria RN, et al (2011). NOS3 gene rs1799983 polymorphism and incident dementia in elderly stroke survivors. Neurobiology of Aging, 32(3), 554.e1-554.e6. Abstract.
Johnson M, Ekonomou A, Hobbs C, Ballard CG, Perry RH, Perry EK (2011). Neurogenic marker abnormalities in the hippocampus in dementia with Lewy bodies. Hippocampus, 21(10), 1126-1136. Abstract.
Ballard C, Khan Z, Clack H, Corbett A (2011). Nonpharmacological treatment of Alzheimer disease. Can J Psychiatry, 56(10), 589-595. Abstract. Author URL.
Jones E, Ballard C, Doherty P (2011). P1â238: the Impact of Genetics Associated with Age of Onset of Alzheimer's Disease in People with Down's Syndrome Upon BetaâAmyloid and Tau Concentrations. Alzheimer's & Dementia, 7(4S_Part_5), s187-s187.
Rognve A, Auning E, Fladby T, Ballard C, Aarsland D (2011). P4â129: the preâdementia stage of dementia with Lewy bodies. Alzheimer's & Dementia, 7(4S_Part_21), s749-s750.
Vallortigara J, Warren F, Ballard C, Boess F, Aarsland D, Targett M, Alghamdi A, Francis P (2011). P4â176: Impairment of the proteasome on frontal cortex in lewy body dementia. Alzheimer's & Dementia, 7(4S_Part_22), s765-s765.
Fox C, Maidment I, Crugel M, Katona C, Livingston G, Ballard C, McShane R, Boustani M, Treloar A, Coulton S, et al (2011). P4â413: Randomized controlled trial of memantine for agitation in dementia. Alzheimer's & Dementia, 7(4S_Part_25), e56-e56.
Fox C, Crugel M, McShane R, Boustani M, Katona C, Maidment I, Ballard C, Treloar A, Livingston G, Coulton S, et al (2011). P4â414: Memantine for agitation in dementia. Alzheimer's & Dementia, 7(4S_Part_25), e56-e57.
Husebo BS, Ballard C, Aarsland D (2011). Pain treatment of agitation in patients with dementia: a systematic review. International Journal of Geriatric Psychiatry, 26(10), 1012-1018. Abstract.
Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, et al (2011). Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. The Lancet, 378(9789), 403-411. Abstract.
Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D (2011). Systematic pain management reduced agitation in nursing home residents with dementia. Annals of Internal Medicine, 155(10).
Corbett A, Stevens J, Aarsland D, Day S, MonizâCook E, Woods R, Brooker D, Ballard C (2011). Systematic review of services providing information and/or advice to people with dementia and/or their caregivers. International Journal of Geriatric Psychiatry, 27(6), 628-636. Abstract.
Ballard C, Smith J, Husebo B, Aarsland D, Corbett A (2011). The role of pain treatment in managing the behavioural and psychological symptoms of dementia (BPSD). Int J Palliat Nurs, 17(9), 420-424. Author URL.
Ballard C, Kahn Z, Corbett A (2011). Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Drugs Aging, 28(10), 769-777. Abstract. Author URL.
Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, et al (2010). CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study. Journal of Neurology, Neurosurgery and Psychiatry, 81(10), 1080-1086. Abstract.
Ballard CG, Jones EL (2010). CSF α-synuclein as a diagnostic biomarker for Parkinson disease and related dementias. Neurology, 75(20), 1760-1761.
Rongve A, Brønnick K, Ballard C, Aarsland D (2010). Core and suggestive symptoms of dementia with lewy bodies cluster in persons with mild dementia. Dementia and Geriatric Cognitive Disorders, 29(4), 317-324. Abstract.
Ballard C, Corbett A (2010). Definitions, criteria and mechanisms for vascular and mixed dementia. Minerva Psichiatrica, 51(1), 1-8. Abstract.
Tildesley N, Scholey, Kennedy, Perry E, Ballard C, Wesnes K (2010). Effects of single doses of oil of Spanish sage (Salvia lavandulaefolia) on mood and cognitive performance in healthy young volunteers. Focus on Alternative and Complementary Therapies, 7(1), 109-109.
Testad I, Mikkelsen A, Ballard C, Aarsland D (2010). Health and well-being in care staff and their relations to organizational and psychosocial factors, care staff and resident factors in nursing homes. Int J Geriatr Psychiatry, 25(8), 789-797. Abstract. Author URL.
Aarsland D, Sardahaee FS, Anderssen S, Ballard C (2010). Is physical activity a potential preventive factor for vascular dementia? a systematic review. Aging and Mental Health, 14(4), 386-395. Abstract.
Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C (2010). Management of behavioral problems in Alzheimer's disease. International Psychogeriatrics, 22(3), 346-372. Abstract.
Ballard C, Corbett A (2010). Management of neuropsychiatric symptoms in people with dementia. CNS Drugs, 24(9), 729-739. Abstract. Author URL.
Vernon AC, Ballard C, Modo M (2010). Neuroimaging for Lewy body disease: is the in vivo molecular imaging of ?-synuclein neuropathology required and feasible?. Brain Research Reviews, 65(1), 28-55. Abstract.
Testad I, Auer S, Mittelman M, Ballard C, Fossey J, Donabauer Y, Aarsland D (2010). Nursing home structure and association with agitation and use of psychotropic drugs in nursing home residents in three countries: Norway, Austria and England. Int J Geriatr Psychiatry, 25(7), 725-731. Abstract. Author URL.
Aarsland D, Johansson C, Ballard C, Hansson O, Palmqvist S, Minthon L, Londos E (2010). O3â05â07: Efficacy of memantine in PDD and DLB: an extension study including washâout and openâlabel treatment. Alzheimer's & Dementia, 6(4S_Part_5), s136-s136.
Jones EL, Sharp S, Aarsland D, Londos E, Ballard C (2010). P1â066: a DYRK1A polymorphism and dementia. Alzheimer's & Dementia, 6(4S_Part_6), s192-s193.
Ballard CG, Corbett A, Clack H, Owen A (2010). P4â113: can Brain Training Games Improve Cognition in Peope over 60?. Alzheimer's & Dementia, 6(4S_Part_21), e55-e56.
Huang L, Abuhamdah S, Howes M-JR, Dixon CL, Elliot MSJ, Ballard C, Holmes C, Burns A, Perry EK, Francis PT, et al (2010). Pharmacological profile of essential oils derived from Lavandula angustifolia and Melissa officinalis with anti-agitation properties: focus on ligand-gated channels†. Journal of Pharmacy and Pharmacology, 60(11), 1515-1522.
Owen AM, Hampshire A, Grahn JA, Stenton R, Dajani S, Burns AS, Howard RJ, Ballard CG (2010). Putting brain training to the test. Nature, 465(7299), 775-778. Abstract.
Lowery DP, Wesnes K, Brewster N, Ballard C (2010). Subtle deficits of attention after surgery: Quantifying indicators of sub syndrome delirium. International Journal of Geriatric Psychiatry, 25(10), 945-952. Abstract.
Larsson V, Aarsland D, Ballard C, Minthon L, Londos E (2010). The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. International Journal of Geriatric Psychiatry, 25(10), 1030-1038. Abstract.
Testad I, Ballard C, Brønnick K, Aarsland D (2010). The effect of staff training on agitation and use of restraint in nursing home residents with dementia: a single-blind, randomized controlled trial. J Clin Psychiatry, 71(1), 80-86. Abstract. Author URL.
Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D (2010). Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 81(2), 160-165. Abstract.
Kirvell SL, Elliott MS, Kalaria RN, HortobĂĄgyi T, Ballard CG, Francis PT (2010). Vesicular glutamate transporter and cognition in stroke: a case-control autopsy study. Neurology, 75(20), 1803-1809. Abstract.
Ballard C (2010). Video decision support affects patients' care choices in dementia care planning. Evidence-Based Mental Health, 13(1).
Ballard C, Jones EL, Londos E, Minthon L, Francis P, Aarsland D (2010). α-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. International Psychogeriatrics, 22(2), 321-327. Abstract.
Jones EL, Hanney M, Francis PT, Ballard CG (2009). Amyloid β concentrations in older people with Down syndrome and dementia. Neuroscience Letters, 451(2), 162-164. Abstract.
Ballard C (2009). Atypical antipsychotics fail to improve functioning or quality of life in people with Alzheimer's disease. Evidence-Based Mental Health, 12(1).
Ballard C, Brown R, Fossey J, Douglas S, Bradley P, Hancock J, James IA, Juszczak E, Bentham P, Burns A, et al (2009). Brief psychosocial therapy for the treatment of agitation in Aalzheimer disease (The CALM-AD trial). American Journal of Geriatric Psychiatry, 17(9), 726-733. Abstract.
Lane R, He Y, Morris C, Leverenz JB, Emre M, Ballard C (2009). BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord, 24(3), 392-400. Abstract. Author URL.
Sharp SI, Francis PT, Elliott MSJ, Kalaria RN, Bajic N, Hortobagyi T, Ballard CG (2009). Choline acetyltransferase activity in vascular dementia and stroke. Dementia and Geriatric Cognitive Disorders, 28(3), 233-238. Abstract.
Chalmers KA, Wilcock GK, Vinters HV, Perry EK, Perry R, Ballard CG, Love S (2009). Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. J Neurol, 256(5), 717-720. Abstract. Author URL.
Jones R, Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, Ballard C, Banerjee S, Barber B, Bentham P, et al (2009). DOMINO-AD protocol: Donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Trials, 10 Abstract.
Ballard CG, Kossakowski K, MacInnes N, Aarsland D (2009). Dementia with Lewy bodies and Parkinson disease dementia. Hot Topics in Neurology and Psychiatry
Huang L, Abuhamdah S, Howes MJR, Dixon CL, Elliot MSJ, Ballard C, Holmes C, Burns A, Perry EK, Francis PT, et al (2009). Erratum: Pharmacological profile of essential oils derived from Lavandula angustifolia and Melissa officinalis with anti-agitation properties: Focus on ligand-gated channels (Journal of Pharmacy and Pharmacology (2008) 59 (1515-1522)). Journal of Pharmacy and Pharmacology, 61(2).
Sonnesyn H, Nilsen DW, Rongve A, Nore S, Ballard C, Tysnes OB, Aarsland D (2009). High prevalence of orthostatic hypotension in mild dementia. Dementia and Geriatric Cognitive Disorders, 28(4), 307-313. Abstract.
Allan LM, Ballard CG, Rowan EN, Kenny RA (2009). Incidence and prediction of falls in dementia: a prospective study in older people. PLoS ONE, 4(5). Abstract.
Elliott MSJ, Ballard CG, Kalaria RN, Perry R, HortobĂĄgyi T, Francis PT (2009). Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. Brain, 132(Pt 7), 1858-1865. Abstract. Author URL.
Ballard C, Corbett A, Chitramohan R, Aarsland D (2009). Management of agitation and aggression associated with AlzheimerĘźs disease: controversies and possible solutions. Current Opinion in Psychiatry, 22(6), 532-540.
Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, Lyketsos CG (2009). Management of agitation and aggression associated with alzheimer disease. Nature Reviews Neurology, 5(5), 245-255. Abstract.
Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L, Londos E, et al (2009). Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. The Lancet Neurology, 8(7), 613-618. Abstract.
Testad I, Auer S, Mittelman M, Ballard C, Aarsland D (2009). P1â236: Agitation and nursing home structureâ how are they related?: a three country study. Alzheimer's & Dementia, 5(4S_Part_8), p245-p245.
Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, Caviness JN, Shill HA, Sue LI, Ziabreva I, et al (2009). Parkinson disease with dementia: Comparing patients with and without alzheimer pathology. Alzheimer Disease and Associated Disorders, 23(3), 295-297. Abstract.
Aarsland D, Londos E, Ballard C (2009). Parkinson's disease dementia and dementia with Lewy bodies: Different aspects of one entity. International Psychogeriatrics, 21(2), 216-219.
Ballard C, Aarsland D (2009). Person-centred care and care mapping in dementia. The Lancet Neurology, 8(4), 302-303.
Huang L, Abuhamdah S, Howes M-JR, Dixon CL, Elliot MSJ, Ballard C, Holmes C, Burns A, Perry EK, Francis PT, et al (2009). Pharmacological profile of essential oils derived from Lavandula angustifolia and Melissa officinalis with anti-agitation properties: focus on ligand-gated channels (vol 59, pg 1515, 2008). JOURNAL OF PHARMACY AND PHARMACOLOGY, 61(2), 267-267. Author URL.
Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu LM, Jacoby R, et al (2009). The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. The Lancet Neurology, 8(2), 151-157. Abstract.
Ballard C, Margallo-Lana M, O'Brien JT, James I, Howard R, Fossey J (2009). Top cited papers in international psychogeriatrics: 6a. quality of life for people with dementia living in residential and nursing home care: the impact of performance on activities of daily living, behavioral and psychological symptoms, language skills, and psychotropic drugs. International Psychogeriatrics, 21(6), 1026-1028.
Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, Jacoby R, Kossakowski K, Yu LM, Juszczak E (2008). A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial). PLoS Medicine, 5(4), 0587-0599. Abstract.
Scholey AB, Tildesley NTJ, Ballard CG, Wesnes KA, Tasker A, Perry EK, Kennedy DO (2008). An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. Psychopharmacology (Berl), 198(1), 127-139. Abstract. Author URL.
Ballard C (2008). Antipsychotics: No quick fix for people with dementia. British Journal of Neuroscience Nursing, 4(6), 261-262.
Tasker A, Ballard CG, Joachim C, Warden DR, Okello EJ, Perry RH, Khan N, Smith AD, Lehmann DJ, Perry EK, et al (2008). Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients. Neuroscience Letters, 442(3), 297-299. Abstract.
Ballard C, Fossey J (2008). Clinical management of dementia. Psychiatry, 7(2), 88-93. Abstract.
Sharp SI, Ballard CG, Ziabreva I, Piggott MA, Perry RH, Perry EK, Aarsland D, Ehrt U, Larsen JP, Francis PT, et al (2008). Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with lewy bodies and Parkinson's disease dementia. Dementia and Geriatric Cognitive Disorders, 26(4), 330-338. Abstract.
Khan A, Ballard C (2008). Current approaches to potential amyloid-based Alzheimer's disease therapies: Defeating dementia. Biochemist, 30(5), 14-17. Abstract.
Aarsland D, Kurz M, Beyer M, Bronnick K, Piepenstock Nore S, Ballard C (2008). Early discriminatory diagnosis of dementia with Lewy bodies: the emerging role of CSF and imaging biomarkers. Dementia and Geriatric Cognitive Disorders, 25(3), 195-205. Abstract.
Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten ECW, van der Flier WM, Hsu C, Wu S, Lane R, et al (2008). Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current Medical Research and Opinion, 24(9), 2561-2574. Abstract.
Wood-Mitchell A, James IA, Waterworth A, Swann A, Ballard C (2008). Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative study. Age and Ageing, 37(5), 547-552. Abstract.
Aarsland D, Rongve A, Piepenstock Nore S, Skogseth R, Skulstad S, Ehrt U, Hoprekstad D, Ballard C (2008). Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dementia and Geriatric Cognitive Disorders, 26(5), 445-452. Abstract.
Mulugeta E, Molina-Holgado F, Elliott MS, Hortobagyi T, Perry R, Kalaria RN, Ballard CG, Francis PT (2008). Inflammatory mediators in the frontal lobe of patients with mixed and vascular dementia. Dement Geriatr Cogn Disord, 25(3), 278-286. Abstract. Author URL.
Wilcock GK, Ballard CG, Cooper JA, Loft H (2008). Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. Journal of Clinical Psychiatry, 69(3), 341-348. Abstract.
Skogseth R, Mulugeta E, Ballard C, Rongve A, Nore S, Alves G, Aarsland D (2008). Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 25(6), 559-563. Abstract.
Skogseth R, Mulugeta E, Jones E, Ballard C, Rongve A, Nore S, Alves G, Aarsland D (2008). Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease (Dementia and Geriatric Cognitive Disorders (2008) 25, (559-563)). Dementia and Geriatric Cognitive Disorders, 26(3).
Ballard C, Day S, Sharp S, Wing G, Sorensen S (2008). Neuropsychiatric symptoms in dementia: Importance and treatment considerations. International Review of Psychiatry, 20(4), 396-404. Abstract.
Andersson M, Hansson O, Minthon L, Ballard CG, Londos E (2008). P2â214: Blood pressure reaction to orthostatic challenge is different in dementia with Lewy bodies. Alzheimer's & Dementia, 4(4S_Part_13), t434-t434.
Rongve A, Aarsland D, Nore SP, Skogseth R, Skulstad S, Ehrt U, Hoprekstad D, Ballard C (2008). P2â225: the frequency of dementia with Lewy bodies in a communityâbased referral sample of mild dementia. Alzheimer's & Dementia, 4(4S_Part_13), t437-t437.
Warren FE, Sharp SI, Lakics V, Boess FG, Ballard CG, Ziabreva I, Perry EK, Aarsland D, Larsen J-P, Francis PT, et al (2008). P2â226: Association of proteasome subunit expression with reduced proteolytic activity in dementia with Lewy bodies and Parkinson's disease dementia. Alzheimer's & Dementia, 4(4S_Part_13), t437-t437.
Mulugeta E, Skogseth R, Alves G, Jones E, Rongve A, Nore E, Tysnes O-B, Ballard C, Larsen JP, Aarsland D, et al (2008). P3â087: Neuropsychiatric correlates of CSF Tau and PâTau in dementia. Alzheimer's & Dementia, 4(4S_Part_16), t543-t543.
Clarke NA, Hartmann T, Tomic I, Jones EL, Ballard CG, Francis PT (2008). P4â064: Neuroleptic medication is associated with selective alterations in VCSF Aβ40 and tau in patients with intractable unipolar depression. Alzheimer's & Dementia, 4(4S_Part_21), t686-t687.
Korczyn AD, Aarsland D, Ballard CG, Kossakowski K, MacInnes N (2008). Parkinson/Dementia complex and Lewy body dementia: perspectives and treatments. Hot Topics in Neurology and Psychiatry
Abuhamdah S, Huang L, Elliott MSJ, Howes MJR, Ballard C, Holmes C, Burns A, Perry EK, Francis PT, Lees G, et al (2008). Pharmacological profile of an essential oil derived from Melissa officinalis with anti-agitation properties: Focus on ligand-gated channels. Journal of Pharmacy and Pharmacology, 60(3), 377-384. Abstract.
Huang L, Abuhamdah S, Howes MJR, Elliot MSJ, Ballard C, Holmes C, Burns A, Perry EK, Francis PT, Lees G, et al (2008). Pharmacological profile of essential oils derived from Lavandula angustifolia and Melissa officinalis with anti-agitation properties: Focus on ligand-gated channels. Journal of Pharmacy and Pharmacology, 60(11), 1515-1522. Abstract.
MacInnes N, Iravani MM, Perry E, Piggott M, Perry R, Jenner P, Ballard C (2008). Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. J Neural Transm (Vienna), 115(6), 869-878. Abstract. Author URL.
Lowery DP, Wesnes K, Brewster N, Ballard C (2008). Quantifying the association between computerised measures of attention and confusion assessment method defined delirium: a prospective study of older orthopaedic surgical patients, free of dementia. International Journal of Geriatric Psychiatry, 23(12), 1253-1260. Abstract.
Ballard C (2008). S5â04–03: Alternative therapies for behavioral problems. Alzheimer's & Dementia, 4(4S_Part_6), t204-t204.
Ekonomou A, Cedar S, Ballard CG, Minger SL (2008). Stem-cells: Prospects for treating dementia. British Journal of Neuroscience Nursing, 4(5), 220-222.
Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, Darreh-Shori T, Soininen H, Pirttilä T, Farlow MR, et al (2008). Synergistic effect of apolipoprotein E ε4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenetics and Genomics, 18(4), 289-298. Abstract.
Jones EL, Margallo-Lana M, Prasher VP, Ballard CG (2008). The extended tau haplotype and the age of onset of dementia in Down syndrome. Dementia and Geriatric Cognitive Disorders, 26(3), 199-202. Abstract.
Andersson M, Hansson O, Minthon L, Ballard CG, Londos E (2008). The period of hypotension following orthostatic challenge is prolonged in dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 23(2), 192-198. Abstract.
Sharp SI, Ballard CG, Chen CPLH, Francis PT (2007). Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with alzheimer disease. American Journal of Geriatric Psychiatry, 15(5), 435-437. Abstract.
Ballard C (2007). Agitation and Psychosis in Dementia. American Journal of Geriatric Psychiatry, 15(11), 913-917.
Ballard C, Fossey J, Sharp S (2007). Antipsychotics in patients with Alzheimer's disease - What is their clinical value?: Commentary. Nature Clinical Practice Neurology, 3(5), 248-249.
Allan LM, Ballard CG, Allen J, Murray A, Davidson AW, McKeith IG, Kenny RA (2007). Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry, 78(7), 671-677. Abstract. Author URL.
Ballard CG, Chalmers KA, Todd C, McKeith IG, O'Brien JT, Wilcock G, Love S, Perry EK (2007). Cholinesterase inhibitors reduce cortical Aβ in dementia with Lewy bodies. Neurology, 68(20), 1726-1729. Abstract.
Ballard C (2007). Decisions are based on flawed models. British Journal of Hospital Medicine, 68(2).
Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, et al (2007). Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine, 357(14), 1382-1392. Abstract.
Robinson L, Hutchings D, Dickinson HO, Corner L, Beyer F, Finch T, Hughes J, Vanoli A, Ballard C, Bond J, et al (2007). Effectiveness and acceptability of non-pharmacological interventions to reduce wandering in dementia: a systematic review. International Journal of Geriatric Psychiatry, 22(1), 9-22. Abstract.
Minger SL, Ekonomou A, Carta EM, Chinoy A, Perry RH, Ballard CG (2007). Endogenous neurogenesis in the human brain following cerebral infarction. Regenerative Medicine, 2(1), 69-74. Abstract.
Rowan EN, Dickinson HO, Stephens S, Ballard C, Kalaria R, Anne Kenny R (2007). Homocysteine and post-stroke cognitive decline [7]. Age and Ageing, 36(3), 339-343.
Ziabreva I, Ballard C, Johnson M, Larsen JP, McKeith I, Perry R, Aarsland D, Perry E (2007). Loss of Musashi1 in Lewy body dementia associated with cholinergic deficit. Neuropathol Appl Neurobiol, 33(5), 586-590. Author URL.
Firbank MJ, Burton EJ, Barber R, Stephens S, Kenny RA, Ballard C, Kalaria RN, O'Brien JT (2007). Medial temporal atrophy rather than white matter hyperintensities predict cognitive decline in stroke survivors. Neurobiology of Aging, 28(11), 1664-1669. Abstract.
Ballard C, Clack H, Green D (2007). Post-operative cognitive decline, dementia and anaesthesia. British Journal of Neuroscience Nursing, 3(7), 302-303.
Ballard C, Clack H, Green D (2007). Postoperative cognitive decline, dementia and anaesthesia. British Journal of Hospital Medicine, 68(11), 576-577.
Aarsland D, Emre M, Lees A, Poewe W, Ballard C (2007). Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology [5]. Neurology, 68(1).
Piggott MA, Ballard CG, Rowan E, Holmes C, McKeith IG, Jaros E, Perry RH, Perry EK (2007). Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline. Synapse, 61(11), 903-911. Abstract.
Lowery DP, Wesnes K, Ballard CG (2007). Subtle attentional deficits in the absence of dementia are associated with an increased risk of post-operative delirium. Dementia and Geriatric Cognitive Disorders, 23(6), 390-394. Abstract.
Piggott MA, Ballard CG, Dickinson HO, McKeith IG, Perry RH, Perry EK (2007). Thalamic D<inf>2</inf> receptors in dementia with Lewy bodies, Parkinson's disease, and Parkinson's disease dementia. International Journal of Neuropsychopharmacology, 10(2), 231-244. Abstract.
Elliott MSJ, Abuhamdah S, Howes MJR, Lees G, Ballard CG, Holmes C, Burns A, Chazot PL, Perry EK, Francis PT, et al (2007). The essential oils from Melissa officinalis L. and Lavandula angustifolia Mill. as potential treatment for agitation in people with severe dementia. International Journal of Essential Oil Therapeutics, 1(4), 143-152. Abstract.
Ballard C, Sharp S, Fossey J (2007). Time to discontinuation similar for atypical antipsychotic drugs and placebo in people with Alzheimer's disease: Commentary. Evidence-Based Mental Health, 10(2).
Robinson L, Hutchings D, Corner L, Beyer F, Dickinson H, Vanoli A, Finch T, Hughes J, Ballard C, May C, et al (2006). A systematic literature review of the effectiveness of non-pharmacological interventions to prevent wandering in dementia and evaluation of the ethical implications and acceptability of their use. Health Technology Assessment, 10(26). Abstract.
Robinson L, Hutchings D, Corner L, Beyer F, Dickinson H, Vanoli A, Finch T, Hughes J, Ballard C, May C, et al (2006). A systematic literature review of the effectiveness of non-pharmacological interventions to prevent wandering in dementia and evaluation of the ethical implications and acceptability of their use. Health technology assessment (Winchester, England), 10(26). Abstract.
Ziabreva I, Perry E, Perry R, Minger SL, Ekonomou A, Przyborski S, Ballard C (2006). Altered neurogenesis in Alzheimer's disease. J Psychosom Res, 61(3), 311-316. Abstract. Author URL.
Ballard C, Lane R, Barone P, Ferrara R, Tekin S (2006). Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. International Journal of Clinical Practice, 60(6), 639-645. Abstract.
Burns A, O'Brien J, BAP Dementia Consensus group, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, et al (2006). Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol, 20(6), 732-755. Abstract. Author URL.
McKeith IG (2006). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. JOURNAL OF ALZHEIMERS DISEASE, 9, 417-423. Author URL.
Rongve A, Aarsland D, Ballard C (2006). Current perspectives in dementia with Lewy bodies. Aging Health, 2(3), 461-472. Abstract.
BALLARD C (2006). Dementia with Lewy Bodies and Parkinson's Disease Dementia Editors: JOHN O'BRIEN, IAN MCKEITH, DAVID AMES AND EDMOND CHIU, London, Taylor and Francis, 2005, £75.00 Hard cover, pp. 264 ISBN 1 8418 4491 8 -. International Psychogeriatrics, 18(4), 763-764.
Sauer J, Ffytche DH, Ballard C, Brown RG, Howard R (2006). Differences between Alzheimer's disease and dementia with Lewy bodies: an fMRI study of task-related brain activity. Brain, 129(7), 1780-1788. Abstract.
Ballard C, Ziabreva I, Perry R, Larsen JP, O'Brien J, McKeith I, Perry E, Aarsland D (2006). Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology, 67(11), 1931-1934. Abstract. Author URL.
Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, Howard R (2006). Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: Cluster randomised trial. British Medical Journal, 332(7544), 756-758. Abstract.
Ballard C, Fox C (2006). Effectiveness of collaborative care for elderly adults with Alzheimer's disease in primary care. Lancet Neurology, 5(8), 644-645.
Kurz MW, Schlitter AM, Larsen JP, Ballard C, Aarsland D (2006). Familial occurrence of dementia and Parkinsonism: a systematic review. Dementia and Geriatric Cognitive Disorders, 22(4), 288-295. Abstract.
Ziabreva I, Ballard CG, Aarsland D, Larsen JP, McKeith IG, Perry RH, Perry EK (2006). Lewy body disease: Thalamic cholinergic activity related to dementia and parkinsonism. Neurobiology of Aging, 27(3), 433-438. Abstract.
Ballard C, Howard R (2006). Neuroleptic drugs in dementia: Benefits and harm. Nature Reviews Neuroscience, 7(6), 492-500. Abstract.
Elliott MSJ, Abuhamdah S, Huang L, Perry EK, Ballard C, Lees G, Chazot PL, Holmes C, Burns A, Francis PT, et al (2006). P1–435: Essential oils as potential treatment for agitation in severe dementia: Elucidation of the pharmacological mechanism of Melissa and Lavender oils. Alzheimer's & Dementia, 2(3S_Part_8), s225-s225.
Lewis H, Beher D, Cookson N, Oakley A, Piggott M, Morris CM, Jaros E, Perry R, Ince P, Kenny RA, et al (2006). Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol Appl Neurobiol, 32(2), 103-118. Abstract. Author URL.
Pimlott SL, Piggott M, Ballard C, McKeith I, Perry R, Kometa S, Owens J, Wyper D, Perry E (2006). Thalamic nicotinic receptors implicated in disturbed consciousness in dementia with Lewy bodies. Neurobiol Dis, 21(1), 50-56. Abstract. Author URL.
Ballard C, Waite J (2006). The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane database of systematic reviews (Online)(1). Abstract.
Allan L, McKeith I, Ballard C, Kenny RA (2006). The prevalence of autonomic symptoms in dementia and their association with physical activity, activities of daily living and quality of life. Dementia and Geriatric Cognitive Disorders, 22(3), 230-237. Abstract.
Perry E, Ziabreva I, Perry R, Aarsland D, Ballard C (2005). Absence of cholinergic deficits in "pure" vascular dementia. Neurology, 64(1), 132-133. Abstract. Author URL.
Stephens S, Kenny RA, Rowan E, Kalaria RN, Bradbury M, Pearce R, Wesnes K, Ballard CG (2005). Association between mild vascular cognitive impairment and impaired activities of daily living in older stroke survivors without dementia. Journal of the American Geriatrics Society, 53(1), 103-107. Abstract.
Allan LM, Kerr SRJ, Ballard CG, Allen J, Murray A, McLaren AT, Kenny RA (2005). Autonomic function assessed by heart rate variability is normal in Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord, 19(2-3), 140-144. Abstract. Author URL.
McLaren A, Kerr S, Allan L, Steen IN, Ballard C, Allen J, Murray A, Kenny RA (2005). Autonomic function is impaired in elderly stroke survivors. Stroke, 36(5), 1026-1030. Abstract. Author URL.
Tasker A, Perry EK, Ballard CG (2005). Butyrylcholinesterase: Impact on symptoms and progression of cognitive impairment. Expert Review of Neurotherapeutics, 5(1), 101-106. Abstract.
Thomas A, Ballard C, Kenny RA, O'Brien J, Oakley A, Kalaria R (2005). Correlation of entorhinal amyloid with memory in Alzheimer's and vascular but not Lewy body dementia. Dementia and Geriatric Cognitive Disorders, 19(2-3), 57-60. Abstract.
McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, et al (2005). Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology, 65(12), 1863-1872. Abstract.
Ballard C, Cream J (2005). Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cosh?. International Psychogeriatrics, 17(1), 4-12. Abstract.
Robinson L, Hughes J, Daley S, Keady J, Ballard C, Volicer L (2005). End-of-life care and dementia. Reviews in Clinical Gerontology, 15(2), 135-148.
Rowan E, Morris CM, Stephens S, Ballard C, Dickinson H, Rao H, Saxby BK, McLaren AT, Kalaria RN, Kenny RA, et al (2005). Impact of hypertension and apolipoprotein E4 on poststroke cognition in subjects >75 years of age. Stroke, 36(9), 1864-1868. Abstract.
Rowan E, Morris CM, Stephens S, Ballard C, Dickinson H, Rao H, Saxby BK, McLaren AT, Kalaria RN, Kenny RA, et al (2005). Impact of hypertension and apolipoprotein E4 on poststroke cognition in subjects >75 years of age. STROKE, 36(9), 1864-1868. Author URL.
Teaktong T, Piggott MA, Mckeith IG, Perry RH, Ballard CG, Perry EK (2005). Muscarinic M2 and M4 receptors in anterior cingulate cortex: Relation to neuropsychiatric symptoms in dementia with Lewy bodies. Behavioural Brain Research, 161(2), 299-305. Abstract.
Sharp SI, Francis PT, Ballard CG (2005). Neurochemistry of severe dementia. Reviews in Clinical Gerontology, 15(2), 105-123.
Aarsland D, Perry R, Larsen JP, McKeith IG, O'Brien JT, Perry EK, Burn D, Ballard CG (2005). Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry, 66(5), 633-637. Abstract. Author URL.
Ballard CG, Perry RH, McKeith IG, Perry EK (2005). Neuroleptics are associated with more severe tangle pathology in dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 20(9), 872-875. Abstract.
Aarsland D, Perry R, Brown A, Larsen JP, Ballard C (2005). Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol, 58(5), 773-776. Abstract. Author URL.
Tildesley NTJ, Kennedy DO, Perry EK, Ballard CG, Wesnes KA, Scholey AB (2005). Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers. Physiol Behav, 83(5), 699-709. Abstract. Author URL.
Allan LM, Ballard CG, Burn DJ, Kenny RA (2005). Prevalence and severity of gait disorders in Alzheimer's and non-Alzheimer's dementias. Journal of the American Geriatrics Society, 53(10), 1681-1687. Abstract.
Purandare N, Ballard C, Burns A (2005). Preventing dementia. Advances in Psychiatric Treatment, 11(3), 176-183. Abstract.
Aarsland D, Sharp S, Ballard C (2005). Psychiatric and behavioral symptoms in Alzheimer's disease and other dementias: Etiology and management. Current Neurology and Neuroscience Reports, 5(5), 345-354. Abstract.
Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, et al (2005). Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial. British Medical Journal, 330(7496), 874-877. Abstract.
Holmes C, Ballard C, Lehmann D, Smith AD, Beaumont H, Day IN, Khan MN, Lovestone S, McCulley M, Morris CM, et al (2005). Rate of progression of cognitive decline in Alzheimer's disease: Effect of butyrylcholinesterase K gene variation. Journal of Neurology, Neurosurgery and Psychiatry, 76(5), 640-643. Abstract.
Ballard C, Morris C, Kalaria R, McKeith I, Perry R, Perry E (2005). The k variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients. Dement Geriatr Cogn Disord, 19(5-6), 357-360. Abstract. Author URL.
Peters N, Opherk C, Danek A, Ballard C, Herzog J, Dichgans M (2005). The pattern of cognitive performance in CADASIL: a monogenic condition leading to subcortical ischemic vascular dementia. American Journal of Psychiatry, 162(11), 2078-2085. Abstract.
Ballard C (2005). When the drugs don't work - Or do they? [1]. British Journal of General Practice, 55(519).
Ballard CG, Thomas A, Fossey J, Lee L, Jacoby R, Lana MM, Bannister C, McShane R, Swann A, Juszczak E, et al (2004). A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. Journal of Clinical Psychiatry, 65(1), 114-119. Abstract.
Cormack F, Gray A, Ballard C, TovĂŠe MJ (2004). A failure of 'pop-out' in visual search tasks in dementia with Lewy Bodies as compared to Alzheimer's and Parkinson's disease. International Journal of Geriatric Psychiatry, 19(8), 763-772. Abstract.
Ballard CG, Morris CM, Rao H, O'Brien JT, Barber R, Stephens S, Rowan E, Gibson A, Kalaria RN, Kenny RA, et al (2004). APOE ε4 and cognitive decline in older stroke patients with early cognitive impairment. Neurology, 63(8), 1399-1402. Abstract.
Aarsland D, Ballard CG, Halliday G (2004). Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?. Journal of Geriatric Psychiatry and Neurology, 17(3), 137-145. Abstract.
Holmes C, Ballard C (2004). Aromatherapy in dementia. Advances in Psychiatric Treatment, 10(4), 296-300. Abstract.
Kenny RA, Shaw FE, O'Brien JT, Scheltens PH, Kalaria R, Ballard C (2004). Carotid sinus syndrome is common in dementia with Lewy bodies and correlates with deep white matter lesions. Journal of Neurology, Neurosurgery and Psychiatry, 75(7), 966-971. Abstract.
Madhani P, Hughes J, Ballard CG (2004). Cholinesterase ihibitors and the heart in old age [1]. Advances in Psychiatric Treatment, 10(5).
Ballard C, Fossey J (2004). Clinical management of dementia. Psychiatry, 3(12), 27-32. Abstract.
Ballard CG (2004). Definition and diagnosis of dementia with Lewy bodies. Dementia and Geriatric Cognitive Disorders, 17(SUPPL. 1), 15-24. Abstract.
James I, Douglas S, Ballard C (2004). Different forms of psychological interventions in dementia. Nursing and Residential Care, 6(6), 288-291.
Ballard C, Hulford L (2004). Drugs used to relieve behavioural symptoms of dementia. Nursing and Residential Care, 6(7), 342-346.
Margallo-Lana M, Morris CM, Gibson AM, Tan AL, Kay DWK, Tyrer SP, Moore BP, Ballard CG (2004). Influence of the amyloid precursor protein locus on dementia in Down syndrome. Neurology, 62(11), 1996-1998. Abstract.
Ray M, Bohr I, McIntosh JM, Ballard C, McKeith I, Chalon S, Guilloteau D, Perry R, Perry E, Court JA, et al (2004). Involvement of alpha6/alpha3 neuronal nicotinic acetylcholine receptors in neuropsychiatric features of Dementia with Lewy bodies: [(125)I]-alpha-conotoxin MII binding in the thalamus and striatum. Neurosci Lett, 372(3), 220-225. Abstract. Author URL.
Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, et al (2004). Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet, 363(9427), 2105-2115. Abstract.
Ballard CG, Burton EJ, Barber R, Stephens S, Kenny RA, Kalaria RN, O'Brien JT (2004). NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia. Neurology, 63(6), 983-988. Abstract.
Ballard CG, Jacoby R, Del Ser T, Khan MN, Munoz DG, Holmes C, Nagy Z, Perry EK, Joachim C, Jaros E, et al (2004). Neuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients with Autopsy-Confirmed Dementia with Lewy Bodies. American Journal of Psychiatry, 161(5), 843-849. Abstract.
Stephens S, Kenny RA, Rowan E, Allan L, Kalaria RN, Bradbury M, Ballard CG (2004). Neuropsychological characteristics of mild vascular cognitive impairment and dementia after stroke. International Journal of Geriatric Psychiatry, 19(11), 1053-1057. Abstract.
Douglas S, James I, Ballard C (2004). Non-pharmacological interventions in dementia. Advances in Psychiatric Treatment, 10(3), 171-179. Abstract.
Cormack F, Aarsland D, Ballard C, TovĂŠe MJ (2004). Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia. International Journal of Geriatric Psychiatry, 19(4), 371-377. Abstract.
Aarsland D, Ballard C (2004). Psychiatric issues in non-Alzheimer dementias. Clinical Neuroscience Research, 3(6), 397-412. Abstract.
Peters N, Opherk C, Danek A, Ballard C, Herzog J, Dichgans M (2004). The pattern of cognitive performance in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Aktuelle Neurologie, 31(S 1).
Burton EJ, Kenny RA, O'Brien J, Stephens S, Bradbury M, Rowan E, Kalaria R, Firbank M, Wesnes K, Ballard CG, et al (2004). White matter hyperintensities are associated with impairment of memory, attention, and global cognitive performance in older stroke patients. Stroke, 35(6), 1270-1275. Abstract.
Karas GB, Burton EJ, Rombouts SARB, Van Schijndel RA, O'Brien JT, Scheltens P, McKeith IG, Williams D, Ballard C, Barkhof F, et al (2003). A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. NeuroImage, 18(4), 895-907. Abstract.
Ballard C, Kalaria R, Kenny RA, Thomas A (2003). Alzheimer's disease - a vascular dementia?. Reviews in Clinical Gerontology, 13(1), 67-74.
Perry E, McKeith I, Ballard C (2003). Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology, 60(11), 1852-1853. Abstract.
Ballard CG, Perry EK (2003). Butyrylcholinesterase: Potential importance for the symptoms and progression of cognitive decline in people with dementia. Acta Neurologica Taiwanica, 12(3), 109-113. Abstract.
McLaren AT, Allen J, Murray A, Ballard CG, Kenny RA (2003). Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord, 15(4), 183-188. Abstract. Author URL.
Kalaria R, Thomas A, Oakley A, Ince P, Tamaoka A, Mori H, Kenny R, Ballard C (2003). Cerebrovascular Amyloidosis and Dementia. Immunology Endocrine & Metabolic Agents - Medicinal Chemistry, 3(4), 317-327.
Margallo-Lana ML, Ballard C, Morris C, Kay D, Tyrer S, Moore B (2003). Cholinesterase inhibitors in the treatment of dementia. Int J Geriatr Psychiatry, 18(5), 458-459. Author URL.
Margallo-Lana ML, Ballard C, Morris C, Kay D, Tyrer S, Moore B (2003). Cognitive decline in Down syndrome. Arch Neurol, 60(7). Author URL.
McKeith IG, Burn DJ, Ballard CG, Collerton D, Jaros E, Morris CM, McLaren A, Perry EK, Perry R, Piggott MA, et al (2003). Dementia with Lewy bodies. Semin Clin Neuropsychiatry, 8(1), 46-57. Abstract. Author URL.
Burton E, Ballard C, Stephens S, Kenny RA, Kalaria R, Barber R, O'Brien J (2003). Hyperintensities and fronto-subcortical atrophy on MRI are substrates of mild cognitive deficits after stroke. Dementia and Geriatric Cognitive Disorders, 16(2), 113-118. Abstract.
Potkins D, Myint P, Bannister C, Tadros G, Chithramohan R, Swann A, O'Brien J, Fossey J, George E, Ballard C, et al (2003). Language impairment in dementia: Impact on symptoms and care needs in residential homes. International Journal of Geriatric Psychiatry, 18(11), 1002-1006. Abstract.
Lee L, Reichelt K, Ballard C, Perry E (2003). Melissa aromatherapy as safe and effective treatment. Nursing and Residential Care, 5(2), 80-82.
Ballard C, Stephens S, Kenny RA, Kalaria R, Tovee M, O'Brien J (2003). Profile of neuropsychological deficits in older stroke survivors without dementia. Dementia and Geriatric Cognitive Disorders, 16(1), 52-56. Abstract.
Ballard C, Rowan E, Stephens S, Kalaria R, Kenny RA (2003). Prospective follow-up study between 3 and 15 months after stroke: Improvements and decline in cognitive function among dementia-free stroke survivors >75 years of age. Stroke, 34(10), 2440-2444. Abstract.
O'Brien KK, Saxby BK, Ballard CG, Grace J, Harrington F, Ford GA, O'Brien JT, Swan AG, Fairbairn AF, Wesnes K, et al (2003). Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics, 13(4), 231-239. Abstract.
Ballard CG (2003). Reply to Reporting Changes in Scores on the Cohen-Mansfield Agitation Inventory Subscales. The Journal of Clinical Psychiatry, 64(6).
Snowdon J, Ballard CG (2003). Reporting changes in scores on the Cohen-Mansfield agitation inventory subscales [2] (multiple letters). Journal of Clinical Psychiatry, 64(6).
Perry NSL, Bollen C, Perry EK, Ballard C (2003). Salvia for dementia therapy: Review of pharmacological activity and pilot tolerability clinical trial. Pharmacology Biochemistry and Behavior, 75(3), 651-659. Abstract.
Tildesley NTJ, Kennedy DO, Perry EK, Ballard CG, Savelev S, Wesnes KA, Scholey AB (2003). Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers. Pharmacol Biochem Behav, 75(3), 669-674. Abstract. Author URL.
O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, et al (2003). Vascular cognitive impairment. Lancet Neurology, 2(2), 89-98. Abstract.
Colloby SJ, Fenwick JD, Williams DE, Paling SM, Lobotesis K, Ballard C, McKeith I, O'Brien JT (2002). A comparison of <sup>99m</sup>Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. European Journal of Nuclear Medicine, 29(5), 615-622. Abstract.
Ballard C, Johnson M, Piggott M, Perry R, O'Brien J, Rowan E, Perry E, Lantos P, Cairns N, Holmes C, et al (2002). A positive association between 5HT re-uptake binding sites and depression in dementia with Lewy bodies. J Affect Disord, 69(1-3), 219-223. Abstract. Author URL.
Ballard CG (2002). Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. European neurology, 47(1), 64-70. Abstract.
Ford GA, Ballard C, Thomas SHL (2002). Anti-psychotic drug use in older people. Age and Ageing, 31(4), 225-226.
Ballard CG, O'Brien JT, Reichelt K, Perry EK (2002). Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. Journal of Clinical Psychiatry, 63(7), 553-558. Abstract.
Ballard C, Powell I, James I, Reichelt K, Myint P, Potkins D, Bannister C, Lana M, Howard R, O'Brien J, et al (2002). Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities. International Journal of Geriatric Psychiatry, 17(2), 140-145. Abstract.
Swann A, Ballard C (2002). Casebook: assessing confusion. The Practitioner, 246(1639).
Singleton AB, Wharton A, O'Brien KK, Walker MP, McKeith IG, Ballard CG, O'Brien J, Perry RH, Ince PG, Edwardson JA, et al (2002). Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies. Dementia and Geriatric Cognitive Disorders, 14(3-4), 167-175. Abstract.
Lowery K, Ballard C, Rodgers H, McLaren A, O'Brien J, Rowan E, Stephens S (2002). Cognitive decline in prospectively studied group of stroke survivors, with a particular emphasis on the >75's. Age and Ageing, 31(SUPPL. 3), 24-27. Abstract.
Fossey J, Lee L, Ballard C (2002). Dementia Care Mapping as a research tool for measuring quality of life in care settings: Psychometric properties. International Journal of Geriatric Psychiatry, 17(11), 1064-1070. Abstract.
Ballard CG, Court JA, Piggott M, Johnson M, O'Brien J, McKeith I, Holmes C, Lantos P, Jaros E, Perry R, et al (2002). Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. Conscious Cogn, 11(3), 461-474. Abstract. Author URL.
Ballard CG, Aarsland D, McKeith I, O'Brien J, Gray A, Cormaak F, Burn D, Cassidy T, Starfeldt R, Larsen JP, et al (2002). Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology, 59(11), 1714-1720. Abstract.
Thomas AJ, O'Brien JT, Davis S, Ballard C, Barber R, Kalaria RN, Perry RH (2002). Ischemic basis for deep white matter hyperintensities in major depression: a neuropathological study. Archives of General Psychiatry, 59(9), 785-792. Abstract.
Burton E (2002). Patterns of Cerebral Atrophy in Dementia with Lewy Bodies Using Voxel-Based Morphometry. NeuroImage, 17(2), 618-630.
Burton EJ, Karas G, Paling SM, Barber R, Williams ED, Ballard CG, McKeith IG, Scheltens P, Barkhof F, O'Brien JT, et al (2002). Patterns of cerebral atrophy in Dementia with Lewy bodies using voxel-based morphometry. NeuroImage, 17(2), 618-630. Abstract.
Ballard C, O'Brien J, Tovee M (2002). Qualitative performance characteristics differentiate dementia with Lewy bodies and Alzheimer's disease. Journal of Neurology Neurosurgery and Psychiatry, 72(5), 565-566. Abstract.
Burns A, Byrne J, Ballard C, Holmes C (2002). Sensory stimulation in dementia. British Medical Journal, 325(7376), 1312-1313.
Burns A, Byrne J, Ballard C, Holmes C (2002). Sensory stimulation in dementia - an effective option for managing behavioural problems. BRITISH MEDICAL JOURNAL, 325(7376), 1312-1313. Author URL.
Hussain RI, Ballard CG, Edwardson JA, Morris CM (2002). Transferrin gene polymorphism in Alzheimer's disease and dementia with Lewy bodies in humans. Neuroscience Letters, 317(1), 13-16. Abstract.
Barber R, McKeith I, Ballard C, O'Brien J (2002). Volumetric MRI study of the caudate nucleus in patients with dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Journal of Neurology Neurosurgery and Psychiatry, 72(3), 406-407. Abstract.
Teahan O, Slade JY, Perry RH, Ballard CG, Kalaria RN (2002). White matter pathology in Alzheimer's disease and vascular dementia: quantification by amyloidâβ precursor protein immunocytochemistry. Neuropathology and Applied Neurobiology, 28(2), 168-168.
Ballard CG, Margallo-Lana M, Fossey J, Reichelt K, Myint P, Potkins D, O'Brien J (2001). A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. Journal of Clinical Psychiatry, 62(8), 631-636. Abstract.
Aarsland D, Ballard C, Larsen JP, McKeith I (2001). A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. International Journal of Geriatric Psychiatry, 16(5), 528-536. Abstract.
Barber R, Mckeith IG, Ballard C, Gholkar A, O'brien JT (2001). A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer's disease: Magnetic resonance imaging volumetric study. Dementia and Geriatric Cognitive Disorders, 12(3), 198-205. Abstract.
Ballard C, O'Brien J, Gray A, Cormack F, Ayre G, Rowan E, Thompson P, Bucks R, McKeith I, Walker M, et al (2001). Attention and fluctuating attention in patients with dementia with lewy bodies and alzheimer disease. Archives of Neurology, 58(6), 977-982. Abstract.
O'Brien J, Thomas A, Ballard C, Brown A, Ferrier N, Jaros E, Perry R (2001). Cognitive impairment in depression is not associated with neuropathologic evidence of increased vascular or Alzheimer-type pathology. Biol Psychiatry, 49(2), 130-136. Abstract. Author URL.
Aarsland D (2001). Comparison of Extrapyramidal Signs in Dementia with Lewy Bodies and Parkinson's Disease. Journal of Neuropsychiatry, 13(3), 374-379.
Aarsland D, Ballard C, McKeith I, Perry RH, Larsen JP (2001). Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. Journal of Neuropsychiatry and Clinical Neurosciences, 13(3), 374-379. Abstract.
Middelkoop HAM, Van Der Flier WM, Burton EJ, Lloyd AJ, Paling S, Barber R, Ballard C, McKeith IG, O'Brien JT (2001). Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology, 57(11), 2117-2120. Abstract.
Campbell S, Stephens S, Ballard C (2001). Dementia with Lewy bodies: Clinical features and treatment. Drugs and Aging, 18(6), 397-407. Abstract.
O'brien JT, Ballard CG (2001). Drugs for Alzheimer's disease: Cholinesterase inhibitors have passed NICE's hurdle. BMJ, 323(7305), 123-124.
Howard R, Ballard C, O'Brien J, Burns A (2001). Guidelines for the management of agitation in dementia. International Journal of Geriatric Psychiatry, 16(7), 714-717.
Jackson EJ, Rajah S, Morris C, Ballard C, Thomas AJ, O'Brien JT (2001). Is apolipoprotein e4 associated with cognitive decline in depression?. Int J Geriatr Psychiatry, 16(4), 436-437. Author URL.
Margallo-Lana M, Reichelt K, Hayes P, Lee L, Fossey J, O'Brien J, Ballard C (2001). Longitudinal comparison of depression, coping, and turnover among NHS and private sector staff caring for people with dementia. British Medical Journal, 322(7289), 769-770.
Kalaria RN, Ballard CG, Ince PG, Kenny RA, McKeith IG, Morris CM, O'Brien JT, Perry EK, Perry RH, Edwardson JA, et al (2001). Multiple substrates of late-onset dementia: Implications for brain protection. Novartis Foundation Symposium, 235, 49-65. Abstract.
Singleton AB, Gibson AM, McKeith IG, Ballard CG, Edwardson JA, Morris CM (2001). Nitric oxide synthase gene polymorphisms in Alzheimer's disease and dementia with Lewy bodies. Neuroscience Letters, 303(1), 33-36. Abstract.
Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, McKeith IG, O'Brien JT (2001). Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology, 56(5), 643-649. Abstract.
Margallo-Lana M, Swann A, O'Brien J, Fairbairn A, Reichelt K, Potkins D, Mynt P, Ballard C (2001). Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. International Journal of Geriatric Psychiatry, 16(1), 39-44. Abstract.
O'Brien JT, Paling S, Barber R, Williams ED, Ballard C, McKeith IG, Gholkar A, Crum WR, Rossor MN, Fox NC, et al (2001). Progressive brain atrophy on serial MRI in dementia with Lewy Bodies, AD, and vascular dementia. Neurology, 56(10), 1386-1388. Abstract.
Ballard C, Fossey J, Chithramohan R, Howard R, Burns A, Thompson P, Tadros G, Fairbairn A (2001). Quality of care in private sector and NHS facilities for people with dementia: Cross sectional survey. British Medical Journal, 323(7310), 426-427.
Ballard C, O'Brien J, James I, Mynt P, Lana M, Potkins D, Reichelt K, Lee L, Swann A, Fossey J, et al (2001). Quality of life for people with dementia living in residential and nursing home care: the impact of performance on activities of daily living, behavioral and psychological symptoms, language skills, and psychotropic drugs. International Psychogeriatrics, 13(1), 93-106. Abstract.
Kalaria RN, Ballard C (2001). Stroke and cognition. Current atherosclerosis reports, 3(4), 334-339. Abstract.
Grace J, Lee KK, Ballard C, Herbert M (2001). The Relationship between Post-Natal Depression, Somatization and Behaviour in Malaysian Women. Transcultural Psychiatry, 38(1), 27-34. Abstract.
Ballard C, Walker M, O'Brien J, Rowan E, McKeith I (2001). The characterisation and impact of 'fluctuating' cognition in dementia with Lewy bodies and Alzheimer's disease. International Journal of Geriatric Psychiatry, 16(5), 494-498. Abstract.
Ballard CG, O'Brien JT, Swann AG, Thompson P, Neill D, McKeith IG (2001). The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: Persistence and new cases over 1 year of follow-up. Journal of Clinical Psychiatry, 62(1), 46-49. Abstract.
Ballard C, O'Brien J, Morris CM, Barber R, Swann A, Neill D, McKeith I (2001). The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. International Journal of Geriatric Psychiatry, 16(5), 499-503. Abstract.
Court JA, Ballard CG, Piggott MA, Johnson M, O'Brien JT, Holmes C, Cairns N, Lantos P, Perry RH, Jaros E, et al (2001). Visual hallucinations are associated with lower αbungarotoxin binding in dementia with Lewy bodies. Pharmacology Biochemistry and Behavior, 70(4), 571-579. Abstract.
Ballard C, Neill D, O'Brien J, McKeith IG, Ince P, Perry R (2000). Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J Affect Disord, 59(2), 97-106. Abstract. Author URL.
Kenny RA, Ballard CG, McLaren A (2000). Cholinesterase inhibitors may exacerbate hypotensive episodes related to neurocardiovascular instability in people with dementia. Neurobiology of Aging, 21
Porter RJ, Lunn BS, Walker LLM, Gray JM, Ballard CG, O'Brien JT (2000). Cognitive deficit induced by acute tryptophan depletion in patients with Alzheimer's disease. American Journal of Psychiatry, 157(4), 638-640. Abstract.
Cormack FK, Tovee M, Ballard C (2000). Contrast sensitivity and visual acuity in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 15(7), 614-620. Abstract.
Cormack FK, Tovee M, Ballard C (2000). Contrast sensitivity and visual acuity in patients with Alzheimer's disease. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 15(7), 614-620. Author URL.
Ballard C, Piggott M, Johnson M, Cairns N, Perry R, McKeith I, Jaros E, O'Brien J, Holmes C, Perry E, et al (2000). Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Annals of Neurology, 48(6), 868-876. Abstract.
Ballard C, Piggott M, Johnson M, Cairns N, Perry R, McKeith I, Jaros E, O'Brien J, Holmes C, Perry E, et al (2000). Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol, 48(6), 868-876. Abstract. Author URL.
Lowery K, Mynt P, Aisbett J, Dixon T, O'Brien J, Ballard C (2000). Depression in the carers of dementia sufferers: a comparison of the carers of patients suffering from dementia with Lewy Bodies and the carers of patients with Alzheimer's disease. Journal of Affective Disorders, 59(1), 61-65. Abstract.
BALLARD CG, MCKEITH IG (2000). Drs. Ballard and McKeith Reply. American Journal of Psychiatry, 157(12).
Thomas AJ, Ferrier IN, Kalaria RN, Woodward SA, Ballard C, Oakley A, Perry RH, O'Brien JT (2000). Elevation in late-life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex. American Journal of Psychiatry, 157(10), 1682-1684. Abstract.
Potkins D, Bradley S, Shrimanker J, O'Brien J, Swann A, Ballard C (2000). End of life treatment decisions in people with dementia: Carers' views and the factors which influence them. International Journal of Geriatric Psychiatry, 15(11), 1005-1008. Abstract.
Terao T, Ballard CG, McKeith IG (2000). Hallucinations in Alzheimer's disease and Charles Bonnet syndrome [12]. American Journal of Psychiatry, 157(12).
Ballard CG, McKeith IG, Ayre G, Gray A, Cormack F, Tovee M, O'Brien JT, Walker MP (2000). Impairments in attention and fluctuating attention distinguish between dementia with lewy bodies and Alzheimer's disease. Neurobiology of Aging, 21
Gibson AM, Singleton AB, Smith G, Woodward R, McKeith IG, Perry RH, Ince PG, Ballard CG, Edwardson JA, Morris CM, et al (2000). Lack of association of the α2-macroglobulin locus on chromosome 12 in AD. Neurology, 54(2), 433-438. Abstract.
Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT (2000). MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer's disease. International Journal of Geriatric Psychiatry, 15(10), 911-916. Abstract.
Barber R, Ballard C, McKeith IG, Gholkar A, O'Brien JT (2000). MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology, 54(6), 1304-1309. Abstract.
O'Brien JT, Metcalfe S, Swann A, Hobson J, Jobst K, Ballard C, McKeith I, Gholkar A (2000). Medial temporal lobe width on CT scanning in Alzheimer's disease: Comparison with vascular dementia, depression and dementia with Lewy bodies. Dementia and Geriatric Cognitive Disorders, 11(2), 114-118. Abstract.
Ballard C, McKeith I, O'Brien J, Kalaria R, Jaros E, Ince P, Perry R (2000). Neuropathological substrates of dementia and depression in vascular dementia, with a particular focus on cases with small infarct volumes. Dement Geriatr Cogn Disord, 11(2), 59-65. Abstract. Author URL.
Court JA, Piggott MA, Lloyd S, Cookson N, Ballard CG, McKeith IG, Perry RH, Perry EK (2000). Nicotine binding in human striatum: Elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. NEUROSCIENCE, 98(1), 79-87. Author URL.
Martin-Ruiz C, Court J, Lee M, Piggott M, Johnson M, Ballard C, Kalaria R, Perry R, Perry E (2000). Nicotinic receptors in dementia of Alzheimer, lewy body and vascular types. Acta Neurologica Scandinavica, Supplement, 102(176), 34-41. Abstract.
Ballard C, McLaren A, Morris C (2000). Non-Alzheimer dementias. CURRENT OPINION IN PSYCHIATRY, 13(4), 409-414. Author URL.
Ballard C, O'Brien J, Swann A, Neill D, Lantos P, Holmes C, Burn D, Ince P, Perry R, McKeith I, et al (2000). One year follow-up of parkinsonism in dementia with Lewy bodies. Dement Geriatr Cogn Disord, 11(4), 219-222. Abstract. Author URL.
Singleton AB, Hall R, Ballard CG, Perry RH, Xuereb JH, Rubinsztein DC, Tysoe C, Matthews P, Cordell B, Kumar-Singh S, et al (2000). Pathology of early-onset Alzheimer's disease cases bearing the Thr113-114ins presenilin-1 mutation. Brain, 123(12), 2467-2474. Abstract.
Bartlett S, Shrimanker J, Ballard C (2000). Prevalence of abnormal eating amongst elderly people in residential care. International Journal of Geriatric Psychiatry, 15(3), 283-284.
O'Brien JT, Paling S, Barber B, Ballard C, McKeith I, Fox NC, Crum W, Williams D (2000). Progressive brain atrophy on serial MRI in dementia with lewy bodies: a comparison with Alzheimer's disease and vascular dementia. Neurobiology of Aging, 21
McKeith IG, Ballard CG, Perry RH, Ince PG, O'Brien JT, Neill D, Lowery K, Jaros E, Barber R, Thompson P, et al (2000). Prospective validation of Consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology, 54(5), 1050-1058. Abstract.
Walker MP, Ayre GA, Perry EK, Wesnes K, McKeith IG, Tovee M, Edwardson JA, Ballard CG (2000). Quantification and characterisation of fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 11(6), 327-335. Abstract.
Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, Ballard CG (2000). Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology, 54(8), 1616-1624. Abstract.
Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, Ballard CG (2000). The clinician assessment of fluctuation and the one day fluctuation assessment scale: Two methods to assess fluctuating confusion in dementia. British Journal of Psychiatry, 177(SEPT), 252-256. Abstract.
Lowery K, Buri H, Ballard C (2000). What is the prevalence of environmental hazards in the homes of dementia sufferers and are they associated with falls. International Journal of Geriatric Psychiatry, 15(10), 883-886. Abstract.
Lowery K, Buri H, Ballard C (2000). What is the prevalence of environmental hazards in the homes of dementia sufferers and are they associated with falls. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 15(10), 883-886. Author URL.
Walker MP, Ayre GA, Ashton CH, Marsh VR, Wesnes K, Perry EK, O'Brien JT, McKeith IG, Ballard CG (1999). A psychophysiological investigation of fluctuating consciousness in neurodegenerative dementias. Human Psychopharmacology, 14(7), 483-489. Abstract.
Bartlett S, Ballard C (1999). Antidepressants in the elderly: a review. Expert Opinion on Investigational Drugs, 8(1), 51-63. Abstract.
Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, Morris CM, O'Brien JT (1999). Apolipoprotein E ε4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Archives of Neurology, 56(8), 961-965. Abstract.
Chapman FM, Dickinson J, McKeith I, Ballard C (1999). Association among visual hallucinations, visual acuity, and specific eye pathologies in Alzheimer's disease: Treatment implications. American Journal of Psychiatry, 156(12), 1983-1985. Abstract.
McKeith IG, O'Brien JT, Ballard C (1999). Diagnosing dementia with lewy bodies. Lancet, 354(9186), 1227-1228.
Harvey GT, Hughes J, McKeith IG, Briel R, Ballard C, Gholkar A, Scheltens P, Perry RH, Ince P, O'Brien JT, et al (1999). Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease: a pilot study. Psychological Medicine, 29(1), 181-187. Abstract.
Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT (1999). Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology, 52(6), 1153-1158. Abstract.
Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N, Kerwin R, Perry R, Perry E (1999). Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem, 73(4), 1590-1597. Abstract. Author URL.
Ballard C, Walker M (1999). Neuropsychiatric aspects of Alzheimer's disease. Current psychiatry reports, 1(1), 49-60. Abstract.
Kalaria RN, Ballard C (1999). Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Disease and Associated Disorders, 13(SUPPL. 3). Abstract.
Ballard C, Holmes C, McKeith I, Neill D, O'Brien J, Cairns N, Lantos P, Perry E, Ince P, Perry R, et al (1999). Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry, 156(7), 1039-1045. Abstract. Author URL.
Ballard C, Gray A, Ayre G (1999). Psychotic symptoms, aggression and restlessness in dementia. Revue Neurologique, 155(SUPPL. 4). Abstract.
Ballard C, Gray A, Ayre G (1999). Psychotic symptoms, aggression and restlessness in dementia. REVUE NEUROLOGIQUE, 155, 4S44-4S52. Author URL.
Neill D, Curran MD, Middleton D, Mawhinney H, Edwardson JA, McKeith I, Ballard C, Morris C, Ince P, Jaros E, et al (1999). Risk for Alzheimer's disease in older late-onset cases is associated with HLA-DRB1*03. Neurosci Lett, 275(2), 137-140. Abstract. Author URL.
Ballard CG, Ayre G, O'Brien J, Sahgal A, McKeith IG, Ince PG, Perry RH (1999). Simple standardised neuropsychological assessments aid in the differential diagnosis of dementia with Lewy bodies from Alzheimer's disease and vascular dementia. Dementia and Geriatric Cognitive Disorders, 10(2), 104-108. Abstract.
Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, Burn D, Johnson M, Perry RH, McKeith IG, et al (1999). Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. BRAIN, 122, 1449-1468. Author URL.
Ballard CG, Shaw F, Lowery K, McKeith I, Kenny R (1999). The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 10(2), 97-103. Abstract.
Ballard C, O'Brien J (1999). Treating behavioural and psychological signs in Alzheimer's disease. British Medical Journal, 318(7203), 138-139.
Ballard C, O'Brien J (1999). Treating behavioural and psychological signs in Alzheimer's disease - the evidence for current pharmacological treatments is not strong. BRITISH MEDICAL JOURNAL, 319(7203), 138-139. Author URL.
Barber R, Scheltens P, Gholkar A, Ballard C, McKeith I, Ince P, Perry R, O'Brien J (1999). White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry, 67(1), 66-72. Abstract. Author URL.
Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, Tsouloufis T, Tzartos S, Ballard C, Perry RH, et al (1999). α4 but not α3 and α7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. Journal of Neurochemistry, 73(4), 1635-1640. Abstract.
Singleton AB, Gibson AM, McKeith IG, Ballard CA, Perry RH, Ince PG, Edwardson JA, Morris CM (1999). α<inf>2</inf>-macroglobulin polymorphisms in Alzheimer's disease and dementia with Lewy bodies. NeuroReport, 10(7), 1507-1510. Abstract.
Ballard CG, O'Brien J, Lowery K, Ayre GA, Harrison R, Perry R, Ince P, Neill D, McKeith IG (1998). A prospective study of dementia with Lewy bodies. Age Ageing, 27(5), 631-636. Abstract. Author URL.
Perry E, Court J, Goodchild R, Griffiths M, Jaros E, Johnson M, Lloyd S, Piggott M, Spurden D, Ballard C, et al (1998). Clinical neurochemistry: developments in dementia research based on brain bank material. J Neural Transm (Vienna), 105(8-9), 915-933. Abstract. Author URL.
Ballard C, Shaw F, McKeith L, Kenny R (1998). High prevalence of neurovascular instability in neurodegenerative dementias. Neurology, 51(6), 1760-1762. Abstract.
Ballard C, Grace J, McKeith I, Holmes C (1998). Neuroleptic sensitivity in dementia with lewy bodies and Alzheimer's disease. Lancet, 351(9108), 1032-1033.
Bannister C, Ballard C, Lana M, Fairbairn A, Wilcock G (1998). Placement of dementia sufferers in residential and nursing home care. Age and Ageing, 27(2), 189-194. Abstract.
Ballard C, McKeith IG (1998). Psychiatric features in diffuse Lewy body disease. Neurology, 50(2).
McKeith' IG, Ince P, Jaros EB, Fairbairn A, Ballard C, Grace J, Morris CM, Perry RH (1998). What are the relations between Lewy body disease and AD?. Journal of Neural Transmission, Supplement(54), 107-116. Abstract.
Ballard C, McKeith I, Harrison R, O'Brien J, Thompson P, Lowery K, Perry R, Ince P (1997). A detailed phenomenological comparison of complex visual hallucinations in dementia with Lewy bodies and Alzheimer's disease. Int Psychogeriatr, 9(4), 381-388. Abstract. Author URL.
Ballard C, O'Brien J, Coope B, Fairbairn A, Abid F, Wilcock G (1997). A prospective study of psychotic symptoms in dementia sufferers: Psychosis in dementia. International Psychogeriatrics, 9(1), 57-64. Abstract.
Ballard C, Massey H, Lamb H, Morris C (1997). Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry, 63(2), 273-274. Author URL.
GRAHAM C, BALLARD C, SHAM PAK (1997). CARERS' KNOWLEDGE OF DEMENTIA AND THEIR EXPRESSED CONCERNS. International Journal of Geriatric Psychiatry, 12(4), 470-473.
Graham C, Ballard C, Sham P (1997). Carers' knowledge of dementia and their expressed concerns. International Journal of Geriatric Psychiatry, 12(4), 470-473. Abstract.
Graham C, Ballard C, Sham P (1997). Carers' knowledge of dementia, their coping strategies and morbidity. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 12(9), 931-936. Author URL.
Graham C, Ballard C, Sham P (1997). Carers' knowledge of dementia, their coping strategies and morbidity. International Journal of Geriatric Psychiatry, 12(9), 931-936.
Graham C, Ballard C, Sham P (1997). Carers' knowledge of dementia, their coping strategies and morbidity. International Journal of Geriatric Psychiatry, 12(9), 931-936. Abstract.
Ballard C, Coope B, Oyebode F, Wilcock G (1997). Depression in dementia sufferers - Comparison of diagnostic criteria. Journal of the American Geriatrics Society, 45(1), 123-124.
CULLEN P, ABID F, PATEL A, COOPE B, BALLARD CG (1997). EATING DISORDERS IN DEMENTIA. International Journal of Geriatric Psychiatry, 12(5), 559-562.
Cullen P, Abid F, Patel A, Coope B, Ballard CG (1997). Eating disorders in dementia. International Journal of Geriatric Psychiatry, 12(5), 559-562. Abstract.
Cullen P, Abid F, Patel A, Coope B, Ballard CG (1997). Eating disorders in dementia. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 12(5), 559-562. Author URL.
Ballard CG, O'Brien JT, Coope B, Wilcock G (1997). Psychotic symptoms in dementia and the rate of cognitive decline. Journal of the American Geriatrics Society, 45(8), 1031-1032.
BALLARD CG, SOLIS M, GAHIR M, CULLEN P, GEORGE S, OYEBODE F, WILCOCK G (1997). SEXUAL RELATIONSHIPS IN MARRIED DEMENTIA SUFFERERS. International Journal of Geriatric Psychiatry, 12(4), 447-451.
Ballard CG, Solis M, Gahir M, Cullen P, George S, Oyebode F, Wilcock G (1997). Sexual relationships in married dementia sufferers. International Journal of Geriatric Psychiatry, 12(4), 447-451. Abstract.
Ballard C, McKeith I, Burn D, Harrison R, O'Brien J, Lowery K, Campbell M, Perry R, Ince P (1997). The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. Acta Neurol Scand, 96(6), 366-371. Abstract. Author URL.
Graham C, Ballard C, Saad K (1997). Variables which distinguish patients fulfilling clinical criteria for dementia with Lewy bodies from those with Alzheimer's disease. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 12(3), 314-318. Author URL.
Graham C, Ballard C, Saad K (1997). Variables which distinguish patients fulfilling clinical criteria for dementia with Lewy bodies from those with Alzheimer's disease. International Journal of Geriatric Psychiatry, 12(3), 314-318. Abstract.
Ballard CG, Eastwood C, Gahir M, Wilcock G (1996). A follow up study of depression in the carers of dementia sufferers. British Medical Journal, 312(7036).
Ballard CG, Patel A, Solis M, Lowe K, Wilcock G (1996). A one-year follow-up study of depression in dementia sufferers. British Journal of Psychiatry, 168(MAR.), 287-291. Abstract.
Ballard CG, Lowery K, Harrison R, McKeith I (1996). A prospective study of dementia with Lewy bodies — Clinical data. European Psychiatry, 11
Ballard C, Boyle A, Bowler C, Lindesay J (1996). Anxiety disorders in dementia sufferers. International Journal of Geriatric Psychiatry, 11(11), 987-990. Abstract.
Ballard C, Patel A, Oyebode F, Wilcock G (1996). Cognitive decline in patients with Alzheimer's disease, vascular dementia and senile dementia of Lewy body type. Age and Ageing, 25(3), 209-213. Abstract.
McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, et al (1996). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology, 47(5), 1113-1124. Abstract.
Ballard CG, Bannister C, Oyebode F (1996). Depression in dementia sufferers. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 11(6), 507-515. Author URL.
Ballard CG, Bannister C, Oyebode F (1996). Depression in dementia sufferers. International Journal of Geriatric Psychiatry, 11(6), 507-515. Abstract.
Ballard C, Davies R (1996). Postnatal depression in fathers. International Review of Psychiatry, 8(1), 65-71. Abstract.
Ballard C, Bannister C, Solis M, Oyebode F, Wilcock G (1996). The prevalence, associations and symptoms of depression amongst dementia sufferers. Journal of Affective Disorders, 36(3), 135-144. Abstract.
Ballard C, Bannister C, Graham C, Oyebode F, Wilcock G (1995). Associations of psychotic symptoms in dementia sufferers. British Journal of Psychiatry, 167(OCT.), 537-540. Abstract.
Ballard CG, Bannister CL, Patel A, Graham C, Oyebode F, Wilcock G, Chung MC (1995). Classification of psychotic symptoms in dementia sufferers. Acta Psychiatrica Scandinavica, 92(1), 63-68. Abstract.
Saad K, Hartman J, Ballard C, Kurian M, Graham C, Wilcock G (1995). Coping by the carers of dementia sufferers. Age and Ageing, 24(6), 495-498. Abstract.
McKeith IG, Ballard CG, Harrison RWS (1995). Neuroleptic sensitivity to risperidone in Lewy body dementia. The Lancet, 346(8976).
Ballard CG, Stanley AK, Brockington IF (1995). Post-traumatic stress disorder (PTSD) after childbirth. British Journal of Psychiatry, 166(APR.), 525-528. Abstract.
Ballard C, Oyebode F (1995). Psychotic symptoms in patients with dementia. International Journal of Geriatric Psychiatry, 10(9), 743-752. Abstract.
Ballard CG, Saad K, Coope B, Graham C, Gahir M, Wilcock GK, Oyebode F (1995). The aetiology of depression in the carers of dementia sufferers. Journal of Affective Disorders, 35(1-2), 59-63. Abstract.
Ballard CG, Saad K, Patel A, Gahir M, Solis M, Coope B, Wilcock G (1995). The prevalence and phenomenology of psychotic symptoms in dementia sufferers. International Journal of Geriatric Psychiatry, 10(6), 477-485. Abstract.
Coope B, Ballard C, Saad K, Patel A, Bentham P, Bannister C, Graham C, Wilcock G (1995). The prevalence of depression in the carers of dementia sufferers. International Journal of Geriatric Psychiatry, 10(3), 237-242. Abstract.
Cassidy G, Ballard CG (1994). Brief reports: Psychiatric sequelae of mdma (ecstasy) and related drugs. Irish Journal of Psychological Medicine, 11(3), 132-133. Abstract.
England SJ, Ballard C, George S (1994). Chronicity in postnatal depression. European Journal of Psychiatry, 8(2), 93-96. Abstract.
Ballard CG, Mohan RN, Patel A, Graham C (1994). Original Papers: Anxiety disorder in dementia. Irish Journal of Psychological Medicine, 11(3), 108-109. Abstract.
Ballard CG, Davis R, Cullen PC, Mohan RN, Dean C (1994). Prevalence of postnatal psychiatric morbidity in mothers and fathers. British Journal of Psychiatry, 164(JUNE), 782-788. Abstract.
Ballard CG, Handy S, McGibben L, Mohan RNC, Silveira WR (1993). Eating disorder in a 6âyearâold Asian girl with ethyl malonic adipic aciduria. International Journal of Eating Disorders, 13(2), 245-248. Abstract.
Chithiramohan RN, Ballard CG, Baxter MA, Jones L, Handy S, Sheikh A, McGibben L, Silveira R (1993). Factors influencing general practitioner referral to a child psychiatric service. Irish Journal of Psychological Medicine, 10(3), 144-147. Abstract.
Ballard CG, Mohan RNC, Patel A, Bannister C (1993). Idiopathic clouding of consciousness—do the patients have cortical lewy body disease?. International Journal of Geriatric Psychiatry, 8(7), 571-576. Abstract.
Ballard CG, Davis R, Handy S, Mohan RNC (1993). Postpartum anxiety in mothers and fathers. European Journal of Psychiatry, 7(2), 117-121. Abstract.
Ballard CG, Cassidy G, Bannister C, Mohan RNC (1993). Prevalence, symptom profile, and aetiology of depression in dementia sufferers. Journal of Affective Disorders, 29(1), 1-6. Abstract.
Ballard CG, Mohan RNC, Davis R (1993). Seasonal variation in the prevalence of postnatal depression. European Journal of Psychiatry, 7(2), 73-76. Abstract.
Ballard CG, Mohan RNC, Handy S (1992). Chronic depersonalisation neurosis au Shorvon - a successful intervention. British Journal of Psychiatry, 160(JAN.), 123-125. Abstract.
McGibben L, Ballard CG, Handy S, Mohan RNC, Silveira WR (1992). Deliberate self-poisoning in Asian and Caucasian 12-15-year-olds. British Journal of Psychiatry, 161(JULY), 110-112. Abstract.
McGibben L, Ballard CG, Handy S, Silveira WR (1992). School attendance as a factor in deliberate self poisoning by 12-15 year old adolescents. British Medical Journal, 304(6818).
Ballard CG, Kurian M, Silveira WR (1992). The phenomena of “bingeing”. Irish Journal of Psychological Medicine, 9(1), 61-62. Abstract.
MCGIBBON L, HANDY S, BALLARD CG, SILVEIRA WR (1991). ANOREXIA-NERVOSA ACROSS CULTURES. BRITISH JOURNAL OF PSYCHIATRY, 158, 284-285. Author URL.
McGibbon L, Handy S, Ballard CG, Silveira WR (1991). Anorexia nervosa across cultures (II). British Journal of Psychiatry, 158(FEB.).
Ballard CG, Mohan RNC, Handy S (1991). Carbamazepine in alcohol withdrawal. British Journal of Psychiatry, 158(JAN.).
McGibben L, Ballard C (1991). Child psychiatry liaison services [7]. British Journal of Psychiatry, 158(APR.).
Ballard C, Bannister C, Davis R, Handy S, Cullen P (1991). Christmas census at a district general hospital psychiatric unit. Irish Journal of Psychological Medicine, 8(1), 46-47. Abstract.
Handy S, Chithiramohan RN, Ballard CG, Silveira WR (1991). Ethnic differences in adolescent self-poisoning: a comparison of Asian and Caucasian groups. Journal of Adolescence, 14(2), 157-162. Abstract.
Ballard CG, Chithiramohan RN, Handy S, Bannister C, Davis R, Todd NB (1991). Information reliability in dementia sufferers. International Journal of Geriatric Psychiatry, 6(5), 313-316. Abstract.
Ballard CG, Chithiramohan RN, Bannister C, Handy S, Todd N (1991). Paranoid features in the elderly with dementia. International Journal of Geriatric Psychiatry, 6(3), 155-157. Abstract.
Ballard C, Ing R, Cullen P, Chithiramohan R (1991). Sexual abuse: Crisis and response to counseling. Journal of Forensic Psychiatry, 2(2), 211-216. Abstract.
Ballard CG, Chithiramohan RN, Handy S (1991). The charles bonnet syndrome associated with vascular pathology — a classical presentation with a very atypical course. Irish Journal of Psychological Medicine, 8(1), 44-45. Abstract.
Handy S, Chithiramohan RN, Ballard CG, Bannister C, Rusca R (1991). The rationale of patient allocation for psychogeriatric assessment. International Journal of Geriatric Psychiatry, 6(4), 249-252. Abstract.
Cullen P, Ballard CG, Ing RP, Mohan RNC (1991). Vulnerability, coping and crisis. European Journal of Psychiatry, 5(4), 210-215. Abstract.
Ballard CG, Mohan RNC, Bannister C, Handy S, Patel A (1991). Wandering in dementia sufferers. International Journal of Geriatric Psychiatry, 6(8), 611-614. Abstract.
Chithiramohan RN, Ballard CG, Measey LG (1990). Acute dystonia induced by clomipramine therapy. Irish Journal of Psychological Medicine, 7(2), 141-142. Abstract.
Ballard C (1990). Cognitive and emotional improvement in a group of dementia patients. Acta psychiatrica Scandinavica, 81(1).
Ballard C (1990). Letter to the editor. Acta Psychiatrica Scandinavica, 81(1), 96-96.
Ballard CG, Chithiramohan RN, Handy S (1990). Skeleton services. British Journal of Psychiatry, 157(SEPT.), 455-456.
Ballard CG (1989). Benign intracranial hypertension and repeated self-mutilation. The British journal of psychiatry : the journal of mental science, 155, 570-571.
Ballard C (1989). NMS and thioxanthenes. The British journal of psychiatry : the journal of mental science, 155, 127-128.
Ballard CG (1989). Nosological problems. The British journal of psychiatry : the journal of mental science, 154
Ballard CG (1989). Physical morbidity of psychiatric patients. The British journal of psychiatry : the journal of mental science, 155
Ballard CG (1989). Successful therapeutic intervention in a schizophrenic patient with blepharospasm. Journal of Neurology Neurosurgery and Psychiatry, 52(11).
Chapters
Corbett A, Ballard C, Creese BA (2018). Evidence-based management of behavioural and psychological symptoms of dementia. In Michel J-P, Beattie BL, Martin FC, Walston JD (Eds.) Oxford Textbook of Geriatric Medicine, Oxford University Press, 1015-1020. Abstract.
Ballard C, Garcia-Ptacek S, van Steenoven I, Aarsland D (2015). Spectrum of Lewy body dementias: relationship of Parkinson’s disease dementia to dementia with Lewy bodies. In (Ed) Cognitive Impairment and Dementia in Parkinson's Disease, Oxford University Press (OUP), 241-260.
Duara R, Rodriguez MJ, Loewenstein DA, Farlow MR, Ballard C, Chui HC, Segal-Gidan F, Perry D, Rosen H, Henry ML, et al (2014). Cognitive Impairment and the Dementias. In (Ed) Geriatric Neurology, 181-286. Abstract.
Ballard C, Corbett A (2012). Management of agitation and aggression: Controversies and possible solutions. In (Ed) Advances in Alzheimer's Disease Management, 69-79.
Wheater HS, Ballard C, Bulygina N, McIntyre N, Jackson BM (2012). Modelling environmental change: Quantification of impacts of land use and land management change on UK flood risk. In (Ed) System Identification, Environmental Modelling, and Control System Design, 449-481. Abstract.
Burn DJ, Perry EK, OâBrien JT, Archibald N, Mukaetova-Ladinska EB, Cerejeira J, Collerton D, Jaros E, Perry R, Piggott MA, et al (2011). Dementia with Lewy Bodies. In (Ed) Neurobiology of Mental Illness, Oxford University Press (OUP), 1010-1031.
Ballard C, Aarsland D (2011). Pharmacological management of neuropsychiatric symptoms in people with dementia. In (Ed) Supportive Care for the Person with Dementia. Abstract.
Aarsland D, Ballard C (2010). Cholinesterase Inhibitors in Parkinson's Disease. In (Ed) Encyclopedia of Movement Disorders, 208-211. Abstract.
Aarsland D, Ballard C (2010). Cholinesterase Inhibitors in Parkinson’s Disease. In (Ed) Encyclopedia of Movement Disorders, Three-Volume Set. Abstract.
Wheater HS, McIntyre N, Jackson BM, Marshall MR, Ballard C, Bulygina NS, Reynolds B, Frogbrook Z (2010). Multiscale Impacts of Land Management on Flooding. In (Ed) Flood Risk Science and Management, 39-59.
Ballard C, Chitramohan R, Khan Z, Beh J (2010). NHS Continuing Care. In (Ed) Principles and Practice of Geriatric Psychiatry: Third Edition, 759-765. Abstract.
Cummings JL, Ballard C, Lowery K, Harrison R, McKeith IG (2010). Noncognitive symptoms in Lewy body dementia. In (Ed) Dementia with Lewy Bodies, Cambridge University Press (CUP), 67-84.
Sharp SI, Francis PT, Ballard CG (2006). Cholinergic and Serotonergic Systems in Severe Dementia. In (Ed) Severe Dementia, 21-31.
Ballard C, Bannister C (2005). Criteria for the diagnosis of dementia. In (Ed) Dementia 3Ed, 24-37.
Purandare NB, Ballard C, Burns A (2005). Prevention of Alzheimer's disease. In (Ed) Dementia 3Ed, 515-521.
Stephens S, Kalaria R, Kenny RA, Ballard C (2005). Progression of Cognitive Impairments Associated with Cerebrovascular Disease. In (Ed) Vascular Dementia, Springer Nature, 145-156.
Aarsland D, Ehrt U, Ballard C (2005). Role of Neuropsychiatric Assessment in Diagnosis and Research. In (Ed) Atypical Parkinsonian Disorders, Springer Nature, 163-183.
McKeith IG, Perry EK, Perry RH, Ballard C, Ince PG, Fairbairn AF, Edwardson JA (2004). Management of Noncognitive Symptoms in Dementia with Lewy Bodies. In (Ed) Mental Disorders in the Elderly: New Therapeutic Approaches, Karger Publishers, 71-75.
Perry EK, Piggott MA, Johnson M, Ballard CG (2003). Neurotransmitter Correlates of Neuropsychiatric Symptoms in Dementia with Lewy Bodies. In (Ed) Mental and Behavioral Dysfunction in Movement Disorders, Springer Nature, 285-294.
Perry EK, Piggott MA, Johnson M, Ballard CG, McKeith IG, Jaros E, Perry RH (2002). Cholinergic and Monoaminergic Correlates of Clinical Symptoms in Dementia with Lewy Bodies. In (Ed) Mapping the Progress of Alzheimerâs and Parkinsonâs Disease, Springer Nature, 491-496.
Cullen PE, Ballard C (2002). Eating Disorders in Alzheimer's Disease. In (Ed) Principles and Practice of Geriatric Psychiatry, Wiley, 245-245.
Conferences
Ranson JM, Khleifat AA, Lyall DM, Newby D, Winchester LM, Proitsi P, Veldsman M, Rittman T, Marzi S, Yao Z, et al (2022). The Deep Dementia Phenotyping (DEMON) Network: a global platform for innovation using data science and artificial intelligence. Abstract. Author URL.
Arathimos R, Fabbri C, Vassos E, Davis K, Pain O, Gillett A, Coleman J, Hanscombe KB, Hagenaars S, Jermy B, et al (2021). LATENT SUBTYPES OF MANIC OR IRRITABLE EPISODE SYMPTOMS IN TWO POPULATION-BASED COHORTS. Author URL.
Ranson JM, Lourida I, Hannon E, Littlejohns TJ, Ballard C, Langa KM, HyppĂśnen E, Kuzma E, Llewellyn DJ (2020). Genetic risk, education and incidence of dementia.
Ranson J, Lourida I, Hannon E, littlejohns T, Ballard C, langa K, hypponen E, Kuzma E, Llewellyn D (2020). Genetic risk, education and incidence of dementia. Alzheimer’s Association International Conference. 27th - 31st Jul 2020.
Ranson J, Lourida ILIANNA, Hannon E, littlejohns T, Ballard C, langa K, hypponen E, Kuzma E, Llewellyn D (2020). Stroke, genetic risk and incidence of dementia. Alzheimer's Association International Conference. 27th - 31st Jul 2020.
Atri A, FrĂślich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Windfeld K, Raket LL, Cummings JL (2018). Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease three randomized clinical trials. Abstract.
Ballard C, Mills R, Williams H, Corbett A, Cummings J (2014). TREATMENT OF PSYCHOSIS IN PARKINSON'S DISEASE AND PARKINSON'S DISEASE DEMENTIA. Author URL.
Blesa R, Ballard C, Orgogozo JM, Lane R, Thomas SK (2007). Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Abstract.
Ballard C, Sorensen S, Sharp S (2007). Pharmacological therapy for people with Alzheimer's disease: the balance of clinical effectiveness, ethical issues and social and healthcare costs. Abstract.
Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S (2005). Cholinesterases: Roles in the brain during health and disease. Abstract.
Ballard CG, Margallo-Lana ML (2004). The relationship between antipsychotic treatment and quality of life for patients with dementia living in residential and nursing home care facilities. Abstract.
Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P, Polvikoski T (2004). Towards defining the neuropathological substrates of vascular dementia. Abstract. Author URL.
Ballard C, Stephens S, McLaren A, Wesnes K, Kenny R (2003). Mild cognitive impairment and vascular cognitive impairment in stroke patients. Abstract.
Kenny RAM, Kalaria R, Ballard C (2002). Neurocardiovascular instability in cognitive impairment and dementia. Abstract.
Ballard C, Stephens S, McLaren A, Wesnes K, Kenny RA, Burton E, O'Brien J, Kalaria R (2002). Neuropsychological deficits in older stroke patients. Abstract.
Ballard C, Lowery K, Powell I, O'Brien J, James I (2000). Impact of behavioral and psychological symptoms of dementia on caregivers.
Ballard C, O'Brien J, Barber B, Scheltens P, Shaw F, Mckeith I, Kenny RA (2000). Neurocardiovascular instability, hypotensive episodes, and MRI lesions in neurodegenerative dementia. Abstract.
Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, Haroutunian V, Buxbaum JD, NĂŁsland J, Davis K, et al (2000). Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Abstract. Author URL.
Martin-Ruiz C, Court J, Lee M, Piggott M, Johnson M, Ballard C, Kalaria R, Perry R, Perry E (2000). Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types. Abstract. Author URL.
